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The health challenges posed by Alzheimer’s disease (AD) continue to grow as societies 
age worldwide. Accumulation of Tau-associated pathology correlates with clinical 
cognitive deterioration in AD. Resident myeloid cells within the central nervous system 
(CNS) have a limited capacity to uptake and degrade Tau; however, the resulting 
secretion of proinflammatory cytokines only acts to accelerate neurodegeneration. 
Therapeutic antibodies can reduce the neurotoxic oligomeric form of Tau (o-Tau), but in 
doing so they also aggravate inflammation. Attenuating mutation of the antibody Fc 
region can silence inflammation but also eliminates its capacity to mediate o-Tau 
clearance by CNS myeloid cells. Thus, there is an unmet need for a novel therapeutic 
that catalyzes o-Tau degradation without triggering neurotoxic inflammation.  In tumor 
immunity, scavenger receptors such as CD163, CD204 and FcgRIIb act to limit the 
proinflammatory responses of the myeloid stroma. We sought to repurpose this system 
to facilitate o-Tau internalization in AD while limiting inflammation.  Unlike microglia in 
late stage AD, monocytes retain the ability to clear Tau assemblies, but also secrete 
inflammatory cytokines. We propose the novel concept of chimeric scavenger receptors 
(CSR) that facilitate clearance of o-Tau while limiting proinflammatory responses in 
monocytes. We successfully engineered a peripheral macrophage/monocyte cell line to 
stably express our CSR consisting of a scavenger receptor scaffold and an anti-o-Tau 
single-chain variable fragment. Our engineered CSR-monocytes not only mediate 
enhanced removal of extracellular o-Tau, but also uncouple phagocytosis from 
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neurotoxic proinflammatory cytokine production. The majority of the monocyte-
associated o-Tau is internalized where it co-localizes with lysosomes, likely as a prelude 
to proteolytic degradation. CSR monocytes demonstrate an elevated lysosome 
consumption activity relative to parental monocytes, indicative of a similarly higher 
degradative capacity.  In primary culture, CSR-monocytes can protect primary neurons 
from o-Tau-induced cytopathology. To validate the therapeutic efficacy of these CSR 
monocytes in relevant in vivo preclinical models, we established a minimally invasive 
procedure enabling repeated intracerebroventricular adoptive transfer of these cellular 
therapeutics. In our early in vivo study, we observed a trend of improved motor functions 
in P301S Tau overexpressing transgenic mice receiving the engineered monocytes. This 
is the first proof of concept that myeloid cell-based immunotherapies engineered to safely 
target and reduce Tau pathology through CSR expression can be harnessed to treat 
neurodegenerative diseases such as AD. 
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Chapter 1: Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that impairs 
the memory and cognitive functions of patients and eventually incapacitates them. AD 
has a broad societal impact because it primarily affects the elderly population, and 
societies worldwide are aging rapidly. Despite its tremendous impact, there is no cure 
yet. Understanding the pathogenesis of AD will help us discover and design better 
therapeutics to help these patients.  
Researchers have gained considerable insight into the complexity of AD from 
decades of investigation, but AD is still incurable. In 1907, Dr. Alois Alzheimer examined 
the brain of a patient presenting with progressive cognitive impairment and found 
neurofibrillary tangles (NFT) and plaques1. NFT and plaques are the aggregation of the 
prion-like proteins hyperphosphorylated Tau (pTau) and b-Amyloid (Ab). In addition to 
proteinopathy, scientific advancements in immunology, human genomics, epidemiology, 
and other areas, in addition to neuroscience, has begun to demonstrate that 
pathogenesis to AD is multifactorial. Other etiologies such as inflammation, genetic 
mutations, and cardiovascular diseases have been reported as risks for developing AD2. 
The complexity of these interlinked etiologies has made treating AD extremely 
challenging. Despite progress and an immense effort invested around the globe, we still 
lack a disease-modifying therapeutic to combat AD.  
To find better treatments for AD patients, we need a comprehensive understanding 
of AD. The following chapter will provide a clinical overview of AD and its predominant 
etiologies, including proteinopathy and inflammation. This chapter will also briefly update 
on the current advancement and challenges of therapeutics against AD, with an 
emphasis on immunotherapy.  
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1.1 Clinical overview of Alzheimer’s disease 
AD is an incurable progressive neurodegenerative disease that impairs patients’ 
memory as well as daily functions, leading to the patient becoming dependent on others 
and, eventually, death. Patients with AD are frequently first noted by their family 
members for the hallmark symptom of memory impairment. As the disease progresses, 
patients lose their high-level executive functions necessary for jobs and their abilities 
essential for independent living, such as shopping, transportation, cooking, and 
managing personal medications. Later, patients also present behavioral and 
psychological symptoms that add considerable stress, especially to close family 
members, which often results in significant caregiver burdens or even burnout3. In the 
late disease stages, patients become increasingly dependent. Eventually, they can no 
longer perform the necessary activities for daily living, including maintaining personal 
hygiene, walking, and even food intake4. The patients usually die from complications due 
to nutrition and infection. The median survival time ranges from 3 to 8 years after 
diagnosis5,6.  
AD has a broad societal impact because patients eventually become dependent on 
long-term care provided by either their family members or from institutions. Family 
members often give up jobs to care for the patient, or set aside a significant proportion 
of income in exchange for care. The global cost for dementia has been estimated to be 
818 billion US dollars per year and is projected to rise over two trillion US dollars by 
20307,8.  
The societal impact will be even greater since the elderly population is on a sharp 
rise, and AD affects this population the most. It is estimated that 5.8 million people aged 
65 and older suffer from AD in the United States in 20209,10. As societies age rapidly 
worldwide, the number of patients diagnosed with dementia, including AD, is projected 
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to be as high as 131 million globally while the number of patients diagnosed with AD is 
estimated to reach 13.8 million in the United States by 20508,9.  
Although AD poses an imminent threat to our aging societies, there is no cure and 
the current treatment provides only mild cognitive improvement. Standard treatment of 
AD includes the neurotransmitter modulator class of drugs that was approved by the US 
Food and Drug Administration (FDA) more than 20 years ago and is still the cornerstone 
of AD treatment today. This class of drugs includes acetylcholine esterase (AChE) 
inhibitors, such as donepezil, rivastigmine, and galantamine, and an N-methyl-D-
aspartate (NMDA) receptor antagonist, memantine, which are approved for various 
disease stages11.  
Acetylcholine is an essential neurotransmitter in the brain. It is associated with 
memory encoding, consolidation, and recall12,13. Loss of acetylcholine-producing 
neurons in the nucleus basalis of Meynert, has been found to correlate with memory 
dysfunction14,15. The mechanism of AChE inhibitors is to prevent the breakdown of 
acetylcholine in the synapses, thereby increasing its concentration in the brain despite 
the degeneration of the cholinergic neurons. Clinically, AChE inhibitors are indicated for 
patients with mild to severe dementia16.  
The other approved medication, memantine, is a non-competitive NMDA receptor 
antagonist with a low to moderate affinity to the receptor-mediated cation channel. Over-
activation of NMDA receptors could lead to excitotoxicity of neurons, and modulation of 
the excessive stimulation helps to prevent neuronal dysfunction17,18. In the clinic, 
memantine is suggested as an add-on therapy to the AChE inhibitors in treating 
moderate-to-severe AD19. Both AChE inhibitors and memantine marginally improve 
cognitive function after 3 months of treatment20,21; however, they do not modify or prevent 
disease progression22. Yet these are the only options we have in the clinic for our patients. 
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Informing this discouraging fact to AD patients in our daily practice not only reminds us 
about our current predicament but also urges us to re-examine the pathogenesis of the 
disease, and to develop a novel therapeutic.  
  
1.2 Pathogenesis of Alzheimer’s disease 
AD is a complex disease that is contributed to by multiple factors including 
inflammation, amyloid plaques, and NFT. Proteinopathy, including amyloid plaques and 
NFT, has been the predominant focus of research; however, increasing evidence 
indicates that AD is a disease of chronic inflammation. It is widely believed that 
dysfunctional innate immunity plays a central role in neuroinflammation in AD23, despite 
a growing literature that also suggests the critical role of adaptive immunity24,25. Other 
potential factors found by epidemiology studies that are associated with higher risks of 
developing AD include hypertension, atherosclerosis, diabetes mellitus, and frailty26,27. 
Studies of early-onset familial AD patients pinpoint specific genetic contributions to 
the disease, while research on the predominant late-onset AD indicates the involvement 
of multiple genes and other factors. Investigations of early-onset familial AD have 
identified causative genes, including amyloid precursor protein (APP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2). Identifying genetic risk factors in the more common 
late-onset AD has been challenging, however, because the disease involves multiple 
genes and potential interactions with environmental factors. Advancement of human 
genomics has helped to establish that high-risk genetic variants, including the e4 alleles 
of apolipoprotein E (ApoE) and TREM2 (triggering receptor expressed on myeloid cells 
2), are strongly associated with late-onset AD28,29. These genes are mainly involved in 
lipid metabolism and immune functions, which further demonstrates the role of 
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inflammation in AD. How these genetic variants interact with proteinopathy, leading to 
the disease state, is the subject of intense research.  
To better understand the pathogenesis of late-onset AD, this section will discuss 
not only the well-established etiologies, proteinopathy and innate immunity, but also the 
interaction between these two etiologies.  
 
1.2.1 Proteinopathy 
In the last few decades, researchers have widely believed that AD is a 
proteinopathy, in which its pathology is caused by abnormal protein accumulation. 
Accumulation of abnormal proteins including amyloid plaques and NFT are the key 
features in AD brain pathology. Amyloid plaques are extracellular aggregates of Ab 
peptides, and NFT are intracellular assemblies of pTau. These abnormal proteins are 
shown to play essential roles in the pathogenesis of AD in both clinical and animal studies. 
This section will review current views on the proteinopathies of AD with an emphasis on 
Tau as increasing data demonstrate its close association with clinical presentation in AD.  
 
1.2.1.1 Amyloid cascade hypothesis 
Amyloid plaques are the result of aggregation of Ab, which is processed from APP. 
Ab is 39 to 42 amino acids, and the two significant species are Ab40 and Ab42. The 
physiologic role of Ab has not been entirely elucidated. Although Ab has been reported 
to regulate synaptic functions30,31, the loss of Ab in mice does not result in significant 
detrimental phenotypic changes32. Ab is only one of the products of APP processing. 
Different APP processing pathways lead to either amyloidogenic Ab or non-
amyloidogenic peptides. While b-secretase and g-secretase catalyze amyloidogenic Ab 
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formation from APP in the clathrin-mediated endosomal compartments, APP can also be 
cleaved by a-secretase and g-secretase on the cell surface to generate non-
amyloidogenic peptides. Although the balance between these two pathways, and hence 
the resultant peptides, prevents excessive amyloidogenic Ab production, the regulation 
governing which processing pathways APP will undergo remains unclear32,33. 
Previous literature has indicated that amyloid plaques contribute to AD 
pathogenesis, and they are hypothesized to initiate multiple pathologies found in AD. 
The role of amyloid plaques in AD pathogenesis has been demonstrated by both 
pathologic and genetic studies. Brain pathology shows a higher amyloid plaque load in 
the later disease stage of AD. Furthermore, studies also showed that Ab can catalyze 
NFT formation, and amyloid plaques appears to occur before distinct NFT34,35. Genetic 
studies identified genetic mutations in APP and g-secretase components (presenilin-1 
and -2) that can cause familial autosomal dominant AD, in which the phenotypes were 
reproduced in animal models by overexpressing APP or introducing the mutations. 
These data established the role of Ab in AD pathogenesis and supported the amyloid 
cascade hypothesis, which hypothesized that the accumulation of Ab leads to the 
neuronal death, vascular damage, and NFT formation in AD pathology36. 
Although the data widely support the amyloid cascade hypothesis, none of the Ab-
targeting treatments have reached the market yet. Based on a disease-initiating role of 
Ab, researchers have developed therapeutics with mechanisms including inhibition of 
essential proteins responsible for Ab formation, administration of Ab-degrading enzymes 
such as neprilysin, and immunotherapies to promote Ab removal37,38.  After years of basic 
research and clinical trials, very few drugs demonstrate significant clinical improvement 
and acceptable safety profiles39.  
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Monoclonal antibody therapy has shown the most promise thus far. Several 
monoclonal antibodies have failed, but one has shown promise. Aducanumab is a fully 
human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes amino acids 3–
7 of the sequence of the Ab peptide. Aducanumab has a more than 10,000-fold increase 
in affinity for soluble Ab oligomer and insoluble fibrils over Ab monomer. It is one of the 
most promising therapeutics against Ab because it shows a dose-dependent and time-
dependent reduction of Ab in the brain as well as an attenuation of reduced cognitive 
functions in a Phase Ib clinical trial40. The Phase III trial was terminated early because 
no significant reduction of cognitive decline was detected in patients. However, in a 
recent re-analysis of the Phase III trial data, the company has reported a significant 
reduction in cognitive decline in patients receiving high-dose aducanumab41. 
Researchers have extensively investigated the role of Ab in AD in the past few 
decades. Their data support the amyloid cascade hypothesis, which argues that 
aggregation of Ab initiates the pathologies in AD including neuronal damage, vascular 
impairment, and NFT formation. To counter Ab accumulation in the brain, several Ab-
targeting therapeutics were developed. While most of the drugs failed, one monoclonal 
antibody, aducanumab, showed promising results in its Phase III clinical trials. The 
limited success in targeting Ab has prompted researchers to re-examine the 
pathogenesis of AD.  
 
1.2.1.2 Tau pathology 
Tau is a microtubule-associated protein enriched in neurons, encoded by the MAPT 
gene on human chromosome 1742. Physiologically, Tau stabilizes intracellular 
microtubules critical in intracellular trafficking in neurons43. Together with other 
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destabilizing proteins involved in microtubule assembly, Tau regulates the dynamics of 
microtubule construction44. The functional domains of Tau protein include an N-terminal 
projection domain, a proline-rich domain, a microtubule-binding domain, and a C-
terminal domain44. Six isoforms of Tau are expressed in the brain with slight differences 
in sizes ranging from 352 to 441 amino acids via alternative splicing of mRNA after its 
transcription from MAPT45. The isoforms differ by having one, two, or no N-terminal 
domains (N1, N1+N2, or N0), and having three or four microtubule-binding domains 
(absence or presence of R2) that result in the six isoforms46.   
An increasing body of research indicates that the abnormal accumulation of Tau 
induces neurotoxicity and is associated with the clinical disease progression of AD. 
Therefore, understanding the mechanisms leading to its accumulation will help to halt 
disease progression. Modifications of Tau, such as hyperphosphorylation, facilitate the 
abnormal aggregation of Tau that results in the pathologic hallmark in AD, NFT. A 
diminished elimination due in part to impaired maturation of autolysosomes containing 
Tau aggregates and a dysfunctional proteasome system also contributes to the 
accumulation of Tau47,48. Tau pathology not only induces neuronal damage directly, but 
also aids Ab-mediated neurotoxicity, in which reduction of Tau expression in Aβ-
overexpressing AD mouse models has been shown to attenuate cognitive impairment49,50. 
Tau pathology also follows a more invariant progression pattern in the brain, and is 
closely associated with disease progression in patients51,52, in that higher levels of Tau 
pathologies in the brain correlate to a more severe cognitive impairment53 and a more 
rapid disease progression54. Because the abnormal accumulation of Tau is clinically 
relevant and critical to neuronal damage, a better grasp of the mechanisms governing 
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the accumulation and elimination of abnormal Tau will help to reverse neurodegeneration 
in AD.  
 
1.2.1.2.1 Post-transcriptional modification of Tau 
The equilibrium of the isoforms of Tau is not only critical in maintaining microtubule 
structure and intracellular trafficking in neurons but is also influential in the aggregation 
of Tau. Alternative mRNA splicing after transcription of MAPT leads to various isoforms 
with slightly different properties. The isoform that contains four microtubule-binding 
domains (4R, with exon 10 inclusion) has a higher affinity for microtubules, while the 3R 
isoform provides a faster dynamic for axonal transport in neurons. The distinction 
between these isoforms might explain the relative abundance of the 3R isoform in the 
fetal brain when synapse formation is active55-57. More importantly, the 4R isoform is 
more prone to aggregate, which can be inhibited by the 3R isoform58. In this way, the 
isoforms in a healthy mature adult brain are usually kept in a balance, where the 3R 
isoform and 4R isoforms remain at a one-to-one ratio45. When mutations affect 
alternative splicing of MAPT transcript resulting in an unfavorable 4R isoform 
overexpression, the imbalance will disrupt intracellular trafficking in neurons, and 
increase free isoforms of Tau that could facilitate abnormal aggregations and subsequent 
pathology59.  
Mutations in MAPT result in alternative splicing that promotes the production of pro-
aggregation isoforms. The role of mutations in MAPT in neurodegeneration and 
dementia has been best demonstrated in a subtype of autosomal dominant 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), where 
significant Tau accumulation and neurodegeneration are caused by preferential 
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production of 4R via alternative mRNA splicing due to mutations in MAPT. These 
mutations in MAPT, including missense point mutations, G272V, P301L, and R406W60, 
not only cause overexpression of the 4R isoform by the inclusion of exon 10, but the 
mutations themselves, such as P301L, also contribute to fibrilization because they shift 
the protein toward a pro-aggregation β-structure61.  
Other isoforms generated by alternative mRNA splicing also play a role in the 
aggregation of Tau. Therefore, elucidating the mechanism governing alternative splicing 
may help to prevent Tau accumulation. In addition to microtubule-binding domains that 
play an essential role in Tau aggregation, the N-terminal domain of Tau also regulates 
Tau binding to microtubules as well as Tau aggregation62,63. These data showed that 
alternative mRNA splicing of MAPT transcripts significantly impacts the aggregation of 
Tau, and that understanding the mechanisms may provide a therapeutic opportunity.  
Previous research has expanded our understanding of the molecular details of Tau 
expression; however, how the mis-splicing of MAPT transcript contributes to sporadic 
neurodegeneration cases, and how to further regulate this splicing process to avoid 
undesired isoforms, is still under active investigation46.   
 
1.2.1.2.2 Post-translational modification of Tau 
The physiologic function and aggregation capability of Tau are markedly influenced 
by post-translational modifications, of which hyperphosphorylation is most crucial. In 
addition to alternative splicing at the mRNA level, Tau function is greatly affected at the 
protein level by post-translational modifications, including hyperphosphorylation, 
acetylation, O-GlcNAcylation (addition of b-N-acetyl-glucosamine), N-glycosylation, and 
truncation64. Hyperphosphorylation is the most extensively studied post-translational 
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modification of Tau. Phosphorylation of Tau negatively affects its physiological function, 
binding to microtubules65. A weaker binding and consequent dissociation from 
microtubules as a result of phosphorylation or alternative splicing further facilitates Tau 
phosphorylation66. Furthermore, hyperphosphorylation has been shown to be a 
necessary modification for the prion-like activity of abnormal Tau, which serves as a 
template to convert normal Tau into aggregates. Removal of the phosphorylation on Tau 
can abolish its self-assembly activity67,68. Other post-translational modifications, like 
acetylation and O-GlcNAcylation, are also involved in the prion-like activity of Tau 
through regulation of phosphorylation, which further demonstrates the central role of 
hyperphosphorylation in governing the prion-like activity of Tau69-71. 
Phosphorylation of Tau is catalyzed by two major categories of kinases 
synergistically, and phosphatases responsible for dephosphorylation are often found 
impaired in AD. The kinases responsible can be largely grouped into two categories: 
proline-directed protein kinases (PDPK) and non-PDPK. The phosphorylation mainly 
takes place at serine or threonine residues, as well as some tyrosine residues, of Tau. 
PDPKs that phosphorylate a serine or threonine followed by proline include glycogen 
synthase kinase-3b (GSK-3b), cyclin-dependent-like kinase-5 (CDK5), and dual-
specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A)72-75. Non-PDPKs, 
such as calcium/calmodulin-activated protein kinase II (CaMKII), microtubule affinity-
regulated kinase 110 (MARK p110), protein kinase A (PKA), and casein kinase 1 (CK1), 
can phosphorylate serine or threonine residues not followed by a proline76-79. PDPK and 
non-PDPK synergistically phosphorylate Tau, in a process in which residues of Tau 
previously-phosphorylated by non-PDPKs facilitate further efficient phosphorylation of 
other residues by other PDPKs80. Conversely, the phosphate groups of Tau are removed 
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by phosphatases such as protein phosphatase 2A (PP2A). PP2A not only regulates 
around 70% of Tau dephosphorylation but also modulates the activity of protein kinases. 
The balance between the activities of kinases and phosphatases determines the 
resultant burden of pTau81. In AD, the activity of PP2A is often found impaired, which 
might explain the accumulation of pTau82-84.  
Many factors, such as inflammation and acidosis, affect the equilibrium between the 
phosphorylation and dephosphorylation of Tau. Inflammation of the central nervous 
system (CNS) contributes to increased neuronal kinase activity: proinflammatory 
cytokine IL-1b overexpression has been demonstrated to result in increased GSK-3b 
activity along with increased pTau in neurons85. Additionally, acidosis has been reported 
to impair PP2A activity, resulting in Tau hyperphosphorylation. Focal brain acidosis from 
pathological conditions like ischemic stroke, traumatic brain injuries, and diabetes 
mellitus may partially explain their association with AD risks81,86. Research pinpointing 
the mechanisms leading to the phosphorylation imbalance is ongoing. 
 
1.2.1.2.3 Oligomeric Tau is the most neurotoxic Tau assembly species 
Aggregation of Tau is a continuous spectrum, and an oligomer with three or more 
monomeric Tau proteins is required for propagation. pTau, similar to Ab, is a prion-like 
protein that is capable of self-assembly and transforms normal protein into pathologic 
secondary structures to catalyze its aggregation. Formation from a monomeric Tau to 
filament or NFT is a continuous and dynamic process that undergoes a critical 
intermediate oligomeric stage, which sets a necessary threshold for its seeding capability. 
Three or more Tau peptides in an oligomer are required for intracellular seeding to cause 
pathologic aggregation87.  
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Not every oligomeric Tau (o-Tau) is the same, as isolation from different Tau-
induced diseases (tauopathies) found different strains of o-Tau. Most of the o-Tau have 
a b-sheet secondary structure that is a crucial characteristic in prion-like proteins88,89. 
Researchers have found that o-Tau prepared from different patients with the same 
diagnosis, or from patients of different tauopathies, have distinct properties. The o-Tau 
isolated from different patients can induce distinct pathological patterns in vivo, and show 
unique proteolysis patterns and aggregation morphologies in vitro. These discrete 
biochemical properties further classify the o-Tau into different strains, which may help 
explain the heterogeneous progression among different patients and diseases. More 
importantly, finding the strains unique to a specific tauopathy may help design precise 
therapeutics that can effectively target the responsible strains90-92.  
Similar to various strains of o-Tau, Tau filaments with different structures have been 
identified in distinct Tau-induced diseases. Using atomic force microscopy and 
transmission electron microscopy, researchers identified that o-Tau is granular in shape. 
This granular o-Tau can further assemble into a linear protofilament like a string of beads, 
then fuse into filaments93. More recently, the detailed structures of filaments, including 
the straight filament and paired helical filament, were unraveled using cryo-electron 
microscopy. The cores of both filaments are composed of two identical proto-filaments, 
but the difference between the straight filament and paired helical filament lies in the 
inter-protofilament packing94. The fact that specific tauopathies have only particular types 
of filament might indicate the differential pathogenicity of the Tau filaments95.  
In contrast to fibril and monomeric Tau, o-Tau is the most neurotoxic species and 
spreads among neurons. Because the deposition of NFT correlates well with the 
neuronal loss in the brain, NFT have long been considered the toxic species causing 
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neuronal death among the spectrum of Tau assemblies51. This concept was challenged 
when researchers identified that o-Tau is in effect the neurotoxic Tau species, as they 
found the most neuronal apoptosis in wild-type mice that were injected with o-Tau, but 
not fibril or monomer, into the brain. Mechanistically, o-Tau disrupts both synaptic and 
mitochondrial functions and also activates apoptosis pathways96,97. Another group also 
demonstrated the neurotoxicity of o-Tau by using a regulatable transgenic mouse model, 
rTg4510, in which transgenic Tau expression could be inhibited by tetracycline treatment. 
When they treated rTg4510 mice with tetracycline, they found that both soluble o-Tau 
and cognitive impairment were reduced, although the NFT pathology progressed98,99. In 
addition, studies found that extracellular o-Tau can be taken up by neurons and serve as 
a seed for further aggregation, which further bolsters the neurotoxic role of o-Tau54,87. 
Furthermore, monoclonal antibodies against o-Tau have been shown to prevent o-Tau 
propagation-induced neuronal toxicity in vitro effectively, and limit Tau pathology in 
vivo100.  
In summary, Tau pathology is a continuous spectrum of Tau assemblies from 
oligomers to fibrils. o-Tau harbors the essential structure to enable prion-like 
transmission, and has distinct strains resulting in differential disease progression. 
Importantly, o-Tau is the species responsible for direct neurotoxicity and, conversely, 
inhibition of o-Tau prevents neuronal damage.   
 
1.2.1.2.4 Tau is closely associated with clinical progression in Alzheimer’s disease 
Tau burden in the brain correlates with the cognitive function decline in AD patients. 
Because aducanumab is the only Ab-targeting therapy which continues in clinical trials 
while many others have aborted40, researchers have begun to shift their focus and 
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reconsider the pathogenic targets in AD. Although more Ab was found in the brain 
pathology of AD patients at late disease stages, studies have not found an association 
between amyloid plaque burden and cognitive function53,101. In contrast, Tau NFT burden 
in the brain is closely associated with cognitive function in AD patients, in which lower 
Tau burden correlates with a higher cognitive function102.  
Tau is associated with the clinical presentations of AD. The propagation of the NFT 
also follows a more invariant pattern compared to amyloid plaques. In the early disease 
stage, NFT are mostly found in the hippocampus, which is critical in memory functions. 
NFT then spread to the neighboring entorhinal cortex, cingulate gyrus, and the limbic 
system, which is vital to both memory and emotional responses. In the later disease 
stages, NFT disseminate to the cerebral cortex that is essential in executive function4,52. 
Overall, the pattern of NFT propagation in the brain pathology at different disease stages 
reflects the clinical presentations. 
Tau is also strongly associated with the clinical progression of AD. Not only did a 
postmortem analysis find a significantly higher concentration of soluble Tau in the 
temporal lobes of AD patients compared to normal subjects103, one retrospective study 
analyzing Tau levels in the cerebrospinal fluid of AD patients also showed a close 
association between high total Tau level (≥ 900 ng/L or 0.02 nM) and rapid clinical 
deterioration104. Additionally, a recent study confirmed that the seeding activity of o-Tau 
in the brain is closely associated with the clinical progression of AD54. These data 
suggest that the dose of Tau as well as its seeding capability may determine the disease 
progression of AD, which suggests Tau as a clinically-relevant target in AD.  
Tau pathology alone is sufficient to induce clinical symptoms of AD. In FTDP-17 
patients with the R406W missense mutation, there is no b-amyloid pathology but the 
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patients also present memory loss similar to AD patients and personality changes105. 
Experimentally, reducing Tau expression in Ab-overexpressing AD mouse models was 
shown to attenuate cognitive impairment49,50. Although the debate over Ab or Tau being 
the dominating pathogen in AD is far from settled106, both clinical and preclinical studies 
suggest that Tau pathology, independent of amyloid plaques, can initiate and dominate 
the pathogenesis of AD, contributing to clinical manifestations.  
In summary, Tau is a clinically-relevant target in AD because Tau pathology reflects 
the disease presentation, and correlates with cognitive decline and disease progression. 
Moreover, the capability of Tau to drive the symptoms of AD independently suggests that 
Tau is an ideal therapeutic target. 
 
1.2.1.2.5 Tau pathology summary 
Tau normally stabilizes microtubules that are essential in the axonal transport of 
neurons. An imbalance between kinases and phosphatases caused by inflammation or 
acidosis increases the level of pTau, which results in the destabilization of microtubules 
as well as neuronal dysfunction. Hyperphosphorylation of Tau promotes its aggregation 
into a spectrum of Tau assembly species, of which o-Tau is the most neurotoxic species, 
and is capable of propagating between neurons. Tau pathology, in comparison to that of 
Ab, closely correlates with the clinical progression of AD patients; thus, targeting Tau 
pathology, especially o-Tau, is a logical treatment strategy in AD. 
 
1.2.1.3 Proteinopathy summary 
Proteinopathy, or abnormal protein aggregation, is a critical pathology in AD. Both 
pTau and Ab proteins possess prion-like activity resulting in aggregation that is the 
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cornerstone of the pathogenesis of AD. They can incapacitate normal functional proteins 
by converting them into toxic assemblies, and even worse, propagate among neurons in 
the CNS akin to a chain reaction. Past extensive research on the amyloid cascade 
hypothesis has established the essential role of Ab in AD pathogenesis, although rational 
therapeutic designs aimed at Ab elimination have yet generated substantial efficacy. 
Increasing evidence demonstrates that Tau deposition has more clinical relevance and 
lays the foundation for designing therapeutics targeting the neurotoxic o-Tau species. 
 
1.2.2 Chronic inflammation in Alzheimer’s disease 
AD is not merely a proteinopathy but a multifactorial disease in which inflammation 
also plays an essential role. The early studies of the brains from AD patients had 
identified abnormal microglial pathology in addition to the evident proteinopathy. Other 
inflammatory changes, including cellular activation and cytokine and chemokine 
secretion, have also been found to precede protein aggregates in the brain of AD 
patients1,107,108. These data, together with the rapidly expanding literature, are bolstering 
the causal role of chronic inflammation in AD23,109.  
Inflammation in the CNS of AD is dominated by myeloid cells, including microglia 
and peripheral monocytes, while the contribution from adaptive immunity is still under 
investigation. Microglia are a unique, innate immune cell population residing in the CNS. 
Although microglia are similar in phenotype to their peripheral counterpart, macrophages, 
microglia are distinct from macrophages in ontogeny and are sequestered early into the 
CNS before peripheral hematopoiesis in fetal liver and bone marrow110. Microglia are 
pivotal in the inflamed CNS in AD, because activated microglia are not only the primary 
source and master regulator of cytokines and chemokines, but are also capable of 
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clearing protein aggregates and cellular debris64-67. Moreover, the peripheral myeloid 
counterpart of microglia, monocytes, have also been shown to traffic into the inflamed 
CNS through an impaired blood–brain barrier (BBB) and contribute to inflammation111,112. 
Burgeoning studies have demonstrated the influence of the adaptive immune system in 
AD; however, there is relatively little presence of adaptive immune cells in the AD brain, 
and their overall significance is under active research24,25.  
This section will provide a focused review of the role of the myeloid compartments 
as well as their secreted cytokines, and how they interact with proteinopathy and 
influence the complex pathogenesis of AD.   
 
1.2.2.1 Microglia play a central role in the inflammation of Alzheimer’s disease 
Microglia form a versatile innate immune population that contributes to inflammation 
in AD. Microglia are capable of phagocytosis and degradation of damaged neuronal 
debris as well as degradation of abnormal Ab and Tau aggregation113-115. In response, 
microglia are activated and orchestrate the production of inflammatory cytokines and 
chemokines, which in part help them clear the waste23,116-119.  
Exacerbated inflammation and impaired clearance of abnormal protein aggregates 
by microglia are critical in the pathogenesis of the late-onset form of AD primarily 
affecting the elderly population9. Aging or senescent microglia are found to be “primed”, 
which makes them more sensitive to environmental stimuli and leads to exaggerated 
responses, including cytokine secretion120-122. Although the mechanism of this “priming” 
process is still unclear, this enhanced microglial inflammation has been shown to 
contribute to the chronic inflammation in the CNS109. Furthermore, these senescent 
microglia have also been shown to have a reduced capability for phagocytosis and 
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degradation of protein aggregates121, and they even exacerbate Tauopathy in vivo123. 
Both the enhanced inflammation and the reduced clearance capacity by senescent 
microglia contribute to the pathogenesis of the late-onset form of AD that is most 
prevalent in the aging population.  
Microglial inflammation damages neurons and is central to AD pathogenesis. 
Clinical samples have demonstrated the presence of reactive microglia in AD pathology1, 
and microglial inflammation occurs early in AD, where reactive microglia induce neuronal 
damage, such as synapse loss, before apparent NFT deposition is observed108. A recent 
preclinical longitudinal study using Tau-overexpressing transgenic mice also showed that 
the elevated microglial activation marker, the 18 kDa translocator protein (TSPO), 
correlates with poor cognitive function, especially at a later disease stage124. These data 
demonstrate that microglia act as central perpetrators that contribute to 
neurodegeneration and disease progression in AD.   
Microglial inflammation not only induces neuronal death but can also exacerbate 
Tau pathology in the CNS. Reactive microglia were reported to both aggravate Tau 
pathology in Tau-overexpressing transgenic mice and induce Tau pathology in non-
transgenic mice after adoptive transfer125. Conversely, depletion of the microglia has 
been shown to slow the propagation of Tau pathology and the progression of the disease 
in vivo126. These observational and experimental studies established the essential role 
of microglia in exacerbating Tau pathology in AD.  
Dysregulated microglia cause inflammation and contribute to AD pathologies. 
CX3CR1 is a specific chemokine receptor expressed on microglia that is critical in 
regulating microglial activation but often found down-regulated in AD patients127,128. 
Although reduced CX3CR1 signaling may enhance Ab phagocytosis in Ab-
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overexpressing mouse models129, reduced CX3CR1 signaling also results in higher 
neurotoxic proinflammatory cytokine secretion and an aggravated Tau pathology that 
contributes to a worse cognitive outcome127,128. In support of these findings, the deletion 
of CX3CR1 in the Tau transgenic mouse model increases Tau hyperphosphorylation130 
and contributes to the spread of Tau pathology125.  
Microglia are also regulated by TREM2, and its mutation can lead to microglial 
dysfunction. Genetic studies have found that patients who carry a key mutation in TREM2 
have a similar risk of developing AD as do patients who bear ApoE e4 alleles29. Myeloid 
cells, including microglia, robustly express TREM2120,131, which can regulate the removal 
of damaged neurons by microglia132, mediate autophagy, and maintain metabolic fitness 
in microglia133. Furthermore, studies showed that TREM2 also signals through the ApoE 
pathway in microglia, and jointly drive microglial transcriptome away from homeostatic 
status toward a reactive state found in neurodegenerative condition134.  
In summary, microglia are an innate immune subset critical in the eliciting of 
inflammation to remove pathogens, including abnormal protein aggregates, in the CNS. 
Aging microglia have impaired clearance of protein aggregates but an exacerbated 
inflammatory response. Dysregulated microglial inflammation not only induces neuronal 
death but also aggravates Tau pathology, which underscores the pivotal role of microglia 
in AD pathogenesis.  
 
1.2.2.2 Microglia inflame Alzheimer’s disease with proinflammatory cytokines 
Microglia secrete proinflammatory cytokines that are deleterious to neurons. 
Microglia are capable of clearing toxic protein aggregates in the early stages of AD but 
become dysfunctional, in that they are ineffective in removing the aggregates, at the later 
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stages and also secrete more proinflammatory cytokines100,114,115,135,136. Although some 
studies have found that proinflammatory cytokines might help clear protein aggregates 
at the early stage of AD, more studies indicate that these cytokines have an overall 
detrimental impact on neurons, especially at the later disease stage, and contribute to 
AD pathogenesis109.  
Proinflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), 
and interleukin-1b (IL-1b) are critical in AD. Studies found elevated levels of TNF-a, IL-6 
and IL-1b in the AD brain137-139, while these proinflammatory cytokines also co-localize 
with protein aggregates in an AD mouse model140. Elevated levels of these cytokines 
and their association with other key pathologies demonstrate their importance in the 
pathogenesis of AD. How these proinflammatory cytokines abet the inflammatory rally in 
the CNS of AD will be discussed below.  
 
1.2.2.2.1 Tumor necrosis factor-a  
TNF-a is a master regulator of microglial inflammation and is elevated in the CNS 
of AD. TNF-a acts in an autocrine manner that promotes and perpetuates microglial 
activation141,142, which stimulates microglia to effectively produce other proinflammatory 
cytokines such as IL-1b and IL-6141. Furthermore, TNF-a expression by reactive 
microglia is elevated both in AD patients139 and in murine AD models140,143. Outside of 
the brain, studies have not shown a consistent trend for TNF-a levels in cerebrospinal 
fluid or serum144,145.  
Increased TNF-a levels induce neurodegeneration and impair clearance of protein 
aggregates by microglia. Overexpression of TNF-a exacerbates neuronal death in an AD 
transgenic mouse model142. In addition to its direct adverse effects on neuronal cells146, 
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TNF-a is also capable of inducing neuronal loss by microglia-mediated phagocytosis in 
vitro147. Furthermore, microglia exposed to TNF-a are found to have a reduced capability 
for clearing protein aggregates, including Ab, which might explain the dysfunctional 
microglia observed in the later stages of AD135. These data demonstrated that chronically 
elevated levels of TNF-a in AD are detrimental to the neurons via various pathways.  
Overall, TNF-a plays a pivotal role in the inflammation of AD. Elevated TNF-a levels 
in AD are shown to damage neurons and impair the clearance capability of microglia.  
 
1.2.2.2.2 Interleukin-6  
The level of IL-6 is elevated in the CNS of AD. Studies found that IL-6 co-localizes 
with amyloid plaques in the brain pathology of AD patients138,139 as well as in animal 
models140,143. Although serum IL-6 level is increased in AD patients in some individual 
studies, a recent meta-analysis of the available studies revealed no statistical 
significance145.  
IL-6 promotes neuronal damage as well as abnormal protein accumulation. In 
murine models, IL-6 has been found to damage neurons by impairing long-term 
potentiation of neurons148,149. It has also been shown that IL-6 together with Ab 
synergistically damages neurons in vitro150. Although one study found that IL-6 can 
suppress Ab plaque deposition in a murine model at the early stage of AD151, other 
studies indicated that elevated IL-6 levels promote abnormal protein aggregation and 
that IL-6 is capable of promoting pTau formation in vitro152,153. These data support the 
hypothesis that the elevated levels of IL-6 in the CNS is an essential contributing factor 
in AD pathogenesis.  
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1.2.2.2.3 Interleukin-1b  
IL-1b promotes direct neuronal toxicity and inflammation in the CNS. IL-1b 
enhances cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) 
expression by neurons that mediate neurotoxicity154,155. Furthermore, IL-1b also 
regulates calcium influx, which is implicated in neuronal death in vitro156. In addition to 
its deleterious effect on neurons, IL-1b can also promote adhesion molecule expression 
on endothelial cells, resulting in increased peripheral leukocyte infiltration and activation 
in the CNS157.  
IL-1b exacerbates proteinopathy in the brain and is essential in AD pathogenesis. 
Locally, IL-1b-expressing microglia are positively associated with deposition of NFT, and 
IL-1b levels are also elevated in the pathologic brain compared to non-demented 
individuals107. Systemically, the plasma level of IL-1b is also elevated in AD patients 
compared to non-demented controls, which suggests its substantial role in AD145,158. 
Furthermore, studies also demonstrated that IL-1b mediates Tau phosphorylation, and 
overexpression of IL-1b aggravates Tau pathologies85,159. Conversely, blockade of IL-1b 
signaling rescues both pathology and cognitive impairment in vivo160. These data 
demonstrate that IL-1b not only damages neurons via several mechanisms but also 
exacerbates the inflammation by activating and recruiting leukocytes into the CNS155-157. 
In summary, reactive microglia and their secreted proinflammatory cytokines are 
essential in the pathogenesis of AD. Elevated levels of these cytokines often co-exist in 
both clinical and preclinical samples. They synergistically promote the inflammation in 
the CNS and jointly contribute to the pathogenesis of AD.  
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1.2.2.3 Proteinopathy incites and fuels microglial inflammation 
AD is a multifactorial disease, and the etiologies often lace together in contributing 
to the disease. Distinct etiologies such as proteinopathy and inflammation damage 
neurons synergistically. These apparently-discrete etiologies also interact with each 
other in a way similar to a feed-forward loop in that they tend to exacerbate each other 
and jointly aggravate the disease progression.  
Proteinopathy stimulates the CNS myeloid cells that result in the inflammation in 
AD. In sporadic AD, although it is not entirely understood how protein aggregates disrupt 
the production–clearance balance and initiate accumulation of the waste, studies have 
revealed how these abnormal protein assemblies impact the immune system even 
before their prominent presence in pathology, and the intertwined consequences that 
follow.  
Abnormal protein aggregates like Ab fibrils activate myeloid cells via the 
inflammasome cascade. Myeloid cells like macrophages in the periphery or microglia in 
the CNS detect and eliminate pathogens by phagocytosis and subsequent clearance 
through intracellular degradation machinery. When the myeloid cells internalize Ab fibrils, 
phagosomes are fused with the lysosomal compartment for degradation. Ab fibrils have 
been found to disrupt lysosome and lead to cathepsin B release into the cytoplasm, 
causing activation of the NLRP3 (nucleotide-binding oligomerization domain, leucine-rich 
repeat containing protein 3) inflammasome. Activation of the NLRP3 inflammasome 
cascade leads to the recruitment of ASC (apoptosis-associated speck-like protein 
containing a caspase-recruitment domain (CARD)) and the activation of Caspase-1. 
Active Caspase-1 subsequently cleaves pro-IL-1b to release functional IL-1b161,162.  IL-
1b signaling in neurons can promote Tau phosphorylation and neuronal damage85,159.  
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Inflammasomes activated by the Ab aggregates aggravate both Tau and Ab 
proteinopathy in return. A recent study showed that the NLRP3 inflammasome and the 
subsequently induced IL-1b are necessary for Ab-induced Tau pathology, in which 
knockout of inflammasome components NLRP3 or ASC led to reduced Tau pathology in 
a Tau-overexpressing transgenic mouse model163. In addition to the exacerbation of Tau 
pathology, ASC specks generated during the NLRP3 inflammasome cascade can be 
released into extracellular compartments and act as seeds for Ab aggregates164. These 
data demonstrated that proteinopathy and reactive microglia constitute a feed-forward 
loop that worsens the pathology of AD.  
Like Ab assemblies, o-Tau activates microglia, which also contribute to the 
neurotoxic feed-forward cycle. Similar to the Ab assemblies that are capable of activating 
microglia, Tau assemblies also can activate microglia. Among the Tau assemblies, which 
are composed of a spectrum of various numbers of monomers, o-Tau is not only the 
most neurotoxic species in vivo96 but is also capable of inducing inflammation. Studies 
have demonstrated that o-Tau can activate microglia, resulting in the secretion of several 
proinflammatory cytokines, including TNF-a, IL-6 as well as IL-1b100,136. Although the 
mechanism of Tau activation of microglia has not been entirely elucidated, one study 
suggested that Tau assemblies activate microglia via two pathways. First, Tau 
assemblies promote pro-IL-1b production via a toll-like receptor (TLR)/Myeloid 
differentiation primary response 88 (MyD88)-dependent pathway in microglia. Second, 
Tau assemblies enable NLRP3 inflammasome activation in microglia, which leads to the 
processing of pro-IL-1b and functional IL-1b secretion165.   
Overall, Tau and Ab proteinopathies in AD are capable of activating microglia. 
These reactive microglia not only serve as a source of neurotoxic proinflammatory 
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cytokines but also aggravate the proteinopathy in the CNS. Together, they perpetuate 
each other and sustain a vicious cycle accelerating neuronal loss and disease 
progression of AD.   
 
1.2.2.4 Peripheral monocytes contribute to the inflammation in the central nervous 
system 
The CNS was once considered an “immune privileged” space, an area free from 
peripheral immune surveillance. Current evidence has demonstrated that the CNS is 
instead constantly monitored by the peripheral immune system. The BBB is a 
multicellular structure physically separating brain parenchyma from peripheral blood that 
limits and regulates the access of the peripheral immune system to the CNS166. However, 
this concept was challenged by researchers in the early 1990s. In the homeostatic 
condition, without inflammation, it was found that a lymph drainage system surrounds 
the CNS, and drains into the deep cervical lymph nodes that constitute an immune 
trafficking route connecting the CNS to the periphery167,168. This concept was reiterated 
recently using more sophisticated imaging modalities, demonstrating the presence of the 
lymphatic system in the CNS that allows the constant surveillance by the peripheral 
immune cells, including T cells and myeloid cells169.  
Peripheral immune cells migrate into the CNS via an impaired BBB in AD. The 
presence of peripheral immune cells like monocytes in postmortem brain samples112 and 
fibrinogen leakage from the brain vasculature of AD patients suggest a compromised 
BBB in AD that allows infiltration of peripheral monocytes into the brain parenchyma170. 
The question of whether an influx of peripheral monocytes to the CNS contributes to 
inflammation was not wholly settled earlier because the markers that were used to 
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identify peripheral monocytes could not separate them from microglia completely, which 
made it difficult to identify the origins of the CNS myeloid cells109. This debate was 
clarified in animal studies, in which peripheral pre-labeled monocytes migrate to the brain 
in AD mouse models. Compared to the healthy brains, researchers demonstrated that 
more pre-labeled monocytes traffic to the CNS after intravenous adoptive transfer into 
AD mouse models171,172. These clinical and preclinical findings both demonstrated that 
the inflamed AD brain is not an isolated island, and peripheral monocytes also contribute 
to its inflammation. 
An upregulation of cytokines, chemokines, and adhesion molecules in addition to 
Tau pathology help to recruit peripheral monocytes into the inflamed CNS in AD. In a 
migration system using primary human astrocyte and endothelial cells for manufacturing 
BBB separation in vitro, researchers found that human peripheral monocytes activated 
by Ab on one side of the artificial BBB promoted the migration of monocytes from the 
other side. They also found a dose-dependent association of chemokines (monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory porotein-1a (MIP-1a), 
MIP-1b and IL-8) as well as cytokines (TNF-a, IL-6 and IL-1b) with migration activity111. 
Furthermore, cytokines, including TNF-a and IL-1b, were shown to disrupt the vascular 
endothelial cell lining and upregulate the adhesion molecules on endothelial cells that 
lead to a more efficient infiltration of peripheral immune cells173,174. Recently, Tau 
pathology was also found to enhance the expression of adhesion molecules on vascular 
endothelial cells that facilitate the infiltration of peripheral immune cells175. These 
mechanisms collectively aid the influx of peripheral immune cells into the inflamed CNS 
of AD.  
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Both peripheral monocytes and microglia contribute to inflammation in the CNS 
after uptake of abnormal protein aggregates. Microglia in the later stages of AD are often 
dysfunctional in phagocytosis and clearance of the protein aggregates135, while 
peripheral monocytes are more capable of clearing protein aggregates such as Tau 
assemblies136. Although peripheral monocytes have a higher capacity to clear protein 
aggregates, we found that peripheral monocytes similar to microglia also produce 
proinflammatory cytokines endangering neurons. A further illustration will be provided in 
the Results section in Chapter 5 (Fig. 2). These data showed that myeloid cells aid 
inflammation in the CNS, and that there exists a common mechanism in myeloid cells 
linking the uptake of abnormal protein aggregates and the secretion of proinflammatory 
cytokines.  
In summary, the CNS is not isolated from the peripheral immune system by the BBB, 
which tightly regulates immune trafficking between the CNS and the periphery. Upon 
inflammation reactive to insults like Ab and Tau pathology in the CNS, this barrier can be 
disrupted and enables an increased influx of peripheral immune cells. Peripheral 
monocytes are recruited to cross the BBB and further contribute to the inflammation 
through the upregulation of cytokines, chemokines, and adhesion molecules originating 
from the reactive responses in the CNS. 
 
1.2.2.5 Chronic inflammation summary 
Microglia are the principal immune population triggering immune responses against 
protein aggregates in AD by secreting proinflammatory cytokines, including TNF-a, IL-6 
and IL-1b, and chemokines, which further recruit peripheral monocytes into the CNS. 
Peripheral monocytes harbor the potential of a more efficient uptake and degradation of 
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Tau assemblies but still secrete proinflammatory cytokines that exacerbate the 
inflammation. The proinflammatory cytokines secreted by both myeloid cell types further 
promote the accumulation of both Ab and Tau. As the disease progresses, the inefficient 
clearance of protein aggregates and the linked secretion of proinflammatory cytokines 
by the myeloid cells lead to a constant feed-forward loop pathology in AD brains.  
 
1.3 Immunotherapy for Alzheimer’s disease 
Although a cure or disease-modifying agent for AD is currently unavailable, novel 
drug development based on the re-examination of the etiologies of AD is bringing hope. 
The drugs of choice prescribed in the clinics are AChE inhibitors and NMDA receptor 
antagonists4. In a meta-analysis, both of them could slightly improve cognitive test scores 
(e.g., Mini-Mental State Exam) of AD patients after 3 months of treatment20,21. But 
because these drugs are not disease-modifying agents, the pathology of AD still 
progresses even under treatment. As the etiologies of AD have been re-examined in 
greater detail as the technology has advanced, novel therapeutics have also been 
developed to target those identified etiologies in the hope of reversing the pathogenesis.  
Although several drugs have been developed against the clinically-relevant Tau 
pathology, only immunotherapy has shown promise thus far. Increased 
hyperphosphorylation of Tau in AD promotes production of neurotoxic Tau species and 
is associated with clinical progression. To restore the pTau and Tau balance, drugs like 
tideglusib and lithium chloride have been used to inhibit kinase GSK-3b, and sodium 
selenate has been used to activate PP2A phosphatase activity176-179. To prevent the 
pTau from aggregation and subsequent spreading, methylene blue was found to keep 
pTau monomer in a conformation that inhibits its aggregation180. In addition to these 
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small molecule drugs, another class of drugs developed to remove pTau has been 
immunotherapy. These approaches have included the infusion of monoclonal antibodies 
to specifically block pTau in the patients and inoculating patients with vaccines to elicit 
self-generated antibodies to remove pTau. Among the therapeutics that have been 
developed, immunotherapy, especially passive immunization with monoclonal antibodies, 
was the most promising and is still active in clinical trials.  
The following discussion will focus on the development of immunotherapy for AD, 
from the suppression of general inflammation to the immunotherapy specific for protein 
pathologies including Ab, and Tau.  
 
1.3.1 General suppression of immune responses 
Inflammation is pivotal in the pathogenesis of AD and general suppression of the 
inflammation with non-steroid anti-inflammatory drugs (NSAIDs) is a rational approach. 
The literature has demonstrated that inflammation of the CNS exacerbates proteinopathy 
and these two etiologies jointly promote neurodegeneration in AD. It has been 
hypothesized that suppression of the inflammation in the CNS could curb the worsening 
pathology in AD. NSAIDs such as naproxen are over-the-counter medications that are 
safely used in patients, and could be an ideal candidate to examine this hypothesis.  
Clinical trials have reported that general suppression of inflammation with NSAIDs 
failed to prevent the progression of AD; hence, fine-tuning of a specific inflammatory 
response in AD is needed. The Alzheimer’s Disease Anti-inflammatory Prevention Trial 
(ADAPT) was a randomized clinical trial using either naproxen or celecoxib (a selective 
COX-2 inhibitor) in older adults with AD family history. Both of the drugs failed to prevent 
the cognitive decline compared to the placebo group181. Another clinical trial in Canada, 
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Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer’s Disease 
(INTREPAD), also echoed this result. Naproxen again did not show protection for 
patients from progression to AD but caused adverse side effects182. These data suggest 
that a therapy fine-tuning the immune responses in a more specific way is warranted 
rather than bluntly suppressing the overall inflammation. 
 
1.3.2 Lessons learned from the anti-Ab immunotherapy 
Only one passive immunotherapy using a monoclonal antibody targeting Ab has 
shown promise thus far, after decades of development of Ab-targeting treatments, which 
has prompted researchers to reconsider the primary etiology for AD. The development 
of Ab-targeting therapy started earlier than Tau-targeting treatment. Small molecule 
therapies inhibiting enzymes like b-secretase or g-secretase to reduce Ab production, 
and immunotherapy such as active vaccination or passive antibody to eliminate existing 
Ab assemblies, were developed37,183. One monoclonal antibody therapy against Ab has 
demonstrated its potential and is still active in the clinical trials. Aducanumab is an IgG1 
monoclonal antibody that recognizes both soluble Ab oligomers and insoluble fibrils over 
monomer. A Phase III study of aducanumab, EMERGE (NCT02484547), found a 
significant reduction of cognitive decline and amyloid plaque in patients who received 
high doses of aducanumab compared to patients who received placebo40,41. Based on 
these results, the developers of aducanumab, Biogen and Eisai, submitted a Biologics 
License Application for aducanumab to the FDA.   
Compared to passive immunotherapy, which infuses exogenous monoclonal 
antibody, the vaccine is active immunotherapy that elicits self-generated antibodies 
against pathogens. Previous clinical trials evaluating several Ab vaccine candidates did 
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not reveal significant cognitive improvement in AD patients despite the level of Ab- 
specific antibodies being elevated. Similar disappointing results were also observed in 
clinical trials evaluating monoclonal antibody therapies. These collective suboptimal 
results were partly attributed to the possibility that Ab pathology may be an 
epiphenomenon rather than a significant disease-driving factor37. These data suggest 
that there exists an equally or more critical etiology other than Ab in AD pathogenesis 
and progression.  
The adverse immune response elicited by immunotherapy hampers the progress of 
the treatment. In addition to the therapeutic target issue, immune responses elicited by 
immunotherapy could also bring adverse effects that limit its clinical application. In one 
clinical trial that is evaluating active immunotherapy agent AN-1792 using full-length Ab1-
42, 6% of patients presented with meningoencephalitis, which is inflammation of 
meninges and brain parenchyma. Researchers found the incidence was not associated 
with the induced anti-Ab antibody level, and suggested that activation of T cell and 
microglia by vaccination could be the mechanism behind the inflammation184. An active 
immunotherapy trial sponsored by Novartis also found that 38% of enrolled patients had 
microhemorrhage in the brain185. These adverse effects were not only limited to active 
immunotherapy; brain vasogenic edema and microhemorrhage were also reported in 
patients receiving monoclonal antibody therapy. In one clinical trial evaluating 
bapineuzumab, an IgG1 that targets the N-terminal of Ab, approximately 5–17% of 
patients presented with vasogenic edema in imaging, which led to an increase in patient 
withdrawal from the study186.  
Late recruitment of AD patients for intervention could be solved using advanced 
diagnostic tools for early detection. The reduced protein aggregate-related neurotoxicity 
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provided by therapy may not be able to rescue the global cognitive function resulting 
from the significant neuronal death, as most patients recruited to the trials had an evident 
cognitive decline. The administration of treatment in patients with a milder disease or 
before evident clinical impairment such as mild cognitive impairment could be beneficial 
and is currently under evaluation37,64. Increasingly, novel non-invasive imaging and 
biomarker technologies are being developed and optimized for the early detection of the 
abnormal accumulation of protein aggregates or inflammation in patients’ brains187-189. 
Although the correlation between these diagnostic results and AD progression are still 
under examination, some of these tools, such as amyloid positron emission tomography 
(PET), are currently helping clinicians select suitable prodromal AD patients for clinical 
trials and treatment190. 
In summary, earlier research on Ab-targeting treatment provides insightful lessons 
for AD therapeutic development. First, the limited success of Ab-targeting treatment has 
urged researchers to develop therapeutics against another primary etiology of AD. 
Secondly, adverse immune reactions induced by immunotherapy hampers the 
development of the treatment, which could be due to activated microglia and T cells. 
Lastly, the recruitment of patients with milder symptoms or prodromal patients identified 
by novel diagnostic modalities for treatments could better benefit patients.  
 
1.3.3 Immunotherapy against Tau pathology 
The observation that immunotherapy capable of reducing Ab burden in the brain 
does not benefit patients suggests that other etiologies such as Tau might play a more 
critical role in AD. Accumulating evidence demonstrates the neurotoxicity of Tau 
pathology, its essential role in pathogenesis, and its close association with clinical 
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progression in AD patients. These data suggest Tau pathology as a potential therapeutic 
target, and more clinical trials and preclinical studies are also directing the 
immunotherapeutic development toward targeting the Tau pathology49-52,96,100,105.  
Anti-pTau antibody can block extracellular pTau propagation among neurons, 
although blocking intracellular spreading is under debate. Unlike extracellular amyloid 
plaques, Tau pathology composed of pTau species is mainly an intracellular pathology, 
which is released to the extracellular compartments upon neuronal death. Because pTau 
species exist in both intracellular and extracellular compartments, it will be ideal to 
develop an antibody therapeutic that can block the cell-to-cell propagation as well as the 
intracellular seeding activity. Whether antibodies generated either by active vaccination 
or passive infusion will be capable of entering neurons to target the intracellular pTau is 
still under debate as different groups have demonstrated opposing results; however, 
these antibodies were all shown capable of blocking the propagation of pathological pTau 
species entering neurons191,192.  
Adverse effects intrinsic to immunotherapy have to be solved to unleash the full 
potential of immunotherapy. Although immunotherapy has shown the most promise in 
treating AD patients, some treated patients withdrew prematurely from the studies due 
to adverse immune reactions, including cerebral hemorrhages and inflammation, which 
were found with both active and passive immunotherapies184-186. Passive 
immunotherapy using a monoclonal antibody appears to have a lower safety concern 
compared to active immunotherapy using vaccines, which may explain why there are 
more clinical trials for monoclonal antibodies64. Revealing the mechanism of these 
adverse immune reactions will advance immunotherapy development.  
Immunotherapy-induced adverse immune reactions may stem from the 
engagement of the Fc domains of the antibodies by activating Fc receptors on immune 
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cells. Experience gained from Ab-targeted immunotherapy indicates that activation of 
microglia by immunotherapy could result from the engagement between Fc receptors 
and the Fc region of antibodies. Different Fc domains have distinct affinities to the Fc 
receptors on immune cells: for instance, human IgG1 has a higher affinity for activatory 
Fcg receptor IIA (FcgRIIA) than inhibitory FcgRIIB while IgG4 has a universally low affinity 
for FcgR193. One preclinical study mutated the antibody Fc region and showed a 
diminished microglial activation, highlighting the importance of selecting an optimal 
antibody backbone100. Further information on FcgR will be discussed in Chapter 2.  
The understanding that different antibody Fc domains have distinct binding and 
activation profiles of Fc receptors has had a significant impact on immunotherapy design. 
Monoclonal antibody therapeutics developed previously have had an IgG1 isotype that 
is known to stimulate activating Fc receptors on myeloid cells, including microglia, for 
inflammation. The adverse effects observed in patients receiving IgG1 immunotherapy 
and a better understanding of the Fc receptor biology have led to a shift in the design of 
antibodies. The monoclonal antibodies that are currently active in clinical trials, including 
gosuranemab (BMS-986168, Bristol-Myers Squibb), ABBV-8E12 (AbbVie), and 
semorinemab (RO 7105705, Genentech and ACImmune) are all IgG4191. Their targets 
and current status in clinical trials will be briefly discussed below.  
Gosuranemab targets the residues 9–18 at the N-terminal of a secreted 
extracellular Tau peptide. Extracellular Tau is elevated in familial AD patients, and it was 
shown to facilitate Ab aggregation in vitro. Gosuranemab was found to decrease the 
levels of both Tau and Ab in vivo194. It has completed a Phase I clinical trial and is 
currently in Phase II64. ABBV-8E12 targets the residues 25–30 at the N-terminus of the 
Tau peptide. It was demonstrated to prevent the uptake of Tau aggregates by neurons 
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and the subsequent seeding activity195. Preclinical testing using the P301S Tau-
overexpressing transgenic mouse model showed a reduced level of pTau and improved 
cognitive function196. ABBV-8E12 is now being evaluated for its safety and efficacy in 
early AD patients in a Phase II clinical trial64. The data for semorinemab are limited as 
its epitope has not been disclosed. The target was speculated to be at pSer409 or the 
N-terminus of Tau peptide, and it has completed a Phase I clinical trial64,191.  
In summary, researchers gained much experience during the early development of 
immunotherapy for Ab. The focus has now shifted to Tau-targeting therapy, with 
improved antibody Fc region design to avoid adverse immune reactions. The 
development of Tau immunotherapy is on a rapid rise, and it will be exciting to learn more 
about these antibodies once the results of the clinical trials become available. 
 
1.3.4 Summary of immunotherapy for Alzheimer’s disease 
Past efforts in general suppression of inflammation and Ab-targeting therapeutic 
research have provided invaluable insights into future therapeutic design and 
development, despite their minimal success. The lessons learned from these pioneering 
studies, including treatment timing, target, and adverse effects of immunotherapy, aid in 
the design of better future immunotherapy. Passive immunotherapy using monoclonal 
antibodies is the most promising approach thus far. Antibodies against Tau pathology 
are under active investigation, and their isotype backbones have been carefully selected 
using IgG4 to avoid inflammatory Fc functions. Clinical trials are ongoing to evaluate the 
efficacy of these treatments.  
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Chapter 2: Modulation of Myeloid Cells—a Lesson from Tumor 
Immunology 
AD is a multifactorial disease in which both Tau pathology and inflammation are 
critical in the pathogenesis. Inflammation in AD is dominated by the activated CNS 
myeloid cells and not only accelerates neurodegeneration but also exacerbates Tau 
pathology. A better understanding of the modulation of myeloid cells will enable us to 
alleviate the CNS myeloid cell-induced inflammation and mitigate the pathology in AD.  
Our knowledge of the suppressive myeloid cell populations has been advanced 
significantly by recent cancer immunology research. Breakthroughs in cancer 
immunology have led to a clearer view of regulatory mechanisms of immune cells, 
including myeloid cells. Inhibitory molecules and checkpoint molecules expressed on 
immune cells such as myeloid cells and T cells were discovered to inhibit tumor rejection 
in patients. These discoveries led to the development of a new class of therapeutic 
modalities that are improving the survival of cancer patients197.  
Although successful immunotherapy has become a new paradigm in cancer 
treatment, only selected immunotherapies have provided marginal benefits to AD 
patients, and none of them have succeeded in entering the market191. Previous studies 
used NSAIDs to suppress the inflamed brain in AD but in vain. Passive immunotherapy 
approaches, such as monoclonal antibodies, appear to be promising but is still under 
investigation.  
Leveraging the knowledge from cancer immunology could benefit the development 
of immune-modulating therapeutics in AD. While how to activate suppressive myeloid 
cells for tumor rejection is the focus of cancer immunology, how to inhibit dysfunctional 
activated myeloid cells for neuron preservation is the key in AD. Learning how to release 
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the brake on inflammation will also help us to decelerate it. A better understanding of 
immune regulatory systems in cancer will significantly help researchers to repurpose the 
knowledge to halt the progression of AD.  
 
2.1 Myeloid cells play an essential role in immune suppression in the tumor 
microenvironment  
In contrast to the proinflammatory environment in AD, the tumor microenvironment 
is a suppressive condition contributed to by myeloid cells that keep the inflammatory 
responses, such as tumoricidal effects from effector T cells, at bay. Suppressed or 
suppressive myeloid cells, which include dendritic cells (DCs), myeloid-derived 
suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), are associated 
with poor outcomes in cancer patients and contribute to the treatment resistance in 
cancer immunotherapy198. Understanding the resistance derived from these suppressive 
myeloid subsets will help overcome these treatment barriers in cancer patients. 
DCs are professional antigen-presenting cells (APCs) that specialize in processing 
and presenting antigens, but their stimulatory functions are often compromised in the 
tumor microenvironment. In response to stimuli, DCs upregulate the expression of co-
stimulatory molecules and cytokines to activate T cells. DCs also upregulate the 
expression of chemokine receptors that facilitate their traffic to lymphoid tissue to further 
promote T cell activation.  In cancer environments that are usually hypoxic, low pH, and 
with abundant adenosine, the stimulatory functions of DCs are often impaired199-201. 
MDSCs inhibit the anti-tumoral effects of T cells via various mechanisms, including 
secretion of anti-inflammatory cytokines and the production of reactive oxygen species 
(ROS). MDSCs are immature myeloid cells that are expanded during a chronic 
unresolved inflammatory response such as cancer. MDSC can be further categorized 
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into polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSC (M-MDSCs) 
based on their morphology and phenotype. M-MDSCs, which are phenotypically similar 
to monocytes, suppress T cells in antigen-specific and non-specific ways. M-MDSCs 
secrete the anti-inflammatory cytokines IL-10 and transforming growth factor-b (TGF-b), 
iNOS, and arginase, which combine to inhibit T cell activation. PMN-MDSCs, the other 
form of MDSC, are phenotypically similar to neutrophils and secrete ROS as their major 
pathway to suppress T cells198. Reactive nitrogen species resulting from ROS reacting 
with nitric oxide can directly modify the T cell receptor and prevent it from effectively 
engaging the antigen in the context of MHC (major histocompatibility complex), blocking 
the subsequent activation202.  Moreover, these MDSCs also upregulate co-inhibitory 
molecules such as programmed death-ligand 1 (PD-L1) to further suppress T cell 
activation203.   
Activated macrophages can be generally categorized into two phenotypes, M1 and 
M2, which have distinct immune functions. Macrophages are also professional APCs that 
are responsible for phagocytosis of pathogens and cellular debris, presentation of 
antigens, and secretion of cytokines and chemokines after sensing danger. Based on 
their surface marker and cytokine production profiles, macrophages can be generally 
categorized into classically (M1) and alternatively (M2) activated phenotypes or 
polarizations204. M1 macrophages have a proinflammatory phenotype and are capable 
of pathogen elimination. They secrete cytokines, including IL-1b, IL-6, IL-12, and TNF-a. 
They also upregulate the expression of surface markers such as MHC class II and CD86, 
which is a critical co-stimulatory molecule for T cell activation. M2 macrophages play 
essential roles in tissue repair and cell proliferation. They secrete anti-inflammatory 
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cytokines such as IL-10 and upregulate markers such as the inhibitory scavenger 
receptors CD163, CD204, and CD206205-207.  
TAMs that contribute to the suppression in the tumor microenvironment are similar 
to M2 macrophages and express inhibitory scavenger receptors. The phenotype of TAMs 
resembles the M2 macrophage phenotype206 that suppresses T cells and prevents 
effective tumor rejection208. The density of TAMs, identified by scavenger receptor 
CD163 alone or with CD204, in the tumor microenvironment, is associated with a higher 
histological grade of cancer and poor clinical outcome. Moreover, the CD163 expression 
level of the tumor samples is also closely linked with poor survival209,210. These data 
demonstrated that the scavenger receptors not only have been used to define TAMs and 
M2 macrophages but also have prognostic value in cancer patients. 
In summary, the unfavorable tumor microenvironment that impedes T cell-driven 
tumor rejection is shaped by various suppressive myeloid cells. These suppressive 
myeloid cells can express inhibitory molecules including scavenger receptors that are 
associated with poor prognosis in cancer patients.  
 
2.2 Scavenger receptors on myeloid cells in the tumor microenvironment 
The definition and classification of scavenger receptors have been split in the past 
but were unified recently. Scavenger receptors are not native to cancer research. Their 
activity was first described in cardiovascular and lipid research211, and the name was first 
coined for an alternative receptor that can bind to a modified low-density lipoprotein 
(LDL)212. Later, other structurally similar or functionally similar receptors have been 
discovered and included in this family, which made the definition and nomenclature of 
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scavenger receptors inconsistent and confusing. Recently, a consensus has been 
reached for the definition and the systemic classification of these scavenger receptors.  
Scavenger receptors are defined as “cell surface receptors that typically bind 
multiple ligands and promote the removal of non-self or altered-self targets213.” They 
usually function in adhesion, phagocytosis, endocytosis, and signaling to remove 
substances that are detrimental or degenerated. The mammalian scavenger receptors 
are currently classified into 12 classes213.  
Scavenger receptors are widely studied in cancer immunology. CD163 and CD204 
are commonly used to define suppressive TAMs or M2 macrophages that are associated 
with poor prognosis of cancer patients209,210. FcgRIIb possesses the properties of a 
scavenger receptor and also inhibits anti-tumoral effects214. The following sections will 
discuss the regulation and signaling pathways of these scavenger receptors in driving an 
inhibitory polarization of myeloid cells. 
 
2.2.1 CD163 
CD163 is classified as a Class I scavenger receptor that has three isoforms. 
Structurally, CD163 has nine scavenger receptor cysteine-rich (SRCR) domains in its 
extracellular domain and a short cytoplasmic tail. Three isoforms are generated from 
alternative splicing. The cytoplasmic tail of all three isoforms has a conserved region that 
contains an internalization motif as well as phosphorylation sites for protein kinase C and 
creatine kinase215. The shortest form is the most abundant and is mostly found on the 
cellular membrane. The longer isoforms largely localize in the endoplasmic reticulum and 
Golgi networks and have been suggested to harbor other potential phosphorylation sites 
at the intracellular tail216,217.   
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CD163 is involved in maintaining the balance of the immune system, and its 
expression can be regulated via various immune mediators. It was reported that 
inflammatory regulators like glucocorticoid, IL-10, and IL-6 induce CD163 expression. 
Glucocorticoid receptor binding sites were also found at the CD163 promoter region218. 
Conversely, proinflammatory mediators such as TNF-a and interferon-g (IFN-g) have 
been shown to suppress the expression of CD163 in monocytes219. CD163 expression 
is also regulated by inflammatory stimuli like lipopolysaccharide (LPS). LPS-induced 
TLR4 activation leads to a rapid cleavage of surface CD163 on monocytes by a 
metalloproteinase, which results in a reduced detection of CD163 on the cells in the early 
phase of LPS stimulation220,221. Upregulation and re-expression of CD163 on the surface 
are observed later, which is due to regulatory secretion of IL-6 and IL-10 in response to 
LPS-induced TLR4 activation222. These data demonstrate that CD163 is associated with 
immune homeostasis.  
CD163 is generally believed to be expressed exclusively by monocytes and 
macrophages, especially in the reticuloendothelial system223,224. Consistently, 
macrophages differentiated from monocytes in vitro using macrophage colony-
stimulating factors (M-CSF) also exhibit enhanced CD163 expression219. Other than 
being expressed on myeloid cells, a recent report suggests that CD163 expression can 
also be found on neurons in an intracerebral hemorrhage model in piglets225.  
One of the major functions of CD163 is to remove the extracellular hemoglobin 
released from erythrocytes during either the breakdown of senescent erythrocytes in the 
spleen or hemolysis in the circulation226. The released hemoglobin is rapidly captured by 
haptoglobin, forming a stable hemoglobin-haptoglobin (Hb-Hp) complex to prevent 
oxidative injury resulted from free heme227. The complex is bound to the third SRCR 
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domain (SRCR3) of CD163 and internalized via the endocytosis pathway in monocytes 
or macrophages228. The internalized heme is further degraded by the induced heme 
oxidase-1 (HO-1) that produces ferrous ion (Fe2+), carbon monoxide, and biliverdin229. In 
addition to Hb-Hp, CD163 can also bind to other ligands such as erythroblasts and 
bacteria at the SRCR2 domain and TNF-like weak inducer of apoptosis (TWEAK) at the 
SRCR1-4, 6, and 7-9 domains230,231. Some viruses have also been reported to utilize 
CD163 as a receptor gaining access into the cells for infection232,233.   
CD163 also has immunomodulatory functions, in addition to facilitating ligand 
internalization and degradation in monocyte and macrophages. Engagement of Hb-Hp 
complex to CD163 can lead to the production of anti-inflammatory cytokine IL-10, while 
inhibition of CD163 by an anti-CD163 blocking antibody (clone RM3/1) abolished IL-10 
production. Although Hb-Hp itself may be implicated in contributing to anti-inflammation, 
administration of an agonist anti-CD163 antibody (clone Ki-m8) in the absence of Hb-Hp 
complex also promoted IL-10 secretion in myeloid cells234.  Another study using 
nanoparticle transfection in the human peripheral monocyte cell line THP-1 to 
overexpress CD163 demonstrated that overexpression of CD163 leads to increased IL-
10 and IL-1 receptor antagonist (IL-1ra) production in an LPS-induced sub-acute 
inflammatory condition. Furthermore, these anti-inflammatory cytokine expressions 
could be inhibited by the anti-CD163 antibody (clone RM3/1)235. Since LPS is not a 
known CD163 ligand, and no Hb-Hp complex was present in the experimental system, 
these data suggest that CD163 can regulate inflammatory responses. Although the 
ligand driving CD163 signaling was not determined in the study, TWEAK was postulated 
to be the ligand because its secretion post LPS has been reported235.  Collectively, these 
studies indicate that activation of CD163 skews myeloid cells toward the anti-
inflammatory phenotype to maintain immune homeostasis.  
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CD163 is essential for the role of M2 myeloid cells in hyperresponsive airway 
disease, while its role in AD is less clear. In asthma, M2 myeloid cells also play a crucial 
role in balancing the homeostasis. One study has reported that abundant CD163-
expressing (M2) macrophages are found in asthmatic lungs in patients. Conversely, 
ovalbumin-induced airway hyperresponsiveness and the number of eosinophils were 
greatly reduced in CD163-deficient mice236. Although hemolysis and the generation of 
Hb-Hp complexes were not determined in the study, prominent hemolysis in an airway 
hypersensitivity condition has not been reported. This study supports a critical role for 
CD163 in M2 polarization, contributing to asthmatic airway remodeling. In AD, CD163 
expression on microglia is increased in patients’ brain parenchyma compared to non-AD 
cases237,238. Because CD163 expression is not correlated with the number of Ab or NFT, 
CD163 expression was postulated to be a general reaction to both neuronal debris and 
abnormal extracellular proteins, but not specific to Ab or NFT170. Given the limitations of 
correlational studies, more evidence on the role of CD163 in AD is needed.   
Different ligands or antibodies can lead to distinct signaling pathways following 
CD163 engagement. Interestingly, a proinflammatory response has also been reported 
after CD163 activation. One study that activated CD163 by cross-linking with antibody  
(clone EDHU1) resulted in IL-6, IL-1b and GM-CSF production via calcium mobilization 
initiated by tyrosine kinase phosphorylations in CD163239. This finding indicates that the 
conformation change of CD163 mediated by ligands or antibodies could direct the 
signaling pathways. The exact mechanism of CD163 activation of IL-10 secretion is still 
under investigation. Different ligands may induce distinct signaling of CD163, which 
makes delineating CD163 signal transduction more challenging. 
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In summary, CD163 can bind to various ligands and has anti-inflammatory functions 
in general. Despite phosphorylation sites in the intracellular domain being identified, the 
signaling pathway from CD163 internalization to IL-10 secretion or anti-inflammatory 
responses has not been entirely elucidated. Correlational studies in tumor immunology 
have demonstrated its anti-inflammatory function in myeloid cells, although the role of 
CD163 in AD remains unclear. CD163 is more than a marker reflecting an anti-
inflammatory state, as in vivo as well as ex vivo studies simulating pathologic state in 
other diseases like asthma demonstrated that activation of CD163 modulates M2 
response in myeloid cells. 
 
2.2.2 CD204 
CD204 is a class A scavenger receptor that is predominantly expressed on myeloid 
cells such as macrophages and microglia240. It is a single-pass transmembrane protein 
with its C-terminal on the extracellular side. CD204 is characterized by a homotrimeric 
structure on the cell surface, and each monomer comprises an SRCR, collagen, and 
coiled-coil domain. The SRCR has been shown to bind to dead cells through spectrin241, 
while the collagen domain is the primary binding domain for ligands, including acetyl-
LDL, LPS, fucoidan, and many others240. LPS can promote CD204 expression on 
myeloid cells via its mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) pathway activation242. Other inflammatory mediators like TNF-a 
and IL-6 have also been reported to upregulate CD204 expression on endothelial cells. 
However, how the induced CD204 further modifies the effect of these cytokines on 
myeloid cells is unclear243.  
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CD204 expression is essential in the removal of amyloid plaques in AD. Microglia 
expressing CD204 were observed near amyloid plaques in the brain pathology of AD 
patients244. CD204 is important in microglial adhesion to amyloid plaques, as both fibrillar 
and soluble Ab were found to be ligands for CD204245,246. Accumulation of amyloid 
plaque was considered to be the result of a decrease in the Ab clearance capacity of 
microglia, which have a reduced level of Ab-degrading enzymes in the later disease 
stages. This diminished capacity of microglia might be due in part to the increased 
proinflammatory cytokines that were stimulated by CD36 activation135,247. 
CD204 also has a critical role in immune modulation in AD. In a common mouse 
model used in AD research, the PS1-APP mouse model, decreasing CD204 expression 
is inversely correlated with increasing proinflammatory cytokine IL-1b and TNF-a 
expression as disease progresses135. On the contrary, crossing the CD204 KO (scara-/-) 
mouse with the PS1-APP mouse resulted in increased Ab accumulation and mortality248. 
Collectively, the evidence demonstrates the critical role of CD204 in the clearance of Ab 
and modulation of proinflammatory responses in AD, although subsequent CD204 
signaling in microglia downstream of Ab engagement has not been elucidated.   
The functional output by CD204 activation is as versatile as its ligand collection, 
which might be due to signaling with co-factors. For instance, polyinosinic acid (poly(I)) 
and fucoidan both compete with fibrillar Ab for the binding of CD204245. In a study of 
astrocytes, nitric oxide and IL-1b secretions were significantly induced by the 
engagement of poly(I) to CD204. However, only low levels of secretion were triggered 
by the engagement of fucoidan to CD204. Furthermore, intracellular signaling analysis 
also showed increased phosphorylation of c-Jun N-terminal Kinase (JNK) and ERK in 
the poly(I)-treated group but not in the fucoidan-treated group. This finding demonstrated 
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that CD204 signaling could be significantly affected by the bound ligands and that CD204 
might transduce signals with the help of other co-factors249.   
CD204 regulates inflammatory responses by modulating their signaling. CD204 
does not have a tyrosine residue in its cytoplasmic domain. Instead of activating typical 
signaling through phosphorylation of tyrosine, CD204 was found to induce signaling 
through serine phosphorylation240,250. Furthermore, studies also found that CD204 
associates with other receptors in regulating their signaling. For instance, modification of 
TLR4 signaling by CD204 has been well demonstrated. Typically, activation of TLR4 by 
LPS induces subsequent phosphorylation of IL-1 receptor-associated kinase 1 (IRAK1) 
that recruits TNF receptor-associated factor (TRAF6) for its dimerization and poly-
ubiquitination. The poly-ubiquitinated TRAF6 further forms a complex with TGF-b-
activated kinase 1 (TAK1) and TAK1-binding protein 2 (TAB2) that activate nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) which results in transcription of 
proinflammatory cytokines. CD204 has been shown to compete with phosphorylated 
IRAK1 in binding TRAF6, and thus interrupts the ubiquitination of TRAF6, the subsequent 
NF-kB activation, and cytokine production251.  
In line with its modulatory function on TLR4, CD204 has also been shown to inhibit 
the downstream interferon regulatory factor 3 (IRF-3) pathway and IFN-b secretion252. 
This inhibitory function has implications in cancer in which decreased IFN-b has been 
shown to be critical in restraining lymphoma growth253. Moreover, inhibition of CD204 by 
a small molecule inhibitor or loss of CD204 by genetic knockout was shown to impede 
ovarian and pancreatic cancer invasion and metastases254. Another example of CD204 
co-signaling is its interaction with Mer tyrosine kinase (MerTK) in M2 macrophages. 
MerTK expression is mostly restricted to M2 macrophages, and its expression is 
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inversely associated with prognosis in cancer patients. Activation of MerTK leads to IL-
10 secretion that further maintains the M2 polarization of the TAMs. CD204 was found 
to be essential for the signaling of MerTK, as loss of CD204 led to reduced MerTK 
phosphorylation and function255,256. These data demonstrate that CD204 is more than 
simply a marker denoting M2 macrophages and that it regulates inflammatory responses 
by associating with other receptors and modulating their signal transduction. 
CD204 can induce distinct inflammatory responses following interaction with 
different ligands. Interestingly, CD204 has also been shown to associate with TLR3 and 
TLR9, leading to proinflammatory cytokine secretion257, which again demonstrated that 
CD204 has a versatile capability in modulating immune responses via its association with 
other receptors, in addition to its vast collection of ligands in different diseases. However, 
in pathologic conditions like cancer and AD, in vivo and in vitro studies have established 
the immune inhibitory role of CD204 in their pathogeneses.   
In summary, CD204 binds a variety of ligands, and does not have a typical 
intracellular signaling domain. CD204 was shown to associate with other receptors to 
facilitate or modulate their signaling transduction. In the tumor microenvironment and AD 
brains, the inhibitory role of CD204 has been established both in vitro and in vivo. This 
modulatory capability could result from inhibiting activation of TRAF6-NFkB and IRF3. In 
contrast to the situation where the suppressive role of CD204 in the tumor 
microenvironment leads to a decrease in the desired anti-tumor effect, loss of CD204 
promotes inflammation and exacerbates neurodegeneration in AD. Harnessing the 
immune-modulatory property of CD204 in AD to mitigate the inflammatory damage 




Fcg receptors (FcgRs) have the properties of scavenger receptors. While FcgR was 
not classified as a scavenger receptor in a recent nomenclature consensus workshop213, 
increasing numbers of studies have shown that FcgRs can bind to multiple ligands such 
as modified LDL and Ab in addition to their typical ligand, IgG258,259. According to the 
definition, that scavenger receptors are surface receptors capable of binding various self- 
or non-self-ligands for removal, FcgRs are indeed scavenger receptors.  
FcgRs are critical in both innate and adaptive immunity, while its dysfunction 
contributes to a range of diseases. FcgRs are predominantly expressed on immune cells 
that are critical in defense mechanisms. For example, natural killer (NK) cells and 
neutrophils use FcgRs for antibody-dependent cell-mediated cytotoxicity (ADCC), while 
myeloid cells use FcgRs to facilitate the removal of opsonized cells or substances. Given 
their essential function in mounting an effective host defense, most of the members in 
the FcgR family are activating receptors, the exception being FcgRIIb193,260. Both 
activatory and inhibitory FcgRs are critical in bridging innate immune responses to 
adaptive immune responses. Immune complexes internalized via activating FcgRs on 
DCs preferentially help T cell activation for adaptive cellular responses, and 
internalization via FcgRIIb on DCs favors activation of B cells for humoral responses261. 
Additionally, inadequate or excessive FcgRIIb function can result in autoimmune 
diseases or tumor progression in cancer, respectively214,262,263. Therefore, FcgRIIb acts 
as a checkpoint molecule that has important implications in maintaining immune 
homeostasis. 
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Expression of FcgRIIb, the only inhibitory FcgR, is regulated by cytokines. FcgRIIb 
is predominantly expressed on B cells, basophils, macrophages, and monocytes264,265. 
Other than the expression on immune cells, the expression of FcgRIIb was also found on 
sinusoidal endothelial cells in the liver, smooth muscles in the airway, and neurons in 
brain259,266,267. FcgRIIb is characterized by a C2-set immunoglobulin-related domain in its 
extracellular region, a single-pass transmembrane domain, and an intracellular 
domain265,268. The expression of FcgRIIb is upregulated by cytokines such as IL-4, IL-10, 
and IL-6, and down-regulated by TNF-a and IFN-g269,270.  
Isoforms of FcgRIIb have different internalization efficiency but the same inhibitory 
signaling domain. Two isoforms, FcgRIIb1 and FcgRIIb2, are generated by alternative 
splicing. FcgRIIb1 is mostly found on B cells, while FcgRIIb2 is found on myeloid cells. 
Compared to the rapid internalization property of FcgRIIb2, FcgRIIb1 has a more 
extended cytoplasmic domain that slows the endocytosis of the receptor271. Nevertheless, 
both of the isoforms contain the endocytosis di-leucine signal and an immunoreceptor 
inhibitory motif (ITIM) domain that is critical in regulating immune activation272,273.  
ITIM stimulation down-regulates activating signaling pathways initiated by other 
receptors. When an immunoreceptor activatory motif (ITAM)-containing receptor is 
activated, a tyrosine residue in ITAM is phosphorylated by Src family kinases such as 
Lyn, which results in the recruitment of Syk family kinases that leads to the generation of 
downstream signaling molecules like phosphatidylinositol (3,4,5)-triphosphate (PIP3)274. 
The ITIM can also be phosphorylated by Lyn and another Src family kinase, Blk. However, 
ITIM phosphorylation will preferentially recruit inositol phosphatases Src homology 2 
(SH2) domain-containing inositol polyphosphate 5-phosphatase (SHIP) 1 and 2 that 
degrade the activating signaling molecule PIP3275,276. SHIP is also critical in the 
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recruitment of p62 Dok and subsequently Ras GTPase activating protein (RasGAP) to 
activate Ras GTPase, which will result in ERK inhibition277,278. While the discoveries of 
the signaling pathways were mostly made in B cells, the inhibitory pathways initiated by 
FcgRIIb are also reportedly applicable in myeloid cells193,279. Overall, the balance 
between activating and inhibitory signaling within a cell determines its inflammatory state.  
Similar to the role of other inhibitory scavenger receptors in tumor 
microenvironments, enhanced FcgRIIb expression in the tumor microenvironment is 
correlated with poor anti-tumor responses and the resistance of the tumor to antibody-
based therapy. Genetic removal of FcgRIIb in mouse models resulted in an enhanced 
anti-tumor effect of antibody therapies, while the removal of activating FcgR led to tumor 
progression214. In line with the genetically modified models, blocking FcgRIIb with an anti-
FcgRIIb monoclonal antibody or modifying the Fc region of the therapeutic antibody for a 
better affinity to activatory FcgR have been shown to promote antibody-based cancer 
treatments280,281.  
Harnessing the potential of the regulatory function of the ITIM in an inflammatory 
condition such as AD has not been well established. The idea of manipulating ITIM 
signaling in the inflammatory state in AD is tempting. However, extra caution should be 
taken, because it was reported that FcgRIIb expressed on neurons mediates 
neurotoxicity of Ab259. Ab1-42 binding to FcgRIIb on neurons activates Lyn kinase that 
induces phosphorylation of the receptor, hyperphosphorylation of Tau, and cellular death, 
which are prevented by Lyn inhibition282. These studies demonstrated that activation of 
the FcgRIIb pathway has the potential to exacerbate Ab toxicity and Tau 
hyperphosphorylation in neurons, although inflammatory responses by myeloid cells 
after inhibition by FcgRIIb were not determined. Based on these data, it would be ideal 
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to specifically either promote FcgRIIb on immune cells or to inhibit FcgRIIb only on 
neuronal cells to avoid potential side effects.  
In summary, FcgRs have the scavenger receptor capability of binding to multiple 
ligands for removal, although they are not officially classified as scavenger receptors. 
Among the FcgRs, FcgRIIb is unique due to its inhibitory function. FcgRIIb comprises an 
intracellular ITIM domain which counters ITAM signaling and ERK activation and is 
critical in maintaining immune homeostasis.  The role of FcgRIIb on myeloid cells has 
been widely studied in cancer immunology as it dampens the inflammatory responses 
required for tumor rejection. While it is undesirable in most cancer settings, specific 
FcgRIIb activation in myeloid cells may help to curb the inflammatory responses in AD 
and remains to be explored.  
 
2.3 Summary 
Knowledge gained from tumor immunology has illuminated how myeloid cells in the 
tumor shape a tolerant microenvironment allowing tumor growth, in which upregulation 
and activation of scavenger receptors CD163, CD204, and FcgRIIb on myeloid cells help 
to regulate inflammatory responses. A better understanding of their signal transduction 
pathways will enable us to harness and apply anti-inflammatory properties to other 
inflammatory diseases, such as AD.  
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Chapter 3: Novel Therapeutic—Engineered Monocytes that Efficiently 




AD is a multifactorial disease in which o-Tau and neuroinflammation are both found 
to be highly clinically relevant in accelerating neurodegeneration23,52,102,109. Moreover, 
they are not independent pathogenic entities but intertwined in promoting 
neurodegeneration in AD. Tau pathology stimulates inflammatory responses of myeloid 
cells, and myeloid cells further catalyze the aggravation of proteinopathy (Fig. 1).  
Disturbed generation and clearance of pTau in neurons results in a net elevation of 
intracellular pTau level, which can be caused by various factors such as mutation of the 
MAPT gene, unfavorable alternative splicing, imbalance of kinase and phosphatase 
activity due to conditions like inflammation and acidosis, and other post-translational 
modifications of Tau60,69,70,81,85,86. As pTau builds up and oligomerizes in the neurons, 
loss of the physiologic function of Tau proteins and the presence of the newly formed 
neurotoxic o-Tau together induce synaptic toxicity, impair mitochondrial function, and 
promote apoptotic pathway activation96,97. In addition to exosome dissemination, 
exocytosis, and synaptic transmission of neurotoxic Tau species from neuron to neuron, 







Figure 1: Neurotoxic oligomeric Tau and chronic inflammation jointly perpetuate 
a positive feedback cycle that damages neurons. 
Hyperphosphorylated Tau (pTau) oligomerizes into a higher order of assembly, including 
a neurotoxic Tau oligomer (o-Tau). These Tau species are released extracellularly and 
can be taken up by other neurons to serve as a seed for further Tau aggregation. Myeloid 
cells, like resident microglia and recruited monocytes, can also take up o-Tau but at the 
cost of proinflammatory cytokine secretion. The myeloid cells even lose clearing capacity 
at a later stage of the disease, despite secreting more proinflammatory cytokines. 
Moreover, the proinflammatory cytokines are neurotoxic and further stress neurons, 
promoting phosphorylation of Tau, which feeds forward in a vicious cycle.  
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The presence of o-Tau and its interaction with myeloid cells creates a positive 
feedback loop for abnormal Tau accumulation. Species of o-Tau composed of three or 
more Tau monomers can be taken up by other neurons and induce conformational 
change in normal Tau inside the neurons54,87. Extracellular o-Tau can also be taken up 
by the scavenger cells in the CNS, such as microglia, that try to degrade them using 
lysosomal pathways but with limited effect113,136. At the same time, microglia secrete 
proinflammatory cytokines100,136 that can have an autocrine effect141,142, attract peripheral 
immune cells like monocytes into the CNS111,112, promote further hyperphosphorylation 
of Tau in neurons, and lead to neuronal death108,125. Monocytes are peripheral myeloid 
cells recruited into the brain that can also contribute to the proinflammatory cytokine 
production, although they possess a better ability to phagocytose and degrade o-Tau136. 
In summary, the myeloid cells in the CNS appear to have “good intentions” to clear 
neurotoxic Tau species to protect neurons, but they end up causing more damage to 
neurons and resulting in even more pTau accumulation in the CNS.  
Targeting Tau pathology using an antibody as a strategy to interrupt the feed-
forward loop could instead lead to a stronger inflammation that causes more neuronal 
death. The most promising therapeutic method to date is immunotherapy to block 
proteinopathy propagation, including a monoclonal antibody that targets pTau species 
including o-Tau. However, observed adverse effects like cerebral inflammation and 
microhemorrhage, and limited cognitive improvement in the clinical trials to date, have 
raised concerns with this approach. Causes underlying the adverse effect were attributed 
to the activation of myeloid cells exacerbated by the antibody or vaccine. One group has 
proposed that the key may lie in the Fc domain of the monoclonal antibody used. They 
have demonstrated that an unmodified monoclonal antibody can prevent o-Tau from 
entering neurons and associated neuronal damages in the absence of microglia. When 
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they mimicked the pathological brain by co-culturing microglia with neurons, 
administration of the unmodified antibody activated Fc receptors on the myeloid cells, 
inducing abundant proinflammatory cytokines and further damaging the neurons. In 
contrast, administration of the antibody with a mutated Fc domain that cannot bind FcgR 
not only prevented o-Tau from entering neurons but also significantly reduced 
proinflammatory cytokine secretion from microglia and preserved the co-cultured 
neuron100.  
Mutating the Fc domain of antibody provides a solution to the undesired FcgR 
activation on myeloid cells and the subsequent inflammatory bursts; however, it impairs 
the clearance of the pathologic Tau burden in the CNS. FcgR-mediated endocytosis and 
the subsequent degradation by myeloid cells is a major pathway to clear o-Tau:antibody 
complexes283. Antibodies are also capable of internalization into neurons via FcgRII/III 
and may target intracellular o-Tau for degradation284,285. Therefore, loss of binding to 
FcgRs reduces the intracellular o-Tau targeting efficacy of antibodies.  
In summary, impaired engagement with FcgRs due to antibody Fc modification 
raises concerns of reduced o-Tau:antibody complex clearance in the CNS. Moreover, it 
is unknown whether o-Tau:antibody complexes retain oligomerization capability and 
prion-like activity. The stability of the complexes makes it unclear if o-Tau would 
eventually dissociate from the antibody.  These data indicate that the modification of the 
Fc region of the antibody may not be able to facilitate simultaneous clearance of o-Tau 
and limitation of inflammation, leaving an opportunity for o-Tau to feed the pathogenesis 
cycle again. However, a therapeutic capable of promoting o-Tau clearance while 
dampening proinflammatory activation is not currently available.  
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3.2 The rationale of engineered monocytes stably expressing a chimeric 
scavenger receptor 
Peripheral monocytes have a higher capacity for neurotoxic o-Tau clearance, but 
their inherent inflammatory response limits their use as a treatment. The most neurotoxic 
Tau species, o-Tau, can be found in the CNS even at the early stage of disease96,286. 
Moreover, o-Tau is not only toxic to the neurons directly but also mediates Ab toxicity. 
Peripheral monocytes were demonstrated to have a higher potential for clearing o-Tau 
compared to microglia136. Introducing peripheral monocytes into the brain to aid 
dysfunctional microglia in providing a more efficient o-Tau clearance seems to be an 
attractive approach. However, the observation that o-Tau induces proinflammatory 
cytokine production in peripheral monocytes in vitro supports the idea that the linked 
proinflammatory cytokine secretion after the uptake of o-Tau is also hard-wired in 
peripheral monocytes as well as microglia100. Therefore, recruited peripheral monocytes 
are also capable of aggravating the ongoing inflammation in the brain.  
To decouple the undesired inherent proinflammatory cytokine production from the 
favorable o-Tau clearance capacity of peripheral monocytes would require 
reprogramming the cellular machinery to redirect the engaged o-Tau from activating 
inflammatory responses. From tumor immunology, we learned that anti-inflammatory 
signaling of scavenger receptors on myeloid cells contributes to a dampened immune 
response against tumors in the tumor microenvironment. Unwelcome as it may seem in 
tumor microenvironments, anti-inflammatory scavenger receptors could be leveraged to 
divert peripheral monocytes to calm the inflammation. However, the idea of harnessing 
the anti-inflammatory properties of scavenger receptors to alter the myeloid response to 
o-Tau in AD has yet to be explored.  
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The concept of the chimeric antigen receptor (CAR) involves redirecting the 
recognition of extracellular antigen and strengthening the intracellular signaling. In tumor 
immunotherapy, the engineering and application of CAR-T cells to treat cancer patients 
have been widely studied. CAR-T cells are equipped with an activating signaling domain 
and an artificial receptor composed of an antigen-recognition domain that is usually a 
single-chain variable fragment (scFv) from a monoclonal antibody. This approach 
enables the CAR-T cell to specifically target tumor cells via the scFv and transduce the 
designed functional signals intracellularly to enhance its cytotoxicity, proliferation, or 
cytokine secretion to better eliminate tumor cells. Such an approach has had great 
success in cancer patients, especially in leukemic patients, for a specific range of 
targets287. The CAR concept is not only limited to T cell receptor signaling and T cells. It 
has recently been applied to engineer other receptors, such as TLRs, and has also been 
used in peripheral myeloid cells like monocytes and macrophages288. Very recently, 
another group demonstrated success in treating ovarian cancer in a humanized mouse 
model with engineered CAR-monocytes289.   
The application of cellular therapy is not only limited to cancer. In the 
neurodegeneration field, the idea of adoptive cell therapy has also been tested, although 
the cells were not engineered to express CAR. Researchers intravenously infused 
peripheral monocytes overexpressing an Ab degrading enzyme neprilysin into an AD 
mouse model in vivo. Although the availability of the engineered monocytes to migrate 
into the brain was limited due to entrapment in the peripheral organs, Ab deposits in the 
brain were reduced171. These data gave support to the concept of CAR technology and 
engineering peripheral monocytes, and their potential application in AD. However, the 
idea of a chimeric scavenger receptor (CSR) has not been examined, let alone in AD.  
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3.3 Specific aims 
Tackling a multifactorial and complex disease like AD requires a multipotent 
therapeutic. Previous efforts by others have allowed us arrive at a vantage point where 
we can consider the two clinically-relevant factors, o-Tau and neuroinflammation, that 
jointly catalyze neurodegeneration in AD. More importantly, the history of the rise and fall 
of therapeutics in pursuit of curing AD has provided invaluable lessons that help reorient 
our focus on a better target when designing a next-generation therapeutic. A therapeutic 
capable of simultaneously resolving more than one etiology, or circumventing 
deterioration of other etiologies, is urgently needed yet does not exist. Thus, there is an 
unmet need for a novel therapeutic that catalyzes o-Tau degradation without triggering 
neurotoxic proinflammatory cytokine release from the CNS myeloid cells.  
Here, we introduce the entirely novel concept in AD treatment of integrating the 
superior o-Tau clearing capability of peripheral monocytes with the anti-inflammatory 
potential of scavenger receptors. We propose to leverage CAR technology to engineer 
monocytes expressing CSR that are capable of efficient internalization of o-Tau without 
inflammatory activation upon o-Tau clearance.  We hypothesize that monocytes 
engineered to bind and internalize o-Tau via antibody-redirected CSR will halt the 
progression of AD by protecting neurons from o-Tau-mediated neurotoxicity, while 
dampening proinflammatory cytokine release. This hypothesis will be addressed by the 
following aims:  
Aim 1. Construct a functional CSR composed of an M2 scavenger receptor and 
anti-o-Tau scFv, and demonstrate stable surface expression by monocytes. 
Aim 2. Assess the capacity of CSR monocytes to internalize and degrade o-Tau 
with limited inflammatory cytokine release and investigate the mechanisms 
of o-Tau internalization and degradation. 
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Aim 3. Determine the capacity of CSR monocytes to halt the progression of 
neurodegeneration both in vitro and in a preclinical model of AD. 
 
3.4 The innovation of engineered monocytes stably expressing chimeric 
scavenger receptors 
This proposed idea is conceptually innovative because it simultaneously targets 
critical etiologies of AD, inflammation, and Tau pathology. As illustrated earlier, previous 
efforts focusing on a single etiology such as targeting Aβ proteins with monoclonal 
antibodies or vaccines, or curbing inflammation by NSAIDs, failed to show clinical 
benefit37,181,182. Trials of monoclonal antibodies against the more clinically-relevant Tau 
pathology have yet to report positive findings in the clinic290. Moreover, the antibody 
approach has been shown to induce undesired inflammatory responses. Modification of 
the Fc domain of the monoclonal antibody to prevent inflammation in turn impairs the 
clearance of pTau100.  
Our innovative CSR approach is an interdisciplinary integration of the knowledge 
from both tumor immunology and AD. We adopt an scFv based on an anti-pTau antibody 
with validated potential to limit o-Tau induced neurodegeneration in an AD mouse model 
in our CSR design. This design not only serves to enhance the clearance of neurotoxic 
o-Tau but also redirects monocyte responses by signaling through anti-inflammatory 
scavenger receptors. The invention of CSRs incorporating an scFv, in this case with 
specificity for o-Tau, is technologically innovative and has never been previously 
reported. Our concept aims to not only attenuate Tau pathology but also to overcome 
the accompanying inflammation, an overarching challenge in the AD field.  
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Adoptively transferring engineered cell therapy via an intracerebroventricular (ICV) 
route is an innovative concept in AD. Injections through ICV devices are safe and widely 
used in the clinic and well tolerated by patients. Their current use has been mostly limited 
to delivering chemicals such as chemotherapy or antibiotics291. To prevent the undesired 
entrapment of the engineered cells during in vivo delivery observed in other studies171, I 
propose to adoptively transfer the engineered cells into cerebral ventricles via an ICV 
device for efficient delivery. As proof of this concept, I have successfully performed 
repeated infusions via an ICV device in mice without significant complications in vivo. 
Transferring cell therapy via an ICV device to avoid off-site loss as well as side effects, 
and to improve delivery efficiency would be a pioneering advance in AD. 
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Chapter 4: Methods 
4.1 Experimental animals 
Male and female C57BL/6J mice, as well as male P301S mice and female non-
carrier mice on a C57BL/6 x C3H/HeJ background, were obtained from The Jackson 
Laboratory (Bar Harbor, ME). The carrier status of the P301S mice was confirmed by 
genotyping. The mice were housed according to the Association for Assessment and 
Accreditation of Laboratory Animal Care and NIH standards. All experiments were 
conducted per the protocols approved by the University of Texas MD Anderson Cancer 
Center Institutional Animal Care and Use Committee.  
 
4.2 Cell lines and media  
The mouse peripheral monocyte/macrophage cell line PMJ2-PC was obtained from 
the American Type Culture Collection (ATCC) and maintained in 10% fetal bovine serum 
(FBS) in RPMI media (GE Health) supplemented with L-glutamine (Gibco) and penicillin– 
streptomycin (Gibco). The cells were detached from the flask using 0.05% Trypsin 
(Gibco).  Dr. Jim Ray, at the Neurodegeneration Consortium, generously provided the 
BV2 microglial cell line. The BV2 cell line was maintained in 5% FBS in DMEM 
supplemented with L-glutamine and penicillin–streptomycin. The cells were dissociated 
from the flask with 2 mM of EDTA (Promega) in phosphate-buffered saline (PBS).  
Primary hippocampal neurons were plated using Neurobasal plating media (10% 
FBS in Neurobasal media (Thermo Fisher) supplemented with B27 (Gibco), L-glutamine 
(Corning), and penicillin–streptomycin). The neurons were maintained in Neurobasal 
feeding media (Neurobasal media supplemented with B27, L-glutamine, and penicillin–
streptomycin)292.  
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4.3 Oligomerization and isolation of Tau 
Drs. Ines Moreno-Gonzalez and Claudio Soto of the Department of Neurology at 
the University of Texas McGovern Medical School generously provided Tau and the 
equipment necessary to extract, oligomerize and isolate o-Tau. The process could not 
have been done without the help of Mr. Nicolas Mendez in the laboratory of Drs. Moreno-
Gonzalez and Soto.  
Human full-length Tau (2N4R) was produced by Escherichia coli from Tau40 
expression plasmids. Protein content was extracted using ammonium sulfate (Sigma-
Aldrich), and the Tau was isolated by size exclusion chromatography (SEC) using an 
AKTA Pure (Cytiva) with a HiTrap SP HP cation exchange chromatography column 
(Cytiva). The product collected was further dialyzed into a buffer containing 10 mM of 
HEPES and 100 mM NaCl, pH 7.4. The monomeric Tau was collected in the supernatant 
after centrifugation. The concentration was determined using the Pierce BCA 
(Bicinchoninic Acid) Protein Assay (Thermo Fisher) before the monomeric Tau stock was 
stored at -80 °C.  
To oligomerize Tau, 25 µM of high molecular weight Heparin (Sigma-Aldrich) was 
added to 50 µM of 2N4R monomeric Tau. The mixture was incubated at 500 rpm, 37 °C 
for 16 hours using a thermomixer (Eppendorf). The mixture was passed through 0.2 µm 
filter (Millipore) to remove large insoluble aggregates before it was injected into the SEC 
Superdex 200 10/300 GL chromatography column. The proteins were eluted with PBS, 
and the fractions containing o-Tau were collected. The collected fractions were further 
passed through a 0.2 µm filter to remove potential microbial contamination. The o-Tau 
fractions were then snap-frozen in liquid nitrogen and stored at -80 °C.  
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The concentration was determined using BCA, and the molar concentration was 
calculated based on the molecular weight of a Tau monomer87. The endotoxin level in 
the o-Tau fractions was also determined by using the Pierce Chromogenic Endotoxin 
Quant Kit (Thermo Fisher). 
 
4.4 Design and synthesis of chimeric scavenger receptor constructs  
The coding sequence sequences of murine FcgRIIb, CD204, and CD163 were 
acquired from the Consensus of Coding Sequence (CCDS) database and UniProt 
database293. The natural ligand-binding domains of these scavenger receptors were 
removed (CD204 and CD163) or modified (FcgRIIb), and replaced with an scFv that can 
limit o-Tau propagation.  
To provide proof-of-concept for our CSR, we used an anti-pTau monoclonal 
antibody that has been shown to effectively limit o-Tau propagation in vitro to build our 
scFv100,294. An anti-pTau affinity-matured variant of the antibody with a Kd 5.2 nM was 
selected, and the amino acid sequences of the variable regions of the heavy and light 
chains were used in our CSR design. To generate the scFv, the heavy chain variable 
region and the light chain variable region were connected with a linker. The scFv was 
further linked to the modified scavenger receptors with a hinge. To obtain the coding 
sequence of the CSR, the amino acid sequence of the scFv was converted to codons 
and integrated with the coding sequence of the modified scavenger receptors.  
The coding sequence of the CSR was further optimized for a more stable 
transcription and higher translation by using an online codon optimizer (Integrated DNA 
Technologies). The sequences were further edited to accommodate restriction enzyme 
sites at the ends of various functional domains using Serial Cloner 2.6. The finalized 
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constructs of CSR were synthesized into pUC57 plasmids by a commercial service 
provider (GenScript). 
 
4.5 Cloning of the chimeric scavenger receptor constructs into retroviral vectors 
To clone the designed constructs into the retroviral vector pMG-Neo containing the 
ampicillin selection gene, synthesized plasmids containing the designed FcgRIIb-CSR, 
CD204-CSR, or CD163-CSR in pUC57 plasmids were enzymatically digested using 
PspOMI and XhoI (NEB). The pMG-Neo vector was digested with NotI and SalI (NEB). 
The digested products were separated in a 0.8% agarose gel by electrophoresis. The 
bands containing the constructs or the vector were individually isolated with a new 
scalpel for each band.  DNA was extracted from the gel using the GeneJET Gel 
Extraction Kit (Thermo Fisher), and the amount and quality of the extracted DNA were 
determined using a Nanodrop Spectrophotometer (Thermo Fisher). Ligation reactions 
with T4 Ligase (NEB) were set up with a construct to vector molar ratio of 1:3, 1:6, and 
1:10. After 2 hours of incubation at room temperature, competent E. coli cells with a low 
recombination rate (NEB) were transformed with the ligation products. The transformed 
cells were plated on ampicillin selection agar plates and incubated at 30 °C overnight. At 
least five ampicillin-resistant clones were picked per plate and expanded for diagnosis. 
For the cloning of FcgRIIb-CSR and FcgRIIb2-CSR into the pMG-YFP retroviral vector, 
the protocol was the same as described above except that the digestion enzymes used 
were NotI and XhoI (NEB). 
The successful cloning was confirmed by restriction enzyme digestion, and its 
accuracy was further validated by Sanger sequencing. The bacterial clones with correct 
sequences were further expanded on a larger scale. The plasmids were extracted using 
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the Macherey-Nagel Maxiprep Kit (Fisher Scientific), and its accuracy was again verified 
by both restriction enzyme digestion and Sanger sequencing.   
 
4.6 Verifying the chimeric scavenger receptor cloning products 
Plasmid DNA from the expanded bacteria was extracted using the ZR Plasmid 
Miniprep Kit (Genesee Scientific) or Maxiprep kit. The plasmids were digested with 
different combinations of restriction enzymes, such as NotI with StuI or SphI with MfeI 
(NEB). The digested products were loaded onto a 0.8% agarose gel. After 
electrophoresis, the gel was imaged by using the ChemiDoc gel imaging system (Bio-
Rad).  
To further verify the accuracy of the genetic material transfer during cloning and 
expansion in the competent E. coli cells, the extracted plasmids were also examined by 
Sanger sequencing performed by the Sequencing and Microarray Facility at the 
Department of Genetics at UT MD Anderson Cancer Center. All the plasmids needed to 
have accurate sequence alignments in both forward and reverse sequencing before they 
were used in the transduction.  
 
4.7 Modular modification of chimeric scavenger receptor constructs 
The restriction enzyme sites at the ends of different functional domains in the CSR 
were designed to enable removal of a specific domain sequence or swapping for another 
functional domain. In the initially-designed CD163-CSR, the cassette domain was 
removed using restriction enzyme MscI (NEB) digestion of the pUC57-CD163-CSR 
plasmid. The remaining part of the plasmid was extracted from the gel and ligated using 
T4 Ligase using the cloning method described above. The successful bacterial clones 
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were selected and their sequence accuracy was determined with enzyme digestion as 
well as sequencing.  
The intracellular domain containing the FcgRIIb1-specific sequence was removed 
from the pUC57-FcgRIIb-CSR plasmid by enzymatic digestion with MfeI and XhoI. The 
DNA was extracted and ligated with the FcgRIIb2-specific sequence using T4 Ligase. 
The ligated product was used to transform competent E. coli cells, and the newly 
generated pUC57-FcgRIIb2-CSR plasmid was confirmed by restriction enzyme digestion 
as well as Sanger sequencing. Both of the modified plasmids were further used for 
cloning into retroviral vectors, as described above. 
 
4.8 Transduction of peripheral monocytes  
The retroviral vectors pMG-Neo containing FcgRIIb-CSR, CD204-CSR, or CD163-
CSR were packaged along with the envelope plasmid (pCI-VSV-G) and packaging 
plasmid (pKF3RSV*GP) using TransIT-293 transfection reagent (Mirus Bio). Phoenix GP 
cells were transfected to produce viral particles. The viral particles were collected 48 
hours post-transfection and were used to transduce the peripheral 
monocyte/macrophage cell line PMJ2-PC in a 6-well plate. Polybrene (Sigma-Aldrich) 
was used to facilitate the uptake of the viral particles by the cells. The cells were then 
centrifuged at 1,363 rcf for 2 hours at 32 °C before they were incubated at 37 °C.  
The cells were transferred to T25 flasks 3 days after the transduction, and cytotoxic 
antibiotic G418 (Gemini Bio) was added at 1 mg/mL to enrich the successfully transduced 
clones. The cells were frozen after they underwent the selection process for at least two 
more passages. Whenever the cells were recovered from freezing, they underwent 
another cycle of selection before the experiments started.  
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4.9 Verification of successful transduction 
Either parental or transduced monocytes were fixed in fixation buffer (Life 
Technologies) overnight at 4 °C and washed with permeabilization wash buffer. A total 
of 5 x 104 cells of each cell type were resuspended in PBS and plated on microscope 
slides using a CytoSpin (Thermo Scientific) at 2,000 rpm for 5 minutes. The cells were 
permeabilized with 0.1% Triton X-100 and stained with a mouse anti-histidine tag primary 
antibody (HIS.H8, Thermo Fisher), then labeled with donkey anti-mouse IgG-Alexa Fluor 
594 (Invitrogen). Prolong-Gold with DAPI mount (Invitrogen) was applied. The cells were 
then imaged using a Leica SP8 confocal microscopy at the Advanced Microscopy Core 
at UT MD Anderson Cancer Center.  
 
4.10 Determination of proinflammatory cytokine secretion by the engineered 
monocytes 
Either parental or engineered monocytes were stimulated with o-Tau in a 96-well 
plate for 24 hours. The supernatant was collected after the plate was centrifuged. The 
supernatant was frozen and stored at -80 °C. Later, the supernatant was thawed on ice, 
and the cytokines were detected using the Cytometric Bead Assay and LSRII flow 
cytometer (BD Biosciences) or ELISA kit (Thermo Fisher). The standard curve for each 
cytokine measured was generated by five-parameter logistic regression using Graphpad 
Prism 8.0. The cytokine concentrations were then calculated using the standard curves. 
 
4.11 Determination of oligomeric Tau uptake by the engineered monocytes 
Either parental or engineered monocytes were stimulated with o-Tau in a 96-well 
plate for 24 hours. The cells were washed with PBS three times before being lysed by 
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RIPA Lysis and Extraction buffer with both Proteinase and Phosphatase inhibitors 
(Thermo Fisher). After 5 minutes of lysis on ice, the lysate was centrifuged at 14,000 rcf 
for 15 min. The supernatant containing the protein extract was transferred to a new 1.5 
mL Eppendorf tube and snap-frozen in liquid nitrogen. The frozen extract was stored at 
-80 °C for later quantification experiments.  
On the day of the quantification experiment, the extract was thawed on ice. The 
protein content was determined by using BCA. Without boiling, an equal amount of 
protein from each extract was loaded to a precast 4–15% protein gel (Bio-Rad). After 
electrophoresis at 100 V for 90 min, the gel was transferred to nitrocellulose paper (Bio-
Rad). The blot was blocked with 5% bovine serum album (BSA) in 1% PBST (1% Tween-
20 in PBS). o-Tau was detected by using anti-o-Tau (T-22) antibody (EMD Millipore)295, 
and a secondary goat anti-rabbit Ig antibody conjugated with horseradish peroxidase 
(HRP) (Abcam). b-Actin was detected with an anti-b-Actin antibody–HRP (Abcam) in a 
subsequent staining of the same blot. After development with Pierce ECL Western 
Blotting Substrate (Thermo Fisher), the blot was imaged using the ChemiDoc gel imaging 
system (Bio-Rad). Band volume and mean intensity were quantified using the software 
included in the imaging system. 
 
4.12 Determination of oligomeric Tau internalization by the engineered monocytes 
Either parental or engineered monocytes were stimulated with 125 nM of o-Tau in 
a 96-well plate for various lengths of time. After incubation with o-Tau for the specific 
duration, half of the FcgRIIb-CSR monocytes were washed with acidic buffer (pH 3) to 
remove o-Tau binding from the scFv of CSR on cellular surfaces296. The other half of the 
monocytes were washed with PBS to retain both surface-bound and intracellular o-Tau. 
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The cells were lysed, and their o-Tau level was quantified using the method described in 
4.11.  
 
4.13 Determination of o-Tau clearance by the engineered monocytes  
To determine the o-Tau remaining in the supernatant using Western blot, either 
parental or engineered monocytes were stimulated with 500 nM of o-Tau in a 96-well 
plate for 24 hours in serum-free media. The supernatant was collected and snap-frozen 
in liquid nitrogen before stored at -80 °C. On the day of the Western blot experiment, the 
supernatant was thawed on ice and loaded to a precast 4–15% protein gel (Bio-Rad) 
with an equal amount of protein from each experimental condition. After electrophoresis 
and transfer of the gel onto a nitrocellulose membrane, o-Tau was detected using an 
anti-o-Tau T-22 primary antibody (EMD Millipore) and a goat anti-rabbit Ig secondary 
antibody–HRP. The blot was imaged and quantified using the ChemiDoc gel imaging 
system (Bio-Rad) developed with Pierce ECL Western Blotting Substrate (Thermo 
Fisher).  
Remaining supernatant o-Tau was also analyzed by ELISA: in an independent 
experiment, engineered monocytes were stimulated with 500 nM of o-Tau in FBS-
containing RPMI media for 24 hours before the supernatant was collected and frozen. 
Later, the supernatant was thawed on ice, and o-Tau was determined using the total Tau 
ELISA kit (Thermo Fisher) and an absorbance reader (SpectraMax M2, Molecular 
Devices).   
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4.14 Harvest of primary mouse hippocampal neurons and their culture in vitro 
The following procedures were modified from those published by Seibenhener et 
al.292. The day before the harvest of primary neurons, the wells of the culture plate were 
coated with 150 µL/cm2 of sterile rat-tail Type I collagen (150 µg/mL, Corning) and poly-
D-Lysine mixture (50 µg/mL, Millipore Sigma). The plate was incubated uncovered under 
UV light at room temperature overnight. The plate was then washed with Hank’s 
Balanced Salt Solution (HBSS, Cytiva) twice, and each well was filled with HBSS to 
prevent drying. The plate was covered and could be used immediately or stored at 4 °C 
for later use.  
E18–E19 C57BL/6J pups were retrieved and decapitated immediately after the 
pregnant mouse was euthanized. The heads of the pups were briefly immersed into 70% 
ethanol and rinsed with PBS before being transferred to a plate with sterile PBS on ice. 
The skull and the meninge were removed from the pup’s brain under dissection 
microscopy. The brain was divided into two hemispheres in which the hippocampi were 
revealed and isolated. All the hippocampi were collected into a plate with sterile PBS on 
ice. The hippocampi were minced with a sterile scalpel and transferred into a 15 mL 
conical tube. The minced tissues were incubated with trypsin (Gibco) at a final 
concentration of 0.05% at 37 °C for 15 minutes. Tissues were washed with HBSS three 
times. A fire-polished Pasteur pipette was used to triturate the masses. The supernatant 
was collected and transferred to a new tube before the cells were spun down. The cells 
were resuspended with the Neurobasal plating media. An automatic counter determined 
the density of the cells right before plating.  
On the first day in vitro (DIV), an equivalent volume of serum-free Neurobasal 
feeding media was added to the well. On the third DIV, 50% of the media was replaced 
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with Neurobasal feeding media and Cytarabine (Cayman Chemical) at the final 
concentration of 5 µM was added to inhibit microglial proliferation. Thereafter, 50% of the 
media was replaced with Neurobasal feeding media every 4 days until the 14th DIV. 
 
4.15 Imaging co-cultured neurons with confocal microscopy 
A glass microscope coverslip was disinfected with 70% ethanol and air-dried before 
being placed into the well of a 6-well plate. The sterile coating described in 4.14 mixture 
was added to the well (150 uL/cm2) and incubated under UV overnight at room 
temperature. The coated glass slip remained in the well during and after washing away 
the excess coating mixture. Primary neurons were harvested, and 2.0 x 105 cells were 
plated and cultured using the method detailed in 4.14.  On the 14th DIV, 5.0 x 105 cells 
of either parental or engineered monocytes were plated in addition to 500 nM o-Tau. The 
co-culture plate was incubated at 37 °C. After 72 hours incubation, the plate was washed 
with PBS and cells were fixed with 4% formaldehyde. The cells were then permeabilized 
with 0.1% Triton X-100 and stained with a primary mouse antibody targeting microtubule-
associated protein 2 (MAP2, Invitrogen), then detected by a donkey anti-mouse 
secondary antibody conjugated with Alexa Fluor 555 (Thermo Fisher). The glass 
coverslips holding neurons were flipped over to a microscope slide after applying 
Prolong-Gold mountant (Invitrogen). The slides were then imaged using SP8 confocal 
microscopy at the Advanced Microscopy Core at UT MD Anderson Cancer Center.  
 
4.16 Imaging co-culture neurons with a high-throughput Operetta imager 
An Operetta imager compatible, clear-bottom 96-well plate with black walls (Corning) 
was coated using the method described in 4.14. Primary hippocampal neurons were 
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plated at a density of 1.5 x 104 cells per well and maintained in vitro as described in 4.14. 
On the 14th DIV, 3.0 x 104 or 6.0 x 104 cells of specific monocytes, in addition to 500 nM 
of o-Tau, were added and incubated at 37 °C. After 72 hours of incubation, the plate was 
fixed and stained with a primary antibody specific for MAP2, then detected with a donkey 
anti-mouse secondary antibody conjugated with Alexa Fluor 555, as in the co-culture 
prepared for confocal imaging (4.15). After the last wash, the wells were filled with PBS, 
and the plate was imaged using an Operetta imager at the Neurodegeneration 
Consortium and the Institution of Applied Cancer Science (IACS) at UT MD Anderson 
Cancer Center. Nine fields around the center of each well were systemically imaged.   
 
4.17 Surgical installation of the intracerebroventricular port 
The ICV port is a device that can be connected to a plastic or silicone catheter. 
During installation, the ICV port was first linked to a plastic catheter 2.0 cm in length and 
was flushed with PBS to remove the gas inside the lumen. After the mouse was 
anesthetized using gaseous isoflurane, the hair over the dorsal scalp and anterior back 
were shaved before the skin was disinfected with povidone-iodine. A mid-line skin 
incision of 8.0 mm was made on the scalp with a scalpel to expose the skull surface. The 
periosteum around 1.0 mm right lateral to the Bregma was gently scratched with a needle 
to create a bony surface area 6.0 mm in diameter. A burr hole on the skull was made 
manually at the point 1.0 mm right lateral and 0.5 mm posterior to the Bregma with a 27G 
needle. A subcutaneous pocket in the back was created using a blunt dissection method 
with a scissor.  The degassed ICV port was attached with a catheter that was placed to 
the burr hole and fixed with superglue297. The port was held in place for 1–2 minutes to 
allow drying of the glue.  
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After the ICV port was secured in place, a Hamilton syringe filled with PBS was 
connected to the end of the catheter and 6 uL of PBS was infused over 1 minute to 
examine the patency and potential leakage of the ICV port. After the removal of the 
syringe, the end of the catheter was sealed using a cauterizer. The catheter was further 
stored into the previously-created subcutaneous pocket. The wound was closed with a 
matrix suture using 5-O nylon thread, and the mouse was placed under a heat lamp for 
recovery. After periodically monitoring the wound for 1 week postoperatively, the stitches 
were removed on day 7. The wound was monitored for another week to ensure its healing.  
 
4.18 Surgical procedure for infusion of engineered monocytes via the 
intracerebroventricular port 
After the wound from the ICV port installation surgery was healed, the mouse was 
ready for infusion via the ICV port. The mouse was anesthetized under gaseous 
isoflurane. The hair on the back was shaved to create an adequate surgical area to 
access the tip of the catheter stored in the subcutaneous pocket. Povidone-iodine was 
used to disinfect the surgical field, and a 2.0 mm incision was created using a scissor. 
The tip of the catheter was exposed and rested on a povidone-iodine pad. The sealed 
end of the catheter was removed with a scissor, and a Hamilton syringe pre-filled with 
monocyte suspension (3.33 x 104 cells/μL) was connected to the catheter. The monocyte 
suspension (3 μL) was infused slowly over 1 minute before the Hamilton syringe was 
disconnected. Another Hamilton syringe pre-filled with PBS was connected to the 
catheter, and 3 μL of PBS was infused slowly over 1 minute.  
The tip was sealed with a cauterizer after the second Hamilton syringe was removed. 
The sealed catheter was stored back into the subcutaneous pocket by retracting the 
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catheter into the previously-created 2.0 mm incision. The wound was then closed with a 
simple suture using 5-O nylon thread or autoclip, and the mouse was placed under a 
heat lamp for recovery. The wound was monitored periodically for a week to ensure 
healing without complications. 
 
4.19 Statistical analysis and illustration 
The difference in cytokine secretion, cell-associated o-Tau, and cellular viability 
across different groups was determined using an unpaired Student’s t-test. The 
association between cytokine production with either o-Tau stimulation concentration or 
cell-associated o-Tau level was established using the Pearson correlation test and linear 
regression. The statistical analysis was performed using GraphPad Prism 8.0. The 
figures and illustrations were created with GraphPad Prism 8.0 and BioRender.com.  
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Chapter 5: Engineered Monocytes are Neuroprotective through 




More than a disease of proteinopathy, AD is also a disease of chronic 
inflammation23. Microglia are the principal innate immune cells in the CNS responsible 
for the phagocytosis and degradation of waste products, including pTau assemblies113. 
As AD progresses, microglia lose their capacity for pTau clearance but secrete more 
proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6100,115. Although peripheral 
monocytes recruited into the CNS retain the ability to clear pTau assemblies111,136,171,175, 
they also release proinflammatory cytokines in response. The reactive microglia and the 
recruited monocytes, along with their secreted proinflammatory cytokines, in return, 
accelerate the progression of Tau pathology and cognitive decline (Fig. 1)85,125,147-149,160. 
Breaking the vicious cycle between these two pathologies provides a novel approach to 
halt AD progression by stopping the accumulation of pTau and limiting 
neuroinflammation.  
We apply knowledge gained from tumor immunology and immunotherapy of AD to 
propose the concept of engineered peripheral monocytes that preferentially target o-Tau 
but limit subsequent proinflammatory polarization. We hypothesize that monocytes 
engineered to bind and internalize o-Tau via antibody-redirected CSR will halt the 
progression of AD by protecting neurons from o-Tau-mediated neurotoxicity while 
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dampening proinflammatory cytokine release. This chapter will demonstrate the proof of 
this novel concept in detail and provide supporting evidence for our hypothesis.  
 
5.2 Results 
5.2.1 Myeloid cells secrete proinflammatory cytokines upon stimulation by Tau 
assemblies. 
The presence of activated microglia in AD brain pathologies is well-documented in 
the literature1. It has also been demonstrated that resident microglia are activated when 
they are stimulated with o-Tau in vitro100. In addition to microglia in the CNS, 
accumulating evidence indicates that peripheral monocytes infiltrate the CNS in AD, 
partly due to the chemokines and cytokines secreted by the activated microglia112. It has 
been shown that peripheral monocytes have a better o-Tau uptake capacity compared 
to microglia136. However, it is unclear if peripheral monocytes have a similar 
proinflammatory response to o-Tau to microglia, or if they can attenuate the inflammatory 
condition in the CNS.  
The goal of this experiment was not to determine a specific Tau species that 
stimulates myeloid cells but to determine the myeloid responses to Tau assemblies in 
general. Therefore, after the Tau assemblies were oligomerized following a published 
protocol87, they were not further fractionated using SEC.  
After stimulation by Tau assemblies for 72 hours, both bone marrow-derived 
peripheral monocytes and a microglia cell line secreted more proinflammatory cytokine 
TNF than unstimulated cells (Fig. 2). In contrast, the anti-inflammatory cytokine IL-10 
level was below the detection limit of the assay (data not shown). The results support the 
concept that peripheral monocytes exhibit a proinflammatory cytokine profile in response 
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to Tau, which is similar to their CNS counterpart, microglia. Peripheral monocytes were 
shown to be capable of enhanced uptake and degradation of Tau species136, but still at 
the cost of exacerbating inflammation100. This experiment suggests that peripheral 




Figure 2: Proinflammatory cytokine production by myeloid cells upon stimulation 
by Tau assemblies. 
Primary bone marrow-derived monocytes and a microglial cell line (BV2) were stimulated 
with either PBS or Tau assemblies (8  µM) for 72 hours before their absolute TNF 
secretion level (A) was determined using the Cytometric Bead Assay, and further 
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5.2.2 Purification of oligomeric Tau 
A range of Tau species of various degrees of aggregation are found in both the 
samples collected in vivo and Tau assemblies induced in vitro298. This continuum 
represents a dynamic reaction between monomers, oligomers, and higher-order fibrils. 
In the spectrum of Tau assemblies, it is o-Tau, rather than Tau fibrils or monomers, that 
is most neurotoxic and causes synaptic dysfunction and activation of the apoptosis 
pathway in vivo96. Others have also demonstrated that o-Tau impairs the integrity of 
primary hippocampal neurons in vitro100. Together with the evidence that Tau pathology 
is closely associated with disease progression, it is believed that o-Tau plays a critical 
role in the pathogenesis of AD102.  
To study the precise effect of this neurotoxic Tau species, it is imperative to isolate 
it from the rest of the pTau assemblies. Oligomerization of the Tau repeat domain, as 
well as its isolation protocol, have been established by others previously87. Together with 
Mr. Nicolas Mendez and Dr. Ines Moreno-Gonzalez, we have further optimized the 
protocol in our institution to maximize the yield of full-length o-Tau.  Briefly, the full-length 
(2N4R) Tau monomer was isolated from E. coli transformed with the Tau40 plasmid and 
purified using a cation exchange chromatography column. Oligomerization of Tau 
monomer was induced by high molecular weight heparin and incubated at 37 °C for 16 
hours in a thermomixer at 500 rpm. The mixed Tau assemblies from the oligomerization 
were centrifuged at 10,000 rcf to remove high-order fibrils. o-Tau in the supernatant was 
further separated by SEC and eluted with PBS (Fig. 3A).  
The fraction of o-Tau was collected and passed through a 0.2 µm filter to remove 
potential microbial contaminants. However, possible endotoxin contamination cannot be 
eliminated via this physical filtration. To confirm that the collected fraction did not contain 
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significant endotoxin levels, which may result in a confounding inflammatory effect, the 
endotoxin level from different preparations was determined using an enzyme-based 
chromogenic assay. The endotoxin level in the o-Tau fraction was 0.88 ± 0.33 EU/mL in 
a µM solution of oligomer (Fig. 3B). From the literature, a o-Tau concentration ranging 
from 50 nM to 1 µM was effective in inducing inflammatory responses and neuronal 
damage100. Therefore, a concentration of o-Tau ranging from 125 nM to 500 nM was 
selected for this study. Accordingly, the final endotoxin level in all the experiments ranged 
from 0.11 ± 0.04 to 0.44 ± 0.17 EU/mL, which was well below the threshold of 1.0 EU/mL 
to effectively induce the production of proinflammatory cytokines TNF and IL-6 by 
peripheral monocytes299.  
In summary, we have developed a protocol to generate and isolate o-Tau species 
efficiently. Furthermore, the endotoxin level in the o-Tau preparation is below the 
threshold for activating monocytes. Therefore, inflammatory responses or neuronal 
damages induced by this o-Tau preparation in the following experiments would be 





Figure 3: Generation and isolation of oligomeric Tau. 
50 µM of monomeric full-length Tau (2N4R) and 25 µM of high molecular weight heparin 
were incubated in thermomixer at 37 °C for 16 hours. (A) Oligomeric Tau (o-Tau) was 
then purified using size exclusion chromatography. Fractioned o-Tau was further passed 
through a 0.2 µm filter to remove potential microbial contamination. (B) Endotoxin levels 
per µM of o-Tau from different preparations (N = 4) were determined using an enzyme-




























5.2.3 Design of the chimeric scavenger receptors 
The canonical scavenger receptors CD163 and CD204, as well as FcgRIIb, have 
been well studied in tumor immunology. They were shown to exhibit anti-inflammatory 
properties that promote tumor growth. The structure of scavenger receptors can be 
generally categorized into three domains: an extracellular domain that engages their 
natural ligands, a transmembrane domain that anchors them on the cell membrane, and 
an intracellular domain that triggers internalization and transduces anti-inflammatory 
signals. To date, there is no literature reporting o-Tau as a natural ligand for the selected 
scavenger receptors. To redirect the signaling initiation through specific activation by o-
Tau, we engineered the murine scavenger receptors and modified the extracellular 
domain with an scFv derived from a monoclonal antibody that prevents o-Tau-induced 
cytopathology in neurons100.  
In the CD163- and CD204-CSR constructs, we replaced the extracellular natural 
ligand-binding domains with the scFv derived from the antibody (Fig. 4A, B). To avoid 
disruptions in their tertiary structures, we replaced the essential ligand-binding regions 
of the extracellular domains with scFv. In the FcgRIIb-CSR construct, we modified the 
ligand-binding domain by inserting the scFv into the area responsible for its original 
binding capability to IgG Fc and Ab, to disrupt the native binding capacity (Fig. 4C).  
Furthermore, in the DNA constructs, we also designed restriction enzyme sites, without 
altering amino acid translation, at the junctions between different functional domains to 




Figure 4: Design of the chimeric scavenger receptors. 
The natural ligand-binding domains of the scavenger receptors (A) CD163, (B) CD204, 
and (C) FcgRIIb were modified and replaced with an scFv of a monoclonal antibody that 




5.2.4 Demonstration of modular modification of domains in the construct 
Our designed construct encoding an anti-o-Tau scFv supported by an FcgRIIb, 
CD163, or CD204 scaffold was synthesized into plasmids by a commercial service. I 
cloned the constructs into a retroviral vector, pMG-Neo, that has a cytotoxic antibiotic 
selection gene. The successfully cloned vectors were validated using various restriction 
enzyme digestions as well as Sanger sequencing to verify that the genetic material had 
been correctly cloned. 
Cloning of the designed CD163-CSR into the retroviral vector was not successful 
initially, and I repeatedly found various sizes of restriction products. This phenomenon 
was observed in both ligation-dependent and ligation-independent cloning methods, in 
using different viral vector backbones, and in multiple strains of competent cells. These 
trials suggested an inherent factor in the construct that was independent of the 
experimental procedures. Upon re-examination of the designed construct, I hypothesized 
that the repeated regions in the cassette domain of the CD163 backbone might cause 
recombination in competent cells, resulting in unsuccessful CD163-CSR cloning.  
By removing the cassette domain using the previously-designed restriction enzyme 
sites, I generated a shorter version of the CD163-CSR plasmid that is free of the cassette 
domain (Fig. 5A). Without the cassette domain, the cloning was successful, which was 
verified by both restriction enzyme digests and Sanger sequencing (Fig. 5B). Re-
introduction of the cassette back into the cassette-free CD163-CSR vector again resulted 
in various sizes of products. This result suggests the repeated sequence in CD163-CSR 
contributed to unsuccessful cloning in competent cells, which might result from 
recombination.  
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This example illustrates the usefulness of the designed restriction enzyme sites 
encasing distinct domains. This design not only helps facilitate cloning when needed, but 
it also makes it possible to swap the original domains with other functional domains in 




Figure 5: Modular modification of domains in the construct via predesigned 
restriction enzyme sites. 
(A) CD163-CSR has four major domains that are separated by three predesigned 
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domain and while keeping the rest intact. (B) Successful modification of CD163-CSR 
plasmid into the cassette-free CD163-CSR plasmid was verified using a different set of 
RE digestions. U: Undigested plasmid; C1: single RE digested plasmid; C2: double RE 
digested plasmid.  
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5.2.5 Generation of engineered monocytes 
As a proof-of-concept, the verified vectors packaged as viruses were transduced 
into a murine peripheral monocyte/macrophage cell line PMJ2-PC, and stable CSR-
expressing cell lines were obtained by drug (G418) selection. To further verify the 
successful transduction, the cells were examined using confocal microscopy. The 
cassette-free CD163-CSR and the FcgRIIb-CSR constructs were both linked to a 
histidine tag, and thus they could be detected using a fluorescein-labeled anti-histidine 
tag antibody. Compared to both parental untransduced and empty vector-transduced 
monocytes, the cassette-free CD163-CSR and FcgRIIb-CSR transduced cells stably 
expressed the histidine tag, indicating their successful transductions (Fig. 6A).  
During the construction of the CSR, modifications of extracellular domains have 
inevitably removed essential sites that can be detected by commercially available 
monoclonal antibodies. An antibody (SinoBiological) that was generated against amino 
acids 83-354 of CD204, which correspond to the remaining coiled-coil and collagen 
domains, showed suboptimal staining (Fig. 6B). This result could be due in part to the 
stereotactic hindrance of scFv preventing effective recognition, which has also been 
observed in ligand–antibody competition studies in other scavenger receptors228.  
We expected to detect CD204 on untransduced parental monocytes because 
monocytes were shown to express CD204 constitutively. CD204 expression found on 
untransduced monocytes might suggest that some of the CD204 staining signal in the 
CD204-CSR transduced cells was from the natural cellular CD204 expression. Because 
the CD204-CSR transduced cells survived repeated rounds of cytotoxic antibiotic 
selection pressure and showed an increased CD204 staining signal, these findings 
suggest that transduction was successful.   
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In summary, we concluded our research Aim 1 by 1) designing CSR constructs 
composed of an scFv that limits o-Tau propagation and M2-skewing scavenger receptor 
cytoplasmic domains, and 2) engineering peripheral monocyte/macrophage cell lines 
that stably express the designed CSRs.   
 107 
 
Figure 6: Validation of the successful retroviral transduction of the chimeric 
















(A) After plating by CytoSpin, the transduced cells (PMJ2-PC) were fixed and stained 
with DAPI and fluorescein-labeled anti-Histidine tag antibody (His-Tag). The cells were 
then imaged using confocal microscopy. (B) Both untransduced parental and CD204-
CSR transduced monocytes were stained with an anti-CD204 monoclonal antibody and 





5.2.6 Engineered monocytes inhibited proinflammatory cytokine secretions 
In our research Aim 1, we successfully generated monocytes stably expressing the 
FcgRIIb-CSR, CD204-CSR, or the cassette-free CD163-CSR.  Because the chosen 
intracellular domains were reported to possess immune regulatory properties, we 
hypothesized that the CSR monocytes would limit their proinflammatory cytokine 
secretion upon o-Tau stimulation. To examine the hypothesis, both the untransduced 
parental monocytes and the engineered monocytes were incubated with o-Tau for 24 
hours before cytokine levels were determined (Fig. 7A). The concentration of 500 nM of 
o-Tau was selected to determine the functions of our engineered monocytes because 
the concentration of soluble Tau in the brain ranges approximately from 150 nM to 900 
nM103,300.  
Compared to the untransduced parental monocytes, FcgRIIb-CSR monocytes had 
lower production of the proinflammatory cytokines TNF (p = 0.0033) and IL-6 (p = 0.0411). 
In this experiment, the CD204-CSR monocytes appeared to have a modest reduction in 
IL-6 secretion compared to the parental line, but the difference was not statistically 
significant. The cassette-free CD163-CSR monocytes appeared to have a lower 
secretion of both TNF and IL-6 in one single experiment with three technical replicates. 
Among the three engineered monocytes, the FcgRIIb-CSR monocytes secreted the 
lowest level of proinflammatory cytokines upon o-Tau stimulation (Fig. 7B-D).  
It is important to note that the decreased cytokine production in the engineered 
monocytes was not due to a specific batch of o-Tau preparation. A similar trend of 
reduced cytokine secretion by the engineered monocytes was reproduced in five 
independent experiments using different batches of o-Tau preparation. These 
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experiments verified that the CSR, especially FcgRIIb-CSR, enables peripheral 





Figure 7: Proinflammatory cytokine secretion and oligomeric Tau uptake capacity 
by the engineered monocytes. 
(A) Either parental or engineered monocytes were incubated with 500 nM of oligomeric 










secretion was determined by the Cytometric Bead Array (N = 5, in triplicate; except for 
CD163 where N = 1, in triplicate). (D) The cytokine profile of the FcgRIIb-CSR monocytes 
is detailed in comparison with parental monocytes and PBS controls. The graphs show 
the mean and SEM of independent experiments. Unpaired Student’s t-test, ns = not 




5.2.7 The inhibited proinflammatory cytokine secretion in CSR monocytes is not 
due to impaired cellular viability 
Independent experiments demonstrated that the engineered monocytes inhibited 
proinflammatory cytokine secretion upon o-Tau stimulation. To further determine that the 
low proinflammatory cytokine output was not due to cytotoxicity or a lower proliferative 
potential of the engineered monocytes, I examined the number of viable cells and 
normalized the cytokine output per 1,000 viable cells for FcgRIIb-CSR and CD204-CSR 
monocytes. After 24 hours of incubation with 500 nM of o-Tau, cellular viability and cell 
numbers as well as proinflammatory cytokine levels were analyzed. When cell number 
was used to normalize cytokine production, I found that FcgRIIb-CSR monocytes 
secreted the lowest amount of TNF (p = 0.0031) and IL-6 (p = 0.0004) per 1,000 cells. 
However, there was no significant difference in cytokine secretion level between CD204-
CSR monocytes and the parental monocyte control (Fig. 8A, B). Additionally, there was 
no statistically significant decrease in viability in either FcgRIIb- and CD204-CSR 
monocytes upon o-Tau stimulation (Fig. 8C). Overall, the normalized cytokine secretion 
level followed the same trend as the non-normalized cytokine secretion level results, 
which indicates that the reduced proinflammatory cytokine production by FcgRIIb-CSR 
monocytes is not due to impaired cell viability, or reduced cell number or proliferation.  
To further evaluate the potential toxicity of o-Tau to the engineered monocytes, I 
incubated FcgRIIb-CSR and CD204-CSR monocytes with a gradient of o-Tau 
concentration for 24 hours and evaluated their cellular viability.  The result indicated that 
there was no significant impairment in the cellular viability of FcgRIIb-CSR and CD204-
CSR monocytes or parental monocytes with the o-Tau levels tested, up to 500 nM (Fig. 
8D). Together, these data support our hypothesis that engineered monocytes, especially 
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FcgRIIb-CSR monocytes, remain viable in the presence of o-Tau and secrete less 





Figure 8: Normalization of proinflammatory cytokine secretion level.   
Either parental or engineered monocytes were incubated with 500 nM of oligomeric Tau 
(o-Tau) for 24 hours before proinflammatory cytokine (TNF and IL-6) secretion levels 
were determined using Cytometric Bead Array. An automatic cell counter also 
determined viable cell numbers. Cytokines were normalized to 1,000 cells (A, B), and 
cell viability was calculated (C). In an independent experiment, monocytes were 
incubated with various concentrations of o-Tau for 24 hours before their viability was 
determined (D). The graphs show the mean and SEM (N = 1, in triplicate). Unpaired 
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5.2.8 Engineered monocytes have enhanced oligomeric Tau clearance  
We have shown that CSR monocytes are capable of limiting their proinflammatory 
cytokine secretion upon o-Tau stimulation. Because the scFv of the CSR was derived 
from a monoclonal antibody that inhibits o-Tau propagation effectively, we hypothesized 
that CSR monocytes are capable of clearing o-Tau by efficient o-Tau uptake. To examine 
the o-Tau uptake capability of CSR monocytes, their cell-associated o-Tau after 
incubation with 500 nM of o-Tau for 24 hours was determined by using Western blot (Fig. 
9A). Quantification of the blots revealed that FcgRIIb-CSR monocytes had significantly 
higher cell-associated o-Tau compared to the parental line (p = 0.0166). The cell-
associated o-Tau of both CD204-CSR and CD163-CSR monocytes appeared to be 
slightly increased compared to the parental line, but this difference was not statistically 
significant (Fig. 9B).  
To further investigate the o-Tau clearing capacity of the FcgRIIb-CSR monocytes, 
a complementary approach was used to assess the remaining o-Tau in the culture 
system. The level of o-Tau remaining in the supernatant after a 24-hour culture with 
FcgRIIb-CSR monocytes was determined by using either Western blot (N = 1) or ELISA 
(N = 1, in triplicate) in independent experiments. In both experiments, o-Tau removal 
from the supernatant of the FcgRIIb-CSR monocyte culture appeared to be modestly 
enhanced compared to the culture of the parental line (Fig. 9C, D). This increased 
elimination of o-Tau from the system complemented the previous finding that FcgRIIb-
CSR monocytes have a greater capacity to bind o-Tau. Together, these data suggest 






Figure 9: Oligomeric Tau clearance capacity of the Fc𝛾RIIb-CSR engineered 
monocytes. 
Either parental or FcgRIIb-CSR monocyte cell lines were incubated with 500 nM 
oligomeric Tau (o-Tau) before lysis for evaluation of the cell-associated o-Tau and 
leftover o-Tau in the system. Representative Western blot of cell-associated o-Tau in the 
cell lysate (A) and quantification from independent experiments (N = 1 or 4) (B). Leftover 
o-Tau in the system after incubation with monocytes was determined by Western blot (N 
= 1) (C), and total Tau was determined by ELISA (N = 1, in triplicate) (D). The graphs 
show the mean and SEM. Unpaired Student’s t-test, * p < 0.05. 
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5.2.9 Chimeric scavenger receptors enable decoupling of proinflammatory 
cytokine secretion from o-Tau uptake 
We and others have demonstrated that both monocytes and microglia have innate 
proinflammatory responses to o-Tau stimulation100. The idea of the CSR is not only to 
remove extracellular o-Tau more efficiently but also to decouple the linked inflammatory 
process after the engagement. To evaluate the dose-dependent association between o-
Tau uptake capacity and proinflammatory cytokine secretion, parental and engineered 
monocytes were incubated with either 0, 125, or 500 nM of o-Tau for 24 hours before 
analysis of the cell-associated o-Tau as well as TNF and IL-6 levels in the supernatant.  
Using Western blot for cell-associated o-Tau quantification, I observed increased 
cell-associated o-Tau with increasing o-Tau incubation concentration. Despite the 
concentration of o-Tau being limited to 500 nM in this experiment, the saturating point 
for o-Tau uptake by monocytes may be more than 500 nM (Fig. 10A). Additionally, 
increasing levels of the proinflammatory cytokines TNF and IL-6 as determined by CBA 
was also observed in both parental and engineered monocytes when stimulated with 
increasing concentrations of o-Tau, suggesting a dose-dependent cytokine production 
(Fig. 10B). Similar to the previous proinflammatory cytokine evaluation studies, this 
experiment also found that FcgRIIb-CSR monocytes have the lowest proinflammatory 
cytokine secretion at both 125 nM and 500 nM of o-Tau stimulation. Unlike the high TNF 
level, IL-6 level was lower in both parental and engineered monocytes. 
Moreover, a threshold was observed for o-Tau to stimulate IL-6 secretion effectively. 
In either parental or engineered monocytes, o-Tau concentration below 125 nM was not 
able to stimulate a sufficient IL-6 to be detected by CBA (≥ 2.8 pg/mL). The more 
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sensitive and dramatic response in TNF secretion suggests that TNF might play a more 
critical role in initiating inflammation in response to o-Tau.  
The association between cellular uptake and cytokine output was further 
investigated by using the Pearson correlation test. I found that there is a significant 
positive correlation between o-Tau stimulation concentration and TNF secretion in both 
parental and CD204-CSR monocytes (Fig. 10C). A statistically significant positive 
correlation between cell-associated o-Tau and cytokine levels was only found in TNF 
secretion by the parental monocytes (Fig. 10D). No significant association was found for 
IL-6 across different monocytes, which might be due to a higher threshold for IL-6 
secretion and a lower range of o-Tau concentration tested in this study. Because the IL-
6 levels were mostly below the detection limit recommended by the assay, the correlation 
between IL-6 and o-Tau uptake should be treated with caution.  
While there was a dose-dependent trend of increased TNF secretion by CD204-
CSR monocytes in response to increasing concentrations of o-Tau, the correlation 
between TNF cytokine level and cell-associated o-Tau was not statistically significant. 
Strikingly, the TNF profile of FcgRIIb-CSR monocytes was not positively associated with 
either o-Tau stimulation concentration or o-Tau uptake level. More importantly, the linear 
regression line demonstrating the association between o-Tau uptake and cytokine 
response had a less steep slope in both engineered monocytes compared to the parental 
monocytes. Collectively, these analyses suggest that the CSRs are capable of 


























































Figure 10: Association of oligomeric Tau uptake and proinflammatory cytokine 
secretion by the engineered monocytes. 
Parental and CSR monocyte cell lines were incubated with 0, 125, or 500 nM of 
oligomeric Tau (o-Tau) for 24 hours before evaluation of their cell-associated o-Tau by 
using Western blot (A), and proinflammatory cytokine secretion by using Cytometric 
Bead Assays (B). The Pearson correlation analyses determined the correlation between 
cytokine secretion with o-Tau stimulation (C) or with o-Tau uptake (D). The association 
was demonstrated by linear regression analyses (C, D) (N = 1, in triplicate). Unpaired 




5.2.10 The phenotype of the chimeric scavenger receptor cells is reproducible in 
a new transduction 
Several independent experiments had shown inhibited proinflammatory cytokine 
production in our FcgRIIb-CSR monocytes. To further confirm that the enhanced o-Tau 
uptake and reduced proinflammatory cytokine secretion in the FcgRIIb-CSR monocytes 
was not limited to one specific transduction experiment or transduced clone, I transduced 
another batch of parental monocyte cell line PMJ2-PC with the FcgRIIb-CSR retroviral 
vector in a new trial. Following the same protocol in the earlier transduction experiment, 
the transduced cells were also enriched by cytotoxic antibiotic selection before any 
functional assays.   
The experimental procedures were similar to the previous assays. The enriched 
clone was stimulated with 500 nM of o-Tau for 24 hours before analysis of the o-Tau 
uptake and proinflammatory cytokine production. Similar to the previous experiments, 
the newly-transduced FcgRIIb-CSR monocytes secreted lower levels of the 
proinflammatory cytokines TNF and IL-6 compared to the parental line (Fig. 11A). There 
appeared to be a small increase in the level of cell-associated o-Tau in the newly-
transduced FcgRIIb-CSR monocytes compared to the parental line in this experiment. 
(Fig. 11B, C).  
The significantly reduced proinflammatory cytokine output and observation of a 
slightly higher o-Tau uptake capacity, similar to the previously generated clone, not only 
demonstrated that the phenotype of FcgRIIb-CSR is reproducible in different transduction 
experiments, but also confirmed the potential of FcgRIIb-CSR to decouple the o-Tau-




Figure 11: Proinflammatory cytokine secretion and oligomeric Tau uptake capacity 
in newly-transduced Fc𝛾RIIb-CSR engineered monocytes. 
The FcgRIIb-CSR construct was retrovirally transduced into the peripheral 
monocyte/macrophage cell line PMJ2-PC. These newly-transduced monocytes 
(FcgRIIb-CSR’) were further selected and enriched by cytotoxic antibiotics. (A) The 
enriched FcgRIIb-CSR’ monocytes were stimulated with 500 nM of oligomeric Tau (o-
Tau) for 24 hours before the cytokines were examined by Cytometric Bead Assay. (B, C) 
Cell-associated o-Tau in the cell lysates was determined by Western blot and quantified. 
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5.2.11 Engineered monocytes may use the lysosomal system for oligomeric Tau 
degradation 
The FcgRIIb-CSR monocytes had the most significant potential for o-Tau uptake 
among the engineered monocytes. To further verify that the CSR monocytes internalize 
the increased cell-associated o-Tau, the ratio of internalized o-Tau versus total cell-
associated o-Tau was determined. After incubation with o-Tau for specific lengths of time, 
FcgRIIb-CSR monocytes were collected and divided into two groups. One group was 
washed with acid buffer (pH 3) to remove surface-bound o-Tau, while the other group 
was washed with PBS to preserve total o-Tau bound to the cells296. The o-Tau level in 
both groups was determined using Western blot. The ratio between the o-Tau level in 
the two groups indicated the proportion of o-Tau being internalized intracellularly.  Over 
the various stimulation times tested, I found that FcgRIIb-CSR monocytes internalized 
most of the cell-associated o-Tau (87.7 ± 2.8%). Increased incubation time resulted in 
elevated o-Tau binding as well as internalization by FcgRIIb-CSR monocytes. The 
internalization efficiency was not significantly impaired up to the 2 hours tested in this 
experiment (Fig. 12A, B).  
It was shown that the engineered monocytes actively internalize o-Tau. However, 
the fate of the internalized o-Tau facilitated by FcgRIIb-CSR remains unclear. Based on 
the evidence indicating that ligand-bound FcgRIIb is transported to the lysosomal 
compartment for degradation271,301, I hypothesize that the o-Tau internalized via FcgRIIb-
CSR is degraded via lysosomes in the engineered monocytes. While a decrease in 
lysosome-associated membrane protein-1 (LAMP-1) staining signal has been used to 
indicate the active consumption of the lysosome302,303, LAMP-1 signal can be used as an 
indicator of lysosomal activity.  Within 2 hours of o-Tau stimulation of FcgRIIb-CSR 
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monocytes, there was a time-dependent decrease of LAMP-1 signal associated with an 
elevated o-Tau internalization (Fig. 12C). Moreover, internalized o-Tau was also shown 
to co-localize with lysosome using Amnis flow cytometry (Fig. 13). Together with the 
increasing time-dependent o-Tau internalization, these data suggest that o-Tau 
internalized via FcgRIIb is processed via the lysosomal system.  
To further validate this observation, a more extended period of o-Tau stimulation of 
FcgRIIb-CSR monocytes was conducted to confirm consistent lysosomal consumption. 
The decrease of the LAMP-1 signal was more evident when FcgRIIb-CSR monocytes 
were stimulated with o-Tau for more than 8 hours. Moreover, compared to parental 
monocytes, FcgRIIb-CSR monocytes had a higher lysosomal consumption activity (Fig. 
14). These results suggest an increased degradation activity of the internalized o-Tau in 




Figure 12: Internalization efficiency of oligomeric Tau by the Fc𝛾RIIb-CSR 
engineered monocytes.  
(A) FcgRIIb-CSR monocytes were incubated with 125 nM of o-Tau for 30, 60, and 120 
minutes before analysis. Cells were washed by acid buffer or PBS, and their oligomeric 
Tau (o-Tau) level was determined by using Western blot. (B) Quantification of the 
Western blot result is plotted against time. (C) Cells were stained with a fluorescently-
labeled antibody specific for lysosome-associated membrane protein-1 (LAMP-1) and 
analyzed using flow cytometry. LAMP-1 fold change relative to the mean fluorescence 














































Figure 13: Co-localization of the internalized oligomeric Tau with lysosomes in the 
FcgRIIb-CSR engineered monocytes. 
After a 6-hour incubation with fluorescently-labeled oligomeric Tau (o-Tau, green), 
FcgRIIb-CSR monocytes were imaged using Amnis flow cytometry. The lysosomes were 
stained with a fluorescently-labeled antibody specific for lysosome-associated 





Figure 14: FcgRIIb-CSR monocytes have a higher lysosomal consumption activity 
after oligomeric Tau stimulation. 
Parental and FcgRIIb-CSR monocytes were incubated with oligomeric Tau (o-Tau) for 
various durations. Lysosome-associated membrane protein-1 (LAMP-1) staining 
indicates lysosomal consumption activity at different time points post-o-Tau stimulation 
using flow cytometry. LAMP-1 mean fluorescence intensity (MFI) fold change is relative 




















5.2.12 FcgRIIb-CSR monocytes have limited proinflammatory cytokine secretion 
and protect neurons from oligomeric Tau toxicity 
The engineered CSR monocytes secrete less neurotoxic cytokines upon o-Tau 
stimulation and show a higher capacity for removal of o-Tau. However, it is unknown if 
monocytes will induce contact-dependent damage to the neurons. A previous study had 
demonstrated that one mechanism of microglial damage to neurons was via microglial 
phagocytosis147. To evaluate the neuroprotectivity of CSR monocytes against o-Tau 
instead of contact-dependent impairment, the E18-19 primary hippocampal neurons 
were co-cultured with engineered monocytes and o-Tau (Fig. 15A). By staining for 
microtubule-associated protein 2 (MAP2), which targets neuronal dendrites, the fitness 
of neurons can be determined by examining the integrity of dendritic staining using 
confocal microscopy and other imaging modalities100.  
Using immunofluorescence confocal microscopy, I found that the neurons co-
cultured with FcgRIIb-CSR monocytes had greater neuronal integrity compared to the 
neurons co-cultured with parental monocytes (Fig. 15B). One caveat of this experiment 
was that parental monocytes, but not the empty vector-transduced monocytes, were 
used as the positive control, although both of the cell lines have a significantly higher 
TNF secretion compared to FcgRIIb-CSR monocytes. This issue was addressed in the 
next co-culture experiment.  
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Figure 15: FcgRIIb-CSR monocytes limit neuronal damage in vitro. 
(A) Primary E18 hippocampal neurons were cultured on a collagen-coated cover slide 
for 2 weeks before incubation with 500 nM oligomeric Tau (o-Tau), and either parental 
or FcgRIIb-CSR monocytes for 72 hours. (B) Neurons on the slide were stained with 
antibody specific for microtubule-associated protein-2 (MAP2) and imaged using 
confocal microscopy (arrowheads indicate fragmentation on neuronal dendrites).  
 
 





5.2.13 Engineered monocytes have the potential to protect neurons from o-Tau 
toxicity  
To further validate that FcgRIIb-CSR monocytes protect neurons from oligomeric 
Tau toxicity observed by confocal imaging, another imaging modality capable of 
efficiently evaluating multiple neurons in various conditions was used. In collaboration 
with Dr. Jim Ray at the Neurodegeneration Consortium, the co-cultured neurons were 
imaged using Operetta, a high-content imaging system. Without the presence of 
monocytes or o-Tau stimulation, primary hippocampal neurons presented intact MAP2 
staining integrity, which suggests their fitness in the in vitro culture system (Fig. 16A). 
Upon stimulation by o-Tau, MAP2 staining showed more fragmentation compared to the 
unstimulated neurons, suggesting neurotoxicity due to o-Tau (Fig. 16B). In AD brains, 
neurons are exposed to both o-Tau as well as myeloid cells such as microglia and 
peripheral monocytes. To simulate the harsh condition neurons face in AD, primary 
neurons were co-cultured with empty-vector monocytes along with o-Tau stimulation in 
vitro. I found that the fragmentation of MAP2 staining of the primary neurons became 
more evident, suggesting an exacerbated damage to the neurons (Fig. 16C). This result 
also supports the hypothesis that both o-Tau and inflammation contribute to the 
neurodegeneration in AD.  
Compared to the neurons co-cultured with parental monocytes, MAP2 staining of 
neurons was substantially preserved when primary neurons were co-cultured with 
FcgRIIb-CSR monocytes, which suggest neuronal fitness in this condition (Fig. 16D). 
These findings validate the neurotoxic effect of o-Tau as well as parental monocytes and 
the neuroprotectivity of FcgRIIb-CSR monocytes observed by using confocal imaging.  
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Furthermore, the neuronal protectivity of CD204-CSR and CD163-CSR monocytes 
was also evaluated using the same method. The primary neurons co-cultured with 
CD204-CSR monocytes had moderate MAP2 staining integrity (Fig. 16E). However, the 
primary neurons co-cultured with CD163-CSR monocytes do not show abundant intact 
MAP2 staining, in comparison to the neurons co-cultured with the FcgRIIb-CSR 
monocytes (Fig. 16F). Albeit not as dramatic as observed in FcgRIIb-CSR monocyte co-
culture, the neurons in CD204-CSR monocyte co-culture still appeared more intact than 
the neurons co-cultured with the parental line.  
Collectively, these data suggest that the engineered CSR monocytes are capable 
of protecting neurons from o-Tau in vitro to varying degrees. In line with the previous 
findings that FcgRIIb-CSR monocytes have a higher o-Tau uptake capability and a limited 
proinflammatory profile, this experiment not only demonstrates the significant 
neuroprotectivity of FcgRIIb-CSR monocytes in vitro, but also demonstrates again the 




Figure 16: Co-culture of primary neurons with the engineered monocytes.  
E18 primary neurons (15 x103 cells) were cultured in vitro for 14 days before co-culture 
with 30 x103 parental monocytes or CSR monocytes in addition to 500 nM of oligomeric 
(A) Without o-Tau (B) o-Tau
(C) o-Tau + Empty-vector monocytes
50 um
(D) o-Tau + FcgRIIb-CSR monocytes
(E) o-Tau + CD204-CSR monocytes (F) o-Tau + CD163-CSR monocytes
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Tau (o-Tau). After 72 hours of incubation, the neurons were fixed and stained with a 
microtubule-associated protein-2 (MAP2)-specific antibody, then imaged using the 
Operetta high-content imager. Representative images show primary neurons in various 
co-culture conditions: (A) without stimulation by o-Tau, (B) with stimulation by o-Tau, (C) 
with stimulation by o-Tau and co-culture with empty-vector monocytes, (D) with 
stimulation by o-Tau and co-culture with FcgRIIb-CSR monocytes, (E) with stimulation 
by o-Tau and co-culture with CD204-CSR monocytes, and (F) with stimulation by o-Tau 




5.2.14 FcgRIIb-CSR monocytes appear to protect neurons against oligomeric Tau 
in a dose-dependent fashion 
FcgRIIb-CSR monocytes had demonstrated the highest neuroprotective capability 
among the CSR monocytes, which might be due to their minimal proinflammatory 
cytokine secretion. It is logical to postulate that a higher number of FcgRIIb-CSR 
monocytes may provide a better neuroprotectivity. However, because FcgRIIb-CSR 
monocytes still produce proinflammatory cytokines, albeit at a deficient level, it is not 
known if an increasing number of FcgRIIb-CSR monocytes will eventually build up 
enough proinflammatory cytokine secretion to harm the primary neurons instead of 
protecting them from o-Tau. Therefore, I conducted a dose exploration study in which I 
incubated FcgRIIb-CSR monocytes at a 4:1 ratio to primary neurons along with 500 nM 
of o-Tau. This dose-dependent analysis of FcgRIIb-CSR monocytes showed that the 
level of the proinflammatory cytokine TNF increased when more FcgRIIb-CSR 
monocytes were present. However, the TNF level was still significantly lower in 
comparison to the group co-cultured with control monocytes (Fig. 17A).  
Examination of the MAP2 staining of primary neurons found that primary neurons 
co-cultured with FcgRIIb-CSR monocyte at a ratio of 4:1 (Fig. 17F) had better dendritic 
integrity compared to the neurons co-cultured with FcgRIIb-CSR monocyte at a ratio of 
2:1 (Fig. 17E), closer to the integrity observed in the unstimulated group (Fig. 17B). Both 
co-culture conditions with FcgRIIb-CSR monocytes showed better MAP2 staining 
integrity compared to the culture condition with o-Tau only (Fig. 17C) or along with 
control monocytes (Fig. 17D).   
In summary, this experiment showed that FcgRIIb-CSR monocytes at a higher ratio 
to neurons (4:1 in this case) helped to preserve the neuronal integrity despite an increase 
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in the TNF level. This effect might result from the capability of FcgRIIb-CSR monocytes 
to decouple o-Tau uptake and proinflammatory cytokine production effectively. A future 
experiment including higher ratios of FcgRIIb-CSR monocytes to primary neurons is 
needed to determine a balance point between a maximal o-Tau clearance and a tolerable 
proinflammatory cytokine level to achieve optimal neuroprotectivity in vitro. Furthermore, 
an assay to investigate the competition between FcgRIIb-CSR monocytes and other 
untransduced myeloid cells, including microglia and monocytes, will also help to shed 





Figure 17: Co-culture of primary neurons with various ratios of the FcgRIIb-CSR 
monocytes. 
(F) o-Tau + FcgRIIb-CSR monocytes 
(4:1 Neuron)
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E18 primary neurons (15 x103) were cultured in vitro for 14 days before co-culture with 
30 x103 parental monocytes, or 30 x103 or 60 x103 FcgRIIb-CSR monocytes, in addition 
to 500 nM of oligomeric Tau (o-Tau). After 72 hours of incubation, the neurons were fixed 
and stained with a MAP2-specific antibody, then imaged using the Operetta high-content 
imager. (A) The TNF level of the supernatant from different conditions was determined 
using ELISA. The graph shows mean and SEM, (N = 1, in five replicates).  
Representative images show primary neurons in various co-culture conditions: (B) 
without stimulation by o-Tau, (C) with stimulation by o-Tau, (D) with stimulation by o-Tau 
and co-culture with empty-vector monocytes at a ratio of 2:1, (E) with stimulation by o-
Tau and co-culture with FcgRIIb-CSR monocytes at a ratio of 2:1, and (F) with stimulation 
by o-Tau and co-culture with FcgRIIb-CSR monocytes at a ratio of 4:1. Unpaired 
Student’s t-test in (A), ** p < 0.01, *** p < 0.001. 
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5.2.15 Improvement of FcgRIIb-CSR design based on an FcgRIIb isoform 
The demonstrated inhibited proinflammatory cytokine profile, enhanced o-Tau 
clearance capacity, and a better neuroprotective capability of FcgRIIb-CSR monocytes 
encouraged us to investigate the biology of FcgRIIb further. Studies have indicated that 
two isoforms exist for FcgRIIb, FcgRIIb1 and FcgRIIb2, due to alternative splicing (Fig. 
18A). Mouse FcgRIIb1 is 47 amino acid longer in length than FcgRIIb2, and this sequence 
functions to tether FcgRIIb on the cell membrane and disrupts the accumulation in 
clathrin-coated pits. Without this sequence in FcgRIIb2, the internalization in myeloid 
cells occurs at a faster rate compared to the B cell-specific FcgRIIb1193,271.  
A more rapid internalization rate after engagement with ligand enhances ligand 
clearance from the environment, which could be advantageous for a more efficient o-Tau 
uptake by engineered monocytes. Therefore, I constructed an FcgRIIb2-CSR by 
removing the differential sequence found in FcgRIIb1. This new vector was cloned into a 
yellow fluorescent protein (YFP) retroviral vector (Fig. 18B). Peripheral monocyte cell 
line PMJ2-PC was successfully transduced with the vector and enriched by FACS sorting. 
The proinflammatory cytokine profile, o-Tau clearance capability, and neuroprotectivity 
will be examined in the future using the methods for the FcgRIIb1-CSR monocytes used 





Figure 18: Modified design of FcgRIIb-CSR based on FcgRIIb isoform.   
(A) A diagram showing FcgRIIb-CSR indicates the sequence difference between 
isoforms with an arrow. (B) Successful cloning of FcgRIIb2-CSR construct into retroviral 



































5.2.16 Optimization of the intracerebroventricular delivery method in vivo 
Engineered CSR monocytes, especially FcgRIIb-CSR monocytes, were shown to 
have a higher capacity for o-Tau clearance by enhanced uptake. More importantly, the 
FcgRIIb-CSR monocytes secreted minimal proinflammatory cytokines and protected 
neurons in vitro. We hypothesized that treatment with CSR monocytes would reduce Tau 
burden and limit proinflammatory cytokine production in the brain, which would improve 
cognitive function in an AD mouse model. To address this hypothesis, I proposed to 
deliver the CSR monocytes into the brain via an ICV port to avoid entrapment of the cells 
in the peripheral organs171.  
Because this delivery route for cellular therapy has not been proposed before, it is 
essential to first validate and optimize the route of delivery before investigating the 
neuroprotectivity of FcgRIIb-CSR monocytes in vivo. The depth of the infusion is a crucial 
parameter as it determines the efficiency of the delivery and prevents the reflux of the 
infused cells. With the stereotactic frame for brain injection, I found that a depth of 2.5– 
3.0 mm below the skull is the optimal depth in C57BL/6 background mice, where delivery 
of trypan blue dye via the ICV port stained the lateral ventricles well. Using a previously-
developed ICV port297, I implanted the port on the skull with a needle penetrating at a 
depth of 2.5 mm (Fig. 19A). The successful access to the ventricles was also 
demonstrated by staining the lateral ventricles with trypan blue (Fig. 19B).  
Both the equipment necessary for the experiment and the critical parameter were 
now validated. Next, I established the surgical protocol for our in vivo experiment. Briefly, 
an 8 mm-long longitudinal wound is created over the scalp of a mouse under general 
anesthesia. A bur hole on the skull is established at 1.0 mm right lateral to the Bregma 
(Fig. 20A). A pre-flushed and degassed ICV port connected to a catheter is then 
 142 
implanted and fixed. The end of the catheter is sealed with a cauterizer to prevent 
communication between the periphery and the lateral ventricles. The sealed catheter is 
then buried in the subcutaneous pocket created on the back of the mouse (Fig. 20B). 
The skin is closed with a nylon suture, and the mouse is allowed to heal for 2 weeks 
before infusion (Fig. 20C). After the wound is healed, a 2 mm incision is made to access 
the sealed end of the catheter. A Hamilton syringe filled with monocytes is connected to 
the catheter after the seal has been removed (Fig. 21A, B) and 3 µL of cell suspension 
is infused slowly over 1 minute. The catheter is next flushed with 3 µL of PBS to expel 
the cells inside the tube toward the ICV. The end of the catheter is sealed again after the 
removal of the Hamilton syringe and stored back into the subcutaneous pocket. The 2-
mm wound is then closed by one stitch with nylon suture or autoclip (Fig. 21C, D).  
In a preliminary experiment, I delivered repeated weekly infusions of either PBS, 
parental, or FcgRIIb-CSR monocytes into P301S mice for a total of eight doses. The mice 
tolerated the surgeries well, and there was no mortality related to the procedures. This 
trial has validated the feasibility of this novel adoptive transfer protocol and has laid the 




Figure 19: Determination of the optimal depth of the intracerebroventricular 
infusion port. 
(A) The intracerebroventricular infusion port (ICV port) is a minimally-invasive device that 
can be subcutaneously installed on the dorsal surface of the skull for long-term 
placement. The needle of the ICV port can penetrate through the skull to the desired 
depth, reaching the lateral ventricle. A catheter attached to the port enables infusion via 
a Hamilton syringe. (B) In the C57BL/6 and P301S mouse model, a depth of 2.5 mm 
below the skull surface was determined as the optimal depth to access lateral ventricles. 
Neither reflux nor resistance was noted during the infusion of trypan blue through the 
catheter into the right lateral ventricle. Successful implantation was demonstrated by 





Figure 20: Demonstration of the intracerebroventricular infusion port installation 
protocol. 
(A) After the mouse is anesthetized, a mid-line skin incision of 8.0 mm is made on the 
scalp with a scalpel to expose the skull surface. A burr hole on the skull is made manually 
at the location 1.0 mm right lateral to the Bregma with a 27G needle. (B) The 
intracerebroventricular infusion port (ICV port) attached with a catheter is degassed with 
PBS before it is placed to the burr hole and fixed. (C) After the ICV port is secured in 






Figure 21: Surgical procedure of the adoptive transfer of engineered monocytes 
via the intracerebroventricular infusion port. 
The port is ready for infusion after a 2-week recovery to allow wound healing post-
intracerebroventricular infusion (ICV) port installation. The end of the catheter is localized 
by palpation over the skin after the mouse is under general anesthesia. A 2.0 mm incision 
is created to expose the infusion catheter after disinfecting the surgical field (A). The 
cauterized seal at the end of the catheter is removed, and 1x105 monocytes in 3 µL are 
infused through the catheter over 1 minute using a Hamilton syringe. The catheter is 
flushed with another 3 µL of PBS over 1 minute to expel the remaining cells into the ICV 
(B). After the Hamilton syringe is removed, the catheter opening is sealed with a 
cauterizer (C), and the incision is closed with a 5-O nylon suture (D).  
 
 
(A) (B) (C) (D)
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5.2.17 FcgRIIb-CSR monocytes may improve motor functions in a preclinical 
Alzheimer’s disease model 
P301S Tau-overexpressing transgenic mice are frequently used when studying 
frontotemporal dementia and AD. Because the literature has demonstrated that o-Tau is 
a more clinically-relevant pathogenic factor in driving AD progression, our engineered 
monocytes were designed to target o-Tau. Moreover, our engineered PMJ2-PC cell line 
is of a C57BL/6 background that will be less likely to be rejected in P301S mice, which 
have a C57BL/6 x C3H/HeJ background. Based on the considerations of its relevance in 
studying AD, the target protein of our engineered monocytes, and the likelihood of fewer 
rejections, we selected the P301S mouse model to study the in vivo efficacy of our 
engineered monocytes.   
Previous research on P301S mice showed abundant pTau tangles in the brain, limb 
paralysis, and cognitive impairment starting at 6-7 months old108,304. Because the co-
existent motor deficit in this model may interfere with the interpretation of cognitive tests, 
it is crucial first to determine the motor functions of these transgenic mice.   
In my preliminary study, I delivered eight doses of weekly 1x105 FcgRIIb-CSR 
monocyte infusions via the ICV port when the P301S mice were 4 months old. Motor 
functions, including wire hang and footprint tests, were examined at the end of treatments 
when they were 6 months old.  In the wire hang test, the mice which received the control 
monocytes were observed to have a shorter mean hanging time compared to the mice 
receiving PBS, although the difference was not statistically significant (p = 0.0789), 
suggesting poor motor function that could be due to exacerbated inflammation. The mice 
receiving FcgRIIb-CSR monocytes had a similar hanging time compared to the PBS 
control (p = 0.4849), indicating no detected improvement in this specific test (Fig. 22A).   
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In the footprint test, the mice that received the FcgRIIb-CSR monocytes were 
observed to have a narrower forepaw base width compared to the PBS control,  but the 
difference was not statistically significant (p = 0.0864). This may suggest an 
improvement in motor function in the FcgRIIb-CSR monocyte group. However, there was 
no difference between the mice receiving control monocytes and the mice receiving PBS 
(p = 1.000) (Fig. 22B). Assessment of other parameters, including stride length and 
forepaw/ hind paw overlap, did not reveal any significant difference between the FcgRIIb-
CSR monocyte treated group and the control monocyte treated group or the PBS control 
(Fig. 22C, D).  
When compared to the control monocyte treated group, there was an indication that 
the  FcgRIIb-CSR monocyte treated group in this preliminary study may have better motor 
function, although the differences were not statistically significant. This result suggests 
that anti-inflammatory modulation by FcgRIIb-CSR may have the potential to halt AD 




Figure 22: Motor tests of the P301S mice treated with engineered monocytes. 
Male P301S mice received eight doses of weekly infusion of either PBS vehicle, control 
monocytes, or FcgRIIb-CSR monocytes from 4 months of age. Motor tests, including wire 
hang test (A) and footprint test (B-D), were performed at the end of eight treatments 
when the mice were 6 months old. The graphs show the mean and SEM. p-values were 














































































5.3 Summary  
To address both of the key pathogenic factors of o-Tau accumulation and 
inflammation in AD progression, we have invented CSR that harbor the potential to target 
o-Tau and to transduce an intracellular inhibitory signal. Using the peripheral 
monocyte/macrophage cell line PMJ2-PC as a model for the proof-of-concept 
experiments, I generated engineered monocytes stably expressing our designed CSR 
constructs, verified using cytotoxic antibiotic selection and confocal immunofluorescence 
microscopy. I demonstrated that compared to parental monocytes, the engineered 
monocytes have a better o-Tau clearance capability though a more efficient uptake, and 
at the same time, secrete limited proinflammatory cytokines. The lower proinflammatory 
cytokine secretion was not due to an impaired proliferation or an enhanced cell death. 
Among the engineered monocytes generated, FcgRIIb-CSR monocytes, in particular, 
had a superior capability to decouple o-Tau uptake from the linked inflammatory 
responses, which could be reproduced in a newly-transduced PMJ2-PC cell line.  
Furthermore, my data show that the o-Tau associated with the FcgRIIb-CSR 
monocytes was mostly internalized and triggers intracellular lysosomal consumption 
which may contribute to its degradation. More importantly, the engineered monocytes, 
especially the FcgRIIb-CSR monocytes, were found to protect primary hippocampal 
neurons from o-Tau toxicity in vitro that could result from an enhanced clearance of o-
Tau, and an inhibited subsequent inflammatory cytokine secretion.  
To further translate this novel cellular therapy into the clinic, the adoptive transfer is 
better performed via an ICV route to prevent off-site entrapment and the related side 
effects.  I have developed a minimally-invasive surgical protocol that enables the 
repeated treatments of engineered monocytes into a preclinical AD mouse model. 
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Moreover, after eight weekly treatments, 6-month old male P301S Tau-overexpressing 
transgenic mice that received the engineered FcgRIIb-CSR monocytes were observed to 
have modestly better motor function as evaluated by the footprint test. On the contrary, 
the mice receiving control monocyte infusions had a worse motor function as assessed 
by the wire hang test.  Neither of these preliminary results reached statistical significance. 
Albeit preliminary, these in vivo data suggest that FcgRIIb-CSR monocytes may have 
immune-modulatory functions that could potentially halt AD progression in vivo.   
Collectively, these results support our hypothesis that monocytes engineered to 
bind and internalize o-Tau via antibody-redirected CSR will protect neurons from o-Tau-
mediated neurotoxicity while dampening proinflammatory cytokine release. 
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Chapter 6: Discussion 
We proposed the novel concept of CSR and designed three CSRs by replacing the 
natural ligand-binding domains of FcgRIIb, CD163, and CD204 with an scFv from an anti-
o-Tau antibody. We also materialized this concept using a peripheral 
monocyte/macrophage cell line PMJ2-PC as our model. Engineered monocytes, 
especially FcgRIIb-CSR monocytes, were shown to be neuroprotective in vitro via an 
enhanced o-Tau clearance and an inhibited linked proinflammatory cytokine secretion. 
Adoptive transfer of FcgRIIb-CSR monocytes via ICV delivery in P301S Tau-
overexpressing transgenic mice also suggested that FcgRIIb-CSR monocytes may 
produce a better motor response, indicating its potential in halting AD progression in vivo.  
In the present study, I demonstrated the capability of FcgRIIb-CSR monocytes in 
protecting neurons both in vitro and in vivo. In the preliminary in vivo study, I evaluated 
the motor functions of the P301S mice. Other assessments, including inflammatory 
status in the CNS and cognitive tests, will also be investigated in future work. Despite 
FcgRIIb-CSR monocytes showing neuroprotective efficacy, the mechanism of FcgRIIb-
CSR internalization and how o-Tau is degraded after its facilitated internalization by 
FcgRIIb-CSR remain unclear. Ascertaining the underlying biology of the FcgRIIb-CSR will 
not only illuminate how the CSR catalyzes o-Tau degradation but will also enhance our 
understanding of how o-Tau clearance can be improved. Therefore, it is also crucial to 
investigate the mechanisms of both internalization and degradation of o-Tau in the 
FcgRIIb-CSR monocytes, as our immediate future directions. 
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6.1 Preclinical studies evaluating the therapeutic efficacy of engineered 
monocytes 
6.1.1 Concurrent ex vivo analysis 
In addition to the motor tests performed in the preliminary in vivo study, brain 
pathology was also obtained to determine pTau burden and neuronal damages in the 
CNS, which will provide additional evidence for the neuroprotective capacity of FcgRIIb-
CSR monocytes in vivo. Furthermore, brain homogenate was also acquired for the 
analysis of cytokine mRNA levels, which will indicate an overall assessment of the 
inflammatory status in the CNS. RT-PCR of a selected panel of cytokines and 
chemokines based on the literature will enable us to evaluate the immunomodulatory 
effects of FcgRIIb-CSR monocytes. Further RNA sequencing will provide not only 
complementary evidence for RT-PCR but also a broader scope in identifying potential 
players. The data will further inform on how to improve the design of our engineered CSR 
monocytes or provide a treatment rationale in combination with other immune modulators. 
 
6.1.2 Optimization of the in vivo study design 
In my preliminary in vivo study, I observed a modest therapeutic effect determined 
by motor tests, which was not statistically significant. In addition to increasing the sample 
size, there are other factors to be considered. Because motor impairment reportedly 
occurs in 6- to 9-month-old P301S mice on average108,304, my results could be due in 
part to the inability of 6-month-old mice to reflect disease severity adequately. Therefore, 
an improved experimental design using older animals (9 months old) is ongoing.  
Because motor deficits might interfere with the interpretation of cognitive tests, 
motor tests, including wire hang and footprint tests, were performed first in my preliminary 
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experiment. In the future study, a battery of cognitive evaluations, including novel object 
recognition, Y-maze, and Morris water maze tests, will also be assessed in addition to 
the motor test.  Moreover, the survival benefit from the engineered monocyte adoptive 
transfer therapy will also be examined. Upon the completion of the proposed exams in 
the optimized aged transgenic mice, we will be able to determine the preclinical 
therapeutic impact on cognitive decline.   
 
6.2 Determination of the mechanism of o-Tau degradation in CSR monocytes 
Evidence indicates that ligand-bound FcgRIIb is transported to the lysosomal 
compartment for degradation271,301. My data also demonstrate co-localization of 
internalized o-Tau and lysosomes, and an enhanced lysosomal activity measured by 
LAMP-1 staining302,303 in FcgRIIb-CSR monocytes upon stimulation with o-Tau. Based 
on the collective evidence, I hypothesize that the o-Tau internalized via FcgRIIb-CSR is 
degraded via lysosomes in the engineered monocytes.  
To evaluate the necessity of lysosome in the degradation of the endocytosed o-Tau, 
the CSR monocytes could be pre-treated with a lysosome inhibitor (e.g., chloroquine or 
bafilomycin A305,306), before pulse stimulation with fluorophore-labeled o-Tau. The 
intensity of the intracellular fluorescence from o-Tau will be determined using Amnis 
imaging flow cytometry and by confocal microscopy. The intracellular signal difference 
between the inhibitor-treated group and the non-treated group will indicate the 
degradation of o-Tau via lysosome.  
My previous data showing the co-localization of o-Tau and increased lysosomal 
consumption in CSR monocytes suggest the involvement of the lysosomal pathway in o-
Tau degradation. However, if the treatment of lysosome inhibitor does not result in 
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different intracellular signals, it would indicate that lysosomes are not necessary for the 
degradation of the internalized o-Tau and that an alternative pathway degrades o-Tau. 
Previous literature shows that the proteasomal pathway is also involved in the 
degradation of ligand-bound FcgR307. To assess the alternative hypothesis that the 
proteasomal system is necessary for the internalized o-Tau degradation, inhibition of the 
proteasomal activities in the CSR monocytes can be achieved using a proteasome 
inhibitor like lactacystin or MG132308,309. An intracellular signal difference in the inhibitor-
treated and non-treated groups would suggest the involvement of the proteasome in 
degrading o-Tau. 
 
6.3 Determination of the mechanism of o-Tau internalization in CSR monocytes 
FcgRIIb-CSR expressed on peripheral monocytes were shown to promote o-Tau 
binding and internalization in vitro. However, the mechanism by which FcgRIIb-CSR 
facilitates o-Tau internalization in monocytes is unknown. Previous literature indicates 
that the internalization pathway of unmodified FcgRIIb is dependent on the size of the 
ligand bound to the receptor. FcgRIIb is internalized via clathrin-mediated endocytosis if 
its ligand is < 1 μm in diameter or via phagocytosis if the ligand is > 3 μm in diameter271,301. 
Even though o-Tau is estimated at ~20 nm in diameter93, it is unclear if the modified 
structure of FcgRIIb-CSR will result in a differential internalization pathway in monocytes 
than its unmodified counterpart.  
Based on the evidence, I hypothesize that the FcgRIIb-CSR-transduced monocytes 
use clathrin-mediated endocytosis to facilitate the internalization of o-Tau. This 
hypothesis can be addressed by stimulation of FcgRIIb-CSR monocytes with 
fluorophore-labeled o-Tau after pre-incubation with a clathrin inhibitor (e.g., Pitstop2 or 
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monodansylcadaverine310,311).  By tracking the location and movement of the fluorescent 
signals indicating the cellular internalization activity, it could be determined if the clathrin-
mediated pathway is necessary for o-Tau internalization via FcgRIIb-CSR.  
Although clathrin-dependent endocytosis is the predominant pathway for receptor-
mediated endocytosis, it is also possible that CSR internalizes through clathrin-
independent pathways. The caveolar pathway is a clathrin-independent pathway for 
receptor-mediated endocytosis312. The necessity of the caveolar pathway in CSR 
internalization can be examined by pre-treatment of the CSR monocytes with the siRNA 
of caveolin, which is the critical component of the pathway313. Another alternative 
mechanism could be receptor-mediated phagocytosis, which is a pathway used by 
monocytes/macrophages and can be determined by the pre-incubation of CSR 
monocytes with a phagocytosis inhibitor like cytochalasin D or latrunculin314.  
Furthermore, the literature indicates that the intracellular di-leucine motif of the FcgRIIb 
is responsible for its internalization273. Therefore, mutating the di-leucine motif should 
prevent the internalization of FcgRIIb-CSR after binding to o-Tau. This FcgRIIb-CSR 
variant will serve as an ideal negative control for o-Tau internalization. In addition to 
knowing how o-Tau is internalized intracellularly, it will also be important to understand 
if FcgRIIb-CSR is being degraded or recycled to the surface. The intracellular location of 
FcgRIIb-CSR can be detected using a fluorescein-labeled anti-histidine tag antibody in a 
pulse-chase experiment.  
In summary, upon the completion of the experiments outlined above, we will learn 
the mechanisms of both internalization and degradation of the FcgRIIb-CSR–bound o-
Tau. Moreover, the gained knowledge will enable us to improve our FcgRIIb-CSR 
monocytes further.   
 156 
6.4 Future generation of CSR monocytes 
6.4.1 FcgRIIb2-CSR monocytes 
The literature indicates that there exist two isoforms of FcgRIIb. Both FcgRIIb1 and 
FcgRIIb2 are expressed on myeloid cells at a lower level than on B cells and basophils, 
respectively193. FcgRIIb2 has a more rapid internalization compared to FcgRIIb1. It will 
be interesting to see if the faster internalization observed in the unmodified receptor can 
also be found in the modified scavenger receptor. To address this question, I have made 
an FcgRIIb-CSR based on the FcgRIIb2 and successfully transduced into the peripheral 
monocyte cell line PMJ2-PC.  
Although FcgRIIb2 has a faster internalization rate that might enhance ligand uptake, 
this also indicates that its signaling capability may be lower than FcgRIIb1. Therefore, in 
addition to investigating the o-Tau uptake efficiency by FcgRIIb2-CSR monocytes, it is 
also crucial to determine its capacity to decouple o-Tau clearance and proinflammatory 
signaling as this parameter will better reflect the neuroprotectivity of the engineered 
monocytes.   
 
6.4.2 Fine-tuning the expression level of FcgRIIb-CSR on monocytes 
By cloning the construct into vectors with fluorescent protein genes such as YFP in 
this study, I have separated the high CSR-expressing cells from the low expressing cells 
after transduction. The differential expression will enable us to examine the dose 
association between CSR expression with o-Tau uptake and the subsequent 
proinflammatory cytokine secretion in vitro. Compared to the cytotoxic antibiotic selection 
gene used earlier in this study, using fluorescent protein allows purification of cells with 
very high expression. However, due to the risk of immunogenicity of YFP when 
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introduced in vivo, a less immunogenic selection method was used to prevent limitations 
on its use in vivo. Nonetheless, the dose relationship between expression and functional 
output of CSR from in vitro assays will further guide us to the optimal dose of viral 
particles to transduce cells when we use a non- or less-immunogenic vector.  
 
6.4.3 FcgRIIb-CSR with a fortified intracellular signaling domain 
No significant anti-inflammatory cytokines such as IL-10 and IL-4 were found to be 
secreted by FcgRIIb-CSR monocytes in response to o-Tau stimulation. While the 
neuroprotectivity by FcgRIIb-CSR monocytes were established, it would be beneficial for 
the CSR monocytes to further express anti-inflammatory cytokines that could further 
counter-balance the proinflammatory environment in the AD brain. Therefore, in addition 
to modifying the intracellular domain for a more efficient internalization, we can also add 
on an anti-inflammatory signaling domain while avoiding impairment of the o-Tau 
degradation activity in the CSR monocytes.   
 
6.4.4 Chimeric scavenger receptors beyond targeting oligomeric Tau 
We have designed the CSR constructs in a modular fashion by strategically placing 
restriction enzyme sites that encase essential functional domains. This feature enables 
us to edit the CSR by swapping the existing domains with other desired functional 
domains. As this dissertation demonstrates the proof-of-concept of our innovative idea 
of engineered CSR monocytes against o-Tau, our concept, and the designs of the CSR, 
can also be applied to other prion-like diseases like a-synuclein in Parkinson’s disease 
which also has an inflammatory component in the pathogenesis315. For example, by 
swapping the extracellular o-Tau-specific scFv domain with the scFv that targets a-
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synuclein, it will enable the monocytes to remove a-synuclein efficiently while preventing 
proinflammatory responses. 
 
6.5 Conclusion  
AD is not only a medical problem but is also becoming a pressing social issue as 
the world ages rapidly. The holy grail of an AD therapy is to halt or even reverse its 
disease course. Searching for a disease-modifying agent to tackle this ever-growing 
disease has been a century of effort after the first discovery of the AD pathology. 
However, we are still searching today, while many giant pharmaceutical firms have 
withdrawn from the pursuit. As we are learning more about AD, our view of the disease 
is no longer limited to one single etiology, and so must be our strategy to treat the 
pathogenesis.  
o-Tau and inflammation were both found to be vital pathogenic factors driving the 
progression of AD. Studies further identified o-Tau as the dominant neurotoxic species 
among Tau assemblies and o-Tau is closely associated with clinical progression. Myeloid 
cells in the CNS are essential in clearing abnormal aggregates of protein, including Tau, 
although at the cost of concomitant proinflammatory responses. Previous efforts to halt 
the propagation of o-Tau using monoclonal antibodies have induced exacerbated 
myeloid cell inflammation due to the activation from engagement of the Fc domain of the 
antibody. Modification of the Fc region helps reduce the inflammation. However, it risks 
the clearance of o-Tau from the CNS because of an impaired engagement of the o-
Tau:antibody complex to Fc receptors. Therefore, a novel therapy that can 
simultaneously target these two etiologies is urgently needed. 
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This study has demonstrated the novel concept that the engineered peripheral 
monocytes stably expressing CSRs can protect neurons from o-Tau and inflammation. 
CSRs on the engineered monocytes, especially FcgRIIb-CSR, not only can efficiently 
internalize o-Tau but also can effectively decouple o-Tau uptake from proinflammatory 
cytokine secretion. Furthermore, FcgRIIb-CSR monocytes were shown to protect 
neurons in vitro from toxicities caused by o-Tau and inflammation. Delivery of cellular 
immunotherapy into the brain has been made possible in this study by developing a 
minimally-invasive surgical protocol that enables repeated ICV infusion of engineered 
monocytes. This protocol for preclinical studies establishes a novel route for the adoptive 
transfer of cellular therapy in AD and other fields such as cancer. Moreover, P301S Tau-
overexpressing transgenic mice that received engineered monocytes through this route 
were observed to have a modest improvement in motor functions, although the difference 
was not significant. Overall, the data suggest that efficient o-Tau uptake and anti-
inflammatory modulation by FcgRIIb-CSR monocytes has the potential to halt AD 
progression in vivo.  
Investigation of the mechanisms of the engineered monocytes and improving the 
CSR designs for second-generation engineered monocytes are ongoing. We hope that 
further understanding the biology of CSR and the engineered monocytes will pave the 
way for the first effective therapy for AD in decades (arguably ever), and also help 
frontotemporal dementia patients who completely lack therapeutic options. We also hope 
that this concept can be applied in other neurodegenerative diseases to help more 
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The lack of murine glioblastoma models that mimic the immunobiology of human disease 
has impeded both basic and translational immunology research.  We therefore 
developed immunocompetent glioblastoma stem cell (QPP) lines derived from Nestin-
CreERT2 QkL/L; Trp53L/L; PtenL/L mice driven by clinically relevant genetic mutations 
common in human glioblastoma. QPP lines are syngeneic to C57BL/6J mice and 
demonstrate varied sensitivities to T cell immune checkpoint blockade ranging from 
curative responses to complete resistance. Infiltrating tumor immune analysis of QPP8 
reveals improved T cell fitness and augmented effector to suppressor ratios when 
implanted subcutaneously (sensitive), which are absent upon implantation in the brain 
(resistant). Upregulation of PD-L1 across the myeloid stroma acts to establish this state 
of immune privilege in the brain. In contrast, QPP7 responds to checkpoint 
immunotherapy even in the brain likely resulting from its elevated mutational burden. 
Together, these findings indicate that dominant glioma-mediated immune suppressive 




Glioblastoma is the most aggressive primary brain tumor with a median survival of 
15 months316. Despite the success of T cell checkpoint blockade therapy in cancers such 
as melanoma and lung adenocarcinoma, recent clinical trials have established that 
antibody blockade of Programmed Death 1 (PD-1) fails to improve survival in 
glioblastoma317. In the broadest sense, immunotherapy resistance in glioblastoma may 
originate at the level of the glioma stem cells (GSCs) and can be associated with the 
inherent intratumoral heterogeneity of this cancer318,319. Further, glioblastoma recruits a 
microenvironment highly enriched for myeloid-derived suppressor cells (MDSCs), tumor 
associated macrophages (TAMs) and microglia, which contribute directly to the exclusion 
and functional suppression of tumor-specific T cells320. Beyond the myeloid stroma, 
inhibitory checkpoint molecules such as programmed cell death ligand 1 (PD-L1) are 
often highly enriched across the glioblastoma microenvironment and act in a cooperative 
fashion to negatively impact both local immune activation and overall prognosis in 
patients321.  
Despite the failure of checkpoint blockade as a therapy for glioblastoma in the clinic, 
the widely utilized murine model, GL261, is highly immune sensitive and readily cured 
by blockade of PD-1322 (Supplementary Fig. S1). This incongruity between encouraging 
preclinical findings in GL261 and the lack of immunotherapy responses in patients 
indicates that new and more robust models are needed which more accurately reflect 
the immune composition and therapeutic sensitivity, or lack thereof, of human disease. 
On the other hand, mice engineered to spontaneously develop glioblastoma in situ using 
the RCAS/Ntv-a system require little or no genetic “second hits” beyond the driver 
oncogenes (e.g. PDGF-b, BCL-2) and therefore likely lack immune targetable mutations 
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which are present, albeit at a low to moderate frequency, in human disease323. CD8 T 
cell infiltration in these models tends to be sparse (< 3% of CD45+ cells) and are of 
uncertain specificity and low affinity324. 
Quaking (QKI) is a tumor suppressor gene which is deleted, mutated or 
suppressed in GSCs in more than half of human glioblastomas, with low or absent 
expression correlating with poor patient survival325,326. The QKI protein post-
transcriptionally regulates, among other processes, cell membrane-endolysosome 
trafficking through selective binding and stabilization of messenger RNAs of 
endolysosomal components. Deletion of QKI also results in dysregulated mitophagy and 
induces reactive oxygen species as well as DNA damage, all of which act together to 
foster genomic instability and potential secondary genetic mutations. With the 
concomitant genetic loss in the commonly mutated or deleted tumor suppressor genes 
PTEN and TP53, we have previously described GSCs derived from Nestin-CreERT2 QkL/L; 
Trp53L/L; PtenL/L (QPP) mice. These QPP tumors demonstrate histopathological 
heterogeneity as well as a transcriptomic profile that can resemble that of all four 
subtypes of human glioblastoma327, features that indicate that they are relevant models 
for preclinical glioblastoma research.  
In the current study, we establish four murine syngeneic QPP tumors and 
determine their distinct immune sensitivities to T cell checkpoint blockade therapy in both 
the brain and subcutaneous niches. Emblematic of the potential utility of these novel 
glioblastoma preclinical models, we utilize comparative analysis of the immune 
microenvironments and mutational profiles of T cell checkpoint blockade sensitive versus 
resistant clones to understand the factors which establish glioma immune privilege in the 
central nervous system (CNS). For the first time, these novel glioblastoma mouse models 
which replicate both the histopathological and transcriptomic features and immune 
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checkpoint insensitivity of human disease may provide critical tools for both 
understanding the immunobiology of glioblastoma, as well as for vetting potential 
immunotherapeutic approaches to select the most promising for clinical advancement. 
 
Results  
Four C57BL/6 syngeneic QPP tumor lines grow with varied kinetics across 
immunocompetent versus immune deficient hosts  
To identify glioma cell lines derived from Nestin-CreERT2 QkL/L; Trp53L/L; PtenL/L 
(QPP) mice with the broadest possible utility for preclinical tumor modeling, we tested 
multiple lines for the capacity to grow progressively in syngeneic C57BL/6 hosts. Eight 
of these QPP glioma-stem cell (GSC) lines were inoculated subcutaneously on the flanks 
of immunocompetent C57BL/6J mice and immune deficient B6 Rag1-/- (RagKO) mice. 
Four QPP cell lines, namely QPP4, QPP5, QPP7 and QPP8, demonstrated the potential 
to grow progressively in both the immune competent and deficient mice (Fig. 1A, 1B). In 
terms of kinetics, QPP7 grows significantly more rapidly than the other lines, while QPP8 
was the slowest in vivo. Further, the growth of QPP7 was significantly attenuated in wild 
type versus RagKO mice suggesting that the adaptive immune response can both 
recognize and impede the progression of this tumor line (Fig. 1B).  
 
QPP tumor lines express a subset of recognized GSC markers but little to no 
immune checkpoint ligands at baseline  
All of these QPP lines can form neurospheres in serum-free media, which has 
been described as a key characteristic of glioma stem cells328. To further define the GSC 
features preserved by these lines, we examined their expression of common stem cell 
surface markers by flow cytometry. In fact, all four QPP lines express classical GSC 
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markers such as CD171 and a2b5, which are critical in tumor initiation, maintenance and 
invasion (Table 1, Supplementary Fig. S2)329-331. While expression of immune inhibitory 
checkpoint ligands such as PD-L1 by glioblastoma has been described332, the range of 
inhibitory ligands expressed by the tumor-initiating GSCs, as well as the conditions 
governing such expression, remain unknown. We observe little to no expression of T cell 
checkpoint molecules, such as PD-L1 or PD-L2, on the syngeneic QPP cell lines in vitro 
without stimulation. Upon stimulation with interferon (IFN)-g, however, a cytokine 
commonly expressed by tumor infiltrating T cells, all of the QPP lines upregulate 
moderate to high levels of PD-L1. QPP7, in particular, is the only line to show measurable 
baseline expression of PD-L1 in vivo and shows the highest levels of inducible 
expression predicting the potential for sensitivity to blockade of the PD-1/PD-L1 
interactions (Table 1, Supplementary Fig. S2).  
 
QPP gliomas are differentially sensitive to blockade of the T cell checkpoints 
CTLA-4 and PD-1 
Although glioma is clearly a disease of the CNS, the capacity for a murine cancer 
model to grow both in the brain and on the flank can be an important advantage for both 
investigating comparative biology and for some therapeutic screening applications. To 
assess the immunotherapeutic sensitivity of the four QPP lines, we implanted these lines 
in the flank and treated them with systemic injection of antibodies which block either PD-
1 (29F.1A12 or RMP1-14) or cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) 
(9H10) on days 7, 10 and 13. As predicted from its PD-L1 expression and slower growth 
in wild-type versus RagKO mice, the QPP7 tumor line proved to be highly sensitive to 
PD-1 blockade (Fig. 2 and Supplementary Fig. S3). In contrast to QPP7 and the 
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prevalent glioma model GL261, however, the QPP4 and QPP5 lines were resistant to 
anti-PD-1 therapy. All four lines did retain significant sensitivity to CTLA-4 blockade. 
QPP8 shows a clinically relevant profile of response to anti-CTLA-4, and in some mice 
to anti-PD-1, in which tumor immunity drives nearly complete tumor regression but lacks 
durability and gives way to subsequent progression. While this pattern of response and 
relapse is common in the clinic, few mouse models exist which replicate it. 
An essential property for any murine model of glioma is the capacity to grow 
progressively in the brain. To evaluate orthotopic growth of these QPP gliomas, we 
implanted each line via stereotactic injection in the brain and treated them with systemic 
administration of anti-PD-1 or anti-CTLA-4 on days 7, 10, and 13. All four lines grew 
progressively in the brain without treatment and, again, manifested varied levels of 
sensitivity to immune checkpoint blockade (Fig. 3). QPP7 demonstrates the most 
aggressive growth (median survival 37.5 days) while QPP8 has the slowest growth 
among the four QPP lines (median survival 63.0 days). As with clinical glioblastoma, 
QPP4 and QPP8 tumors are resistant to both CTLA-4 and PD-1 blockade. QPP5 and 
QPP7 are both sensitive to CTLA-4 blockades (p < 0.01 and p < 0.05, respectively); 
however, QPP7, unlike QPP5, also shows a trend toward anti-PD-1 sensitivity as well (p 
= 0.0692) (Fig. 3). In this model, the unique combination of Pten, p53 and Qk loss 
appears capable of imprinting varied patterns of immune sensitivities likely reflecting 
underlying genomic heterogeneity.  
 
Elevated ratios of CD8 T cells relative to suppressive T and myeloid cells drive 
CD8 response in the flank versus resistance in the brain 
 We investigated changes in the QPP8 immune infiltrate when treated in the flank 
(sensitive) versus in the brain (resistant). Surprisingly, there is no significant change in 
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cellular density of CD45+ immune cells in response to either CTLA-4 or PD-1 blockade 
regardless of implantation site suggesting primary mechanisms of immune suppression 
that are conserved (Fig. 4A). Although brain QPP8 fails to respond therapeutically to 
checkpoint blockade, CD8 T cell frequencies in the tumor are more significantly 
increased in comparison to when QPP8 is implanted subcutaneously. This CTLA-4 
antibody can deplete Tregs in peripheral tumors, which we observed as a trend (p = 
0.084) in this setting, an effect that may be contributing to the response in the flank (Fig. 
4B). Consistent with this effect, we observed significantly enhanced ratios of CD8 T cells 
relative to Treg in QPP8 in the flank with both anti-CTLA-4 and anti-PD-1 therapy (Fig. 
4C and Supplementary Fig. S4). Further, ratios of CD8 T cells relative to suppressive 
myeloid stroma are all elevated following checkpoint blockade in flank QPP8 indicative 
of pro-inflammatory conditioning of the tumor microenvironment. In contrast, the 
enhanced ratio of CD8 to suppressive T or myeloid populations were not observed in 
brain-resident QPP8 with the exception of an improved ratio of CD8 T cells to 
granulocytic MDSC (Gr-MDSC). Of note, Gr-MDSC are the least abundant myeloid 
population in QPP8 regardless of site of implantation. The capacity of checkpoint 
blockade to reshape the cellular composition of the flank, but not brain, QPP8 tumors to 
favor anti-tumor immunity partially explains QPP8 immunotherapy resistance in the brain. 
Next, we explored whether changes in the functional phenotypes of these populations 
might also play a role in dictating sensitivity to immunotherapy.  
In flank QPP8, CD8 T cells increase expression of Granzyme B and Ki67 and 
decrease their expression of PD-1 in response to PD-1 blockade (p < 0.05) (Fig. 4d). 
Effector CD4 T cells also show elevated expansion (i.e. Ki67) following both anti-PD-1 
and anti-CTLA-4 therapy, which together suggest better cytotoxicity and fitness post 
checkpoint blockade. A subset of these improvements to T cell fitness are also found in 
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brain QPP8, where PD-1 blockade results in enhanced Granzyme B expression coupled 
with reduced PD-1 fold change – a marker of T cell fitness that is also observed with 
CTLA-4 blockade. A critical difference between the flank and brain, however, occurs at 
the level of T cell proliferation. Whereas T cells expand in response to checkpoint 
blockade in subcutaneous QPP8, in the brain their proliferation remains static or even 
declines. This suggests either the presence of additional mechanisms of dominant T cell 
proliferative suppression operating the brain tumor site, and/or that checkpoint antibodies 
no longer protect the T cells once they reach the QPP8 brain tumor microenvironment 
(TME). Consistent with these findings, the highly immune checkpoint sensitive GL261 
glioma model shows an immune infiltrate pattern more similar to flank QPP8 than 
resistant brain-implanted QPP8 (Supplementary Fig. S5). In brain GL261, like flank 
QPP8, we find, as others have reported, that Granzyme B and Ki67 significantly increase 
following PD-1 blockade in the CD8 and CD4 effector compartments, while PD-1 
expression in the CD4 effector compartment decreases322.  
Across the myeloid stroma of both flank and brain QPP8, checkpoint blockade 
triggers upregulation of PD-L1 (Fig. 4D). The most significant induction occurs in brain 
QPP8 for both CTLA-4 and PD-1 blockade perhaps contributing to the additional 
immunotherapy resistance observed in this site. As our T cell analysis revealed signs of 
increased T cell effector function (i.e. elevated Granzyme B) with checkpoint blockade, 
it is likely that adaptive PD-L1 upregulation is triggered, at least in part, by increased T 
cell effector cytokine production (e.g. IFN-g). Changes in TGF-b (LAP, latency associated 
peptide) and arginase between flank and brain QPP8 were either inconsistent between 
CTLA-4 and PD-1 blockade (LAP) or did not reach statistical significance (arginase). We 
cannot rule out that the enhanced immune resistance of brain QPP8 results, at least in 
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part, from the expression of arginase by microglia which are among the most prevalent 
myeloid cells in brain QPP8 while absent in the flank (Fig. 4d). Despite the significant 
induction of PD-L1 in flank QPP8, ratios of CD8 T cells to nearly all suppressive myeloid 
stromal populations increase in the presence of PD-1 blockade and, to a lesser extent, 
CTLA-4 blockade (Fig. 4C). In contrast, brain QPP8 CD8 to suppressor ratios are 
unaffected by checkpoint blockade excepting those relative to Gr-MDSC density. These 
findings suggest that PD-1 blockade can successfully counteract the PD-L1 upregulation 
observed in flank QPP8, but that the antibody may not effectively block PD-L1 induced 
by brain QPP8, perhaps due to a limited capacity to access the brain TME. 
 
QPP7 remains checkpoint sensitive in the CNS despite adaptive upregulation of 
arginase  
Comparative analysis of the tumor microenvironments of resistant brain QPP8 
versus sensitive flank QPP8 indicated the importance of lack of checkpoint-induced 
upregulation of T cell proliferation and adaptive upregulation of PD-L1 on the myeloid 
stroma (including microglia in the brain) as potentially key factors driving immunotherapy 
responsiveness versus resistance in glioblastoma. While the QPP lines share a common 
set of driver mutations, the loss of Qki drives histopathological heterogeneity that yielded 
lines with substantially divergent immune sensitivity suggesting underlying genomic 
heterogeneity. To understand the influence of these alterations on the immune 
microenvironment of glioblastoma, we performed comparative analysis of checkpoint-
sensitive brain QPP7 and checkpoint resistant brain QPP8. Although sensitive to PD-1 
blockade, brain QPP7 ratios of CD8 versus suppressive T and myeloid cells improved 
less in response to PD-1 blockade than those in resistant QPP8 (Fig. 5A). Similarly, 
CTLA-4 blockade generated a more pro-inflammatory profile in brain QPP8 than in 
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sensitive QPP7 where ratios of CD8 T cells versus Gr-MDSC and microglia actually 
declined relative to untreated controls. As immune sensitivity of QPP7 could not be 
explained by these observations of cellular changes to the stroma, we examined 
phenotypic changes to key T cell and myeloid populations in response to therapy.  
Compared to resistant QPP8, sensitive QPP7 showed less PD-L1 induction in the 
myeloid stroma, particularly following CTLA-4 blockade, but also more consistent 
upregulation of arginase and TGF-b (LAP) (Fig. 5B). CD8 T cells elevated Granzyme B 
expression in response to both checkpoint antibodies in both tumors, with the only 
immunologic advantage for QPP7-infiltrating T cells being a trend toward higher 
proliferation in the CD4 effector compartment in response to CTLA-4 blockade. This 
finding is counterbalanced, however, by the higher expression of both the proliferation 
marker Ki67 and TGF-b (LAP) in Treg from QPP7 versus QPP8. Among these lines, only 
QPP7 expresses GFP that interfered with PD-1 measurement using our standard flow 
cytometry panel. In a separate study, we found that PD-1 is downregulated with 
treatment as in QPP8 (Supplementary Fig. S6). This comparative analysis reinforces 
the importance of the broad-based upregulation of PD-L1 as an adaptive resistance 
mechanism for QPP8, but raises questions as to why the arginase upregulation by QPP7 
in the brain fails to shield these tumors from checkpoint-blockade mobilized T cell 
responses. 
 The role of arginase in suppressing T cell anti-tumor immunity has been well 
established333,334; however, there are also reports in the literature that glioblastoma cells 
are sensitive to arginine depletion especially in the context of the loss of p53, a shared 
feature of QPP tumors and the majority of patients335,336. Administration of arginase as a 
therapeutic intervention to deplete arginine has been shown to limit glioblastoma growth 
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and enhance the efficacy of the standard of care chemotherapeutic agent temozolomide 
as well as radiotherapy335,337. Consistent with prior findings in glioblastoma335, we found 
that QPP7 and QPP8 undergo proliferative arrest in the absence of arginine in vitro (Fig. 
5C, 5D). These data indicate that while upregulation of arginase by QPP7 in response to 
checkpoint blockade may cause some inhibition of T cell responses, that deleterious 
impact on anti-tumor immunity may be outweighed by the more substantial negative 
impact on the proliferation and survival of the QPP tumor cells themselves. 
 Even in the context of less pronounced PD-L1 upregulation and a potentially tumor 
damaging impact of arginase induction, the extreme immune sensitivity of QPP7 relative 
to QPP8 in the brain seemed incompletely explained. Across immunotherapy, tumors 
with higher mutational burden generally respond better to checkpoint blockade338, and 
pediatric glioma patients with biallelic mismatch repair deficiency are highly responsive 
to PD-1 blockade339. As QPP7 was the most checkpoint blockade sensitive glioblastoma 
line in both the flank and brain and showed the most evidence for immune editing moving 
from Rag1-/- mice to wild-type mice, we hypothesized that QPP7 might have a higher 
mutational burden compared to QPP4, 5, and 8. We performed whole exome sequencing 
of each QPP line and sequence analysis relative to the C57BL6 reference genome 
revealed that QPP7 has the highest density of mutations including non-synonymous 
single nucleotide variants (SNV) (Fig. 6A), as well as insertions and deletions (indels) in 
coding regions (Fig. 6B). The other QPP lines show lesser and relatively homogenous 
mutational frequencies of ~7.5 mutations/MB that fall within the upper normal range for 
human glioblastoma, but below QPP7 (~ 12 mutations/MB) and well below the frequency 
for nearly all transplantable mouse models that average 37 mutations/MB340. QPP7 and 
GL261 have a similar frequency of SNV in coding regions, perhaps explaining their 
shared sensitivity to anti-PD-1; however, GL261 still has more than 8 times the frequency 
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of highly immunogenic frameshift mutations almost certainly as a result of its generation 
by chemical mutagenesis341. This finding suggests an important role for neoantigen load 
in predicting checkpoint sensitivity in glioblastoma, even in the context of a significantly 
suppressive microenvironment such as that of brain QPP7. 
 
Discussion  
More than 8 years after Food and Drug Administration (FDA) approval of the first 
T cell checkpoint blocking antibody, ipilimumab, development of immunotherapy for 
glioblastoma remains hampered by the lack of preclinical tumor models which reflect the 
immunogenicity of clinical disease. The most commonly used preclinical model, GL261, 
predicts exceptional sensitivity to PD-1 blockade, an approach that in general does not 
benefit glioblastoma patients317,322. Genetically engineered mouse models (GEMM) 
capture key tumor driver genes and can be useful models for preclinical evaluation of 
targeted or chemotherapy approaches; however, the strength of these mutations often 
obviates the need for acquisition of secondary and/or passenger mutations leaving an 
absence of immune-targetable tumor neoantigens. Xenograft tumor models allow study 
of human cancer, but the lack of a functional immune system in the host mice renders 
these models mostly useless for evaluation of immune-based therapies that rely on 
adaptive immunity342. In this manuscript, we describe QPP cell lines driven by mutations 
common in human glioblastoma that can be implanted either subcutaneously or 
intracranially in immune competent C57BL/6J mice. The presence of the Qk mutation 
confers histopathological heterogeneity to these tumor lines327, which is reflected in their 
differential sensitivity to T cell checkpoint blockade therapy. Like human glioblastoma, 
two of these lines (QPP4, QPP8) are completely resistant to anti-CTLA-4 and anti-PD-1 
therapy when growing in the brain. Not only will these new lines be valuable tools to 
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study the origins of immune resistance in glioblastoma as we have done here, but they 
will also provide critical tools for preclinical evaluation of prospective immunotherapies 
so that, in the future, only the most promising approaches advance to patients. 
  Previously, the PD-1/PD-L1 axis has been identified as a valuable prognostic tool 
in glioblastoma patients, where higher PD-L1 expression correlates with a poor 
prognosis321. PD-L1 is often implicated in “acquired resistance” to immunotherapy in 
which the IFN-g produced by infiltrating T cells elicits compensatory upregulation of PD-
ligands that dampen the response343,344. We established the capacity of IFN-g to potently 
induce PD-L1 on the QPP tumor lines. In addition, our comparative analysis also 
revealed significantly enhanced PD-L1 expression on the QPP myeloid stroma after anti-
CTLA-4 and anti-PD-1 antibody treatment, particularly in the resistant brain QPP8 tumor. 
The findings illustrate that the potential prognostic value of PD-L1 expression both by the 
tumor cells themselves and by the surrounding myeloid stroma. Analysis of the distinct 
tumor microenvironments of QPP8 in the subcutaneous versus orthotopic niches reveals 
multiple factors associated with treatment resistance. Even in resistant brain QPP8, we 
do observe an increased CD8 T cell frequency in the tumor following checkpoint 
blockade. As such, modest increases in their frequency should not be interpreted as an 
absolute indication of therapeutic response. In response to the IFN-g and other 
inflammatory cytokines produced by these cells, PD-L1 is upregulated across the QPP8 
myeloid stroma including on the microglia. In addition to TGF-b and arginase, these cells 
can also act through PD-L1 to suppress anti-glioblastoma T cells345-347. Whereas PD-1 
blockade likely prevents induced myeloid PD-L1 from adversely impacting the T cell 
response in flank QPP8, the PD-1 antibodies fail to rescue T cell function in brain QPP8. 
This failure could result from inadequate quantities of the antibody reaching the brain 
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TME in sufficient therapeutic concentrations to protect or rescue tumor-infiltrating T cells, 
or from other suppressive mechanisms exerting dominant suppression over the release 
of T cells from PD-1 inhibition348,349. These findings are consistent with the key role 
recently attributed to myeloid cells in human glioblastoma in mediating immune 
resistance to immune checkpoint inhibitors350. 
QPP7 is the most aggressive of the tumor cell lines we generated; however, it is 
also the most immune and immunotherapy sensitive. Among the four lines tested, QPP7 
is the only one to respond therapeutically to both CTLA-4 and PD-1 blockade in both the 
subcutaneous and orthotopic sites. In the brain, QPP7 showed signatures of a 
suppressive microenvironment with sub-optimal ratios of CD8 T cells versus suppressive 
stroma, high expression of arginase in the myeloid stroma, and modest induction of PD-
L1 in response to checkpoint blockade. While these adaptations would often be sufficient 
to grant tumor immune privilege, in this case they may fail due to a combination of both 
the adverse impact of arginase on the tumor stem cells and the more diverse anti-tumor 
T cell repertoire likely resulting from the higher mutation frequency of QPP7. Although 
potentially a driver of accelerated tumorigenesis and, potentially the aggressive 
phenotype of this tumor, this elevated rate of mutation also elicits more diverse and 
higher affinity anti-tumor T cell responses which may underlie the checkpoint sensitivity 
observed in the current study351. Although mutation frequencies are generally low in 
spontaneous glioblastoma and mismatch repair defects are uncommon352,353, studies 
across many cancers including pediatric gliomas have validated that higher sensitivity to 
immune checkpoint blockade therapy is linked with higher mutational burden339,354-361. 
Despite its relatively low antigen density, systemically administered tumor neoantigen 
vaccines have proven capable of mobilizing T cells that traffic to glioblastoma growing in 
the brain362. 
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In conclusion, we have created and characterized four murine syngeneic GSC 
lines driven by clinically relevant genetic mutations which reflect the heterogeneity of 
human glioblastoma including differential patterns of sensitivity and resistance to 
immune checkpoint blockade. Through comparative analysis of the same line (QPP8) in 
a resistant (brain) versus sensitive (flank) TME, and cross-comparison of a sensitive 
(QPP7) versus a resistant (QPP8) line growing in the brain, we identified key factors 
influencing resistance to immune checkpoint inhibitors. Enhanced PD-L1 expression 
across the myeloid stroma of QPP8 in the brain appears to be one of these key factors 
in checkpoint resistance and mirrors the established negative prognostic association with 
PD-L1 expression in patients. We believe that these QPP models provide the most 
accurate reflection of the immunobiology of human glioblastoma and will contribute to 
advancing effective immunotherapeutic interventions into clinical practice. 
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Methods  
Animals. Male and female C57BL/6J mice and male RagKO (B6.129S7-Rag1tm1Mom/J) 
mice were obtained from The Jackson Laboratory (Bar Harbor, ME). The mice were 
housed according to the Association for Assessment and Accreditation of Laboratory 
Animal Care and NIH standards. All experiments were conducted in accordance with the 
protocols approved by the University of Texas MD Anderson Cancer Center Institutional 
Animal Care and Use Committee.  
 
Cell lines and reagents. The QPP stem cells were derived from QPP mice327 and 
cultured in DMEM/F12 media with B-27 supplement (Gibco), epidermal growth factor 
(EGF) and fibroblast growth factor (FGF) (STEMCELL technologies)327. Arginine-
deficient media was used for the QPP arginine auxotrophy experiment. Interferon-g 
(PeproTech) (200 ng/mL) was used to induce PD-L1 expression in QPP in vitro. GL261 
was obtained from Dr. Amy Heimberger (MDACC) and cultured in Dulbecco’s Modified 
Eagle Media (DMEM) with 15% fetal bovine serum (FBS) and non-essential amino acids.  
 
Subcutaneous tumor growth studies. 1x106 cells of each QPP cell line were mixed 
with 30% collagen matrix (Matrigel, Corning) and subcutaneously implanted into the 
flanks of male C57BL/6J or male RagKO mice. The tumor dimensions were measured 
with calipers.  
 
Phenotypic characterization of QPP cell lines. In vitro QPP cell lines were prepared 
as a single cell suspension and stained for surface markers CD171 (Miltenyi Biotec), 
a2β5, CD44, CD133 (Biolegend), Sca-1 (Thermo), PD-L1 and PD-L2 (BD Biosciences). 
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Tumors extracted from tumor challenged mice were digested with Collagenase H (Sigma) 
and DNase (Roche) into a single cell suspension as described363. Cells were stained for 
the above surface markers in addition to CD45.2 (Biolegend) to exclude immune cells. 
Expressions of the indicated markers on cells were measured by using a BD LSRII flow 
cytometer. 
 
Immune sensitivity studies. For subcutaneous study, 1x106 cells of QPP4, 5 ,7 and 8 
were mixed with 30% Matrigel and subcutaneously implanted at the left flank of male 
C57BL/6J mice. For intracranial study, 1x105 cells (QPP7 and GL261), 2x105 cells 
(QPP4 and 5), and 3x105 cells (QPP8) for optimal engraftment and growth kinetics were 
mixed with 50% of methyl cellulose (Acros Organics) to a total volume of 5 μL. The cells 
were injected into right striatum of C57BL/6J mice, at approximately 2 mm anterior and 
2 mm right lateral to the Bregma at a depth of 4 mm, using a stereotactic device. 
Therapeutic antibodies modulating T cell co-inhibitory molecules CTLA-4 (9H10 [Syrian 
Hamster Ig], 100 µg/dose) and PD-1 (29F.1A12 [Rat IgG2a], 200 µg/dose or RMP1-14 
[Rat IgG2a], 250 µg/dose) were purchased from Bio X cell and Leinco technologies. All 
doses indicate quantity administered per injection. In all in vivo treatment studies, 3 
doses of antibody treatment or phosphate buffer saline (PBS) were given i.p. on day 7, 
10 and 13. Subcutaneous tumor volume was measured with calipers until tumors reach 
1,000 mm3 and the survival of brain tumor bearing mice was recorded.  
 
Flow cytometry analysis of tumor immune infiltrate. For subcutaneous analysis, 
1x106 of QPP8 cells were mixed with 30% Matrigel and implanted into the left flank of 
male C57BL/6J mice. 3 doses of antibody treatment as described in the immune 
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sensitivity study or PBS were given i.p. every 3 days when tumor volume grew to > 250 
mm3. For orthotopic analysis, 1x105 cells of QPP7 and GL261; and 5x105 cells of QPP8 
were mixed with 30% Matrigel to a total volume of 5 μL and inoculated into right striatum 
of C57BL/6J mice. Three doses of antibody treatment or PBS were given i.p. every 3 
days starting on day 5 for GL261, on day 33 for QPP7 and on day 48 for QPP8. All mice 
were sacrificed 2 days after the last dose of treatment. Tumors were harvested and 
digested with Collagenase H and DNase for 30 minutes and the cell numbers are 
counted using automatic cell counter. After removal of myelin via Percoll gradient 
separation (Sigma) for brain tumors364, the live infiltrating immune cells were enriched by 
Ficoll gradient centrifugation (Sigma; 1119 density). The enriched immune cells were 
stained for surface markers LAP (Thermo) and TMEM119 (Abcam), then fixed, 
permeabilized (eBioscience FoxP3 Fix/Perm kit), and stained in Brilliant Stain Buffer (BD 
Biosciences) for markers CD45.2, NK1.1, CD4, CD11c, CD11b, Ly6G, Ly6C, Ki67, PD-
L1 (BD Biosciences), CD3, CD8a, FoxP3, F4/80, PD-1 (Thermo), Granzyme B 
(Biolegend), and Arginase 1 (R&D Systems). Expressions of the indicated markers on 
cells were measured by using 18-color flow cytometry on a BD LSRII flow cytometer365. 
FlowJo Version 10 was utilized to analyze the data. Analysis of immune subsets are 
defined in Supplementary Fig. S7.  
 
Analysis of genomic alterations in QPP cell lines. Genomic DNA was extracted from 
the fresh cultured QPP lines using GeneJET Genomic DNA Purification Kit (Thermo 
Fisher). The integrity of purified DNA was validated on 1% agarose gels and the 
concentration was determined by using Qubit® DNA Assay Kit in Qubit® 2.0 Fluorimeter 
(Life Technologies). A total of 1.0 µg genomic DNA per sample was used as input 
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material for the DNA sample preparation. Sequencing libraries were generated using 
Agilent SureSelectXT Mouse All Exon kit (Agilent Technologies). Briefly, fragmentation 
was carried out by the hydrodynamic shearing system (Covaris) and the fragments were 
enriched by polymerase chain reaction (PCR). Exons were captured and enriched using 
PCR, and index tags added to prepare for hybridization. Products were purified using 
AMPure XP system (Beckman Coulter) and quantified using the Agilent high sensitivity 
DNA assay on the Agilent Bioanalyzer 2100 system. The qualified libraries were then 
sequenced by utilizing Illumina sequencing platform using the paired end 150 method 
with the depth of 50-100X and coverage of > 99%.  
 
Construction of heat maps. All heat maps are showing the log of fold changes of the 
indicated ratio or specific parameter MFI compared to the QPP line and tissue site 
matched PBS control group. Each ratio or MFI fold change in the treatment groups was 
normalized to the mean of the same parameter of the PBS group in each tumor immune 
infiltrate experiment. The normalized results in each independent experiment were then 
combined. For each parameter, Student’s t-test was used to compare the combined 
normalized fold changes in the treatment groups with the combined fold changes in the 
PBS group (mean = 1). “*” indicate differences with a p-value < 0.05. 
 
Statistical analysis. All statistics were calculated using Graphpad Prism Version 8 for 
Macintosh. Two-sided Student’s t-test applying Welch’s correction for unequal variance 
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Fig. 1. Four QPP lines grow in both immune-deficient and immunocompetent 
C57BL/6J mice.  1x106 cells of each QPP cell line were subcutaneously implanted 
in both (A) C57BL/6J (n=4) and (B) B6 Rag1 knockout (RagKO) mice (n=2) and their 
growth measured with calipers. Each curve and error bar represents mean (a and b) 
and SEM (a) of each QPP line. 
 
Fig. 2. T cell checkpoint blockade sensitivity of flank-implanted QPP cell lines.  
1x106 cells were implanted on the left flank of male C57BL/6J mice on day 0 and mice 
were treated via i.p. injection of anti-PD1 (29F.1A12 or RMP1-14) or anti-CTLA-4 
(9H10) monoclonal antibodies or control (phosphate buffer saline, PBS) on day 7, 10 
and 13. Tumors were measured with calipers until reaching 1,000 mm3. Each curve 
and error bar represent cumulative mean over time and SEM from two independent 










Fig. 3. QPP lines engraft in the brains of C57BL/6J mice and are differentially 
sensitive to checkpoint blockade.  1x105 (QPP7), 2x105 (QPP4 and 5) and 3x105 
(QPP8) cells were implanted via stereotactic injection to the right striatum of male 
C57BL/6J mice. On days 7, 10 and 13, mice were treated via i.p. injection of anti-PD1 
(29F.1A12 or RMP1-14) or anti-CTLA-4 (9H10) or control (PBS). Survival was 
monitored and significance is shown based on the Log-Rank (Mantel-Cox) test. 2 
(QPP4 and 5) to 3 (QPP7 and 8) independent experiments were performed with 4-5 
mice per group. 
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Fig. 4. Comparative infiltrate analysis of flank versus brain implanted QPP8.  
1x106 cells and 5x105 cells of QPP8 were implanted at the flank and in the brain of 
C57BL6/J male mice respectively. QPP8 tumor bearing mice were treated with 3 
doses of i.p. anti-CTLA-4 (9H10) or anti-PD-1 (RMP1-14) antibody or PBS every 3 
days starting when average flank tumor volume was > 250 mm3 or on day 48 for brain 
tumor bearing mice. The mice were sacrificed 2 days after the last dose of treatment 
and the extracted tumors were digested with Collagenase H and DNAse. Tumor-
infiltrating immune cells were enriched by Ficoll gradient centrifugation after removal 
of myelin via Percoll gradient separation (brain tumors only). The enriched immune 
cells were stained with phenotypic and functional markers and analyzed by flow 
cytometry. Immune infiltrate density fold changes compared to the control group (A) 
and T cell subset frequencies (B) in response to T cell checkpoint blockade in both 
flank and brain tumors are shown as mean ± SEM. Fold changes of CD8 T cells over 
suppressive subset ratios (C) and functional marker MFI fold changes compared to 
the matched control group for each immune subset in the indicated site (D) were 
calculated and are presented on a log scale. Data are cumulative of 3 independent 
experiments with 3-8 mice per group. Statistical significance was determined by using 
Student’s t-test. *p < 0.05. (Gzmb: Granzyme B; LAP: latency associated peptide; 
PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CD4 
Teff/Treg: CD4 effector/regulatory T cells; Gr-/Mo-MDSC: granulocytic-/ monocytic- 
myeloid derived suppressor cells; TAMs: tumor associated macrophages; DC: 
dendritic cells) 
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Fig. 5. QPP7 remains checkpoint sensitive in the CNS despite adaptive 
upregulation of Arginase.  1x105 cells of QPP7 or 5x105 cells of QPP8 were 
implanted in the right striatum of male C57BL/6J mice. The mice were treated with 3 
doses of i.p. anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14) or PBS every 3 days starting 
on day 33 for QPP7 and on day 48 for QPP8. Tumors were digested with Collagenase 
H and DNAase for 30 minutes. Next, the tumor infiltrating immune cells were enriched 
by Ficoll gradient centrifugation after removal of myelin via Percoll gradient 
separation. The enriched immune cells were stained for phenotypic and functional 
markers and analyzed by flow cytometry. Fold changes of CD8 T cells over 
suppressive subset ratios (A) and functional marker MFI fold changes compared to 
the matched control group for each immune subset in the indicated site (B) were 
calculated and are presented on a log scale. Data are cumulative of 3 independent 
experiments with 3-8 mice per group. Statistical significance was determined by using 
Student’s t-test (*p < 0.05). QPP7 and QPP8 cells were cultured in F12/DMEM media 
supplemented with B27, FGF and EGF for 5 days before they were collected and 
washed twice using PBS. 6x105 cells (dash line) were then seeded in 10 mL of the 
above culture media either with or without arginine. After in vitro incubation for 6 days, 
the cells were imaged using fluorescence or light microscope (C) and viable cell 
number was counted using automatic cell counter (D). Graph shows mean and SEM 
from 2 independent experiments. (†Separate evaluation of PD-1 expression in 
Supplementary Fig. S6. Gzmb: Granzyme B; LAP: latency associated peptide; PD-
1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CD4 Teff/Treg: 
CD4 effector/regulatory T cells; Gr-/Mo-MDSC: granulocytic-/monocytic-myeloid 









Fig. 6. Genomic profile of QPP cell lines.  DNA was extracted from the cultured 
QPP lines and sent for whole exome sequencing using the paired end 150 method 
with a depth of 50-100X and coverage of > 99%. Tumor mutational burden in each 
QPP line is presented as number of single nucleotide variants (SNV) in coding 
regions and non-synonymous SNV (A); as well as number of small insertion and 












QPP4 + ++++ - - - - - +++ 
QPP5 + ++++ - - - - - ++++ 
QPP7 + ++ + - - - - ++++ 





QPP4 ++ ++++ - - - - - 
N/A 
QPP5 ++ +++ - - - - - 
QPP7 + + + - + + - 
QPP8 + ++ - - - - - 
 
Table 1. Expression of glioma stem cell (GSC) markers and checkpoint molecules 
on QPPs. Cells were cultured in vitro in F12/DMEM supplemented with B27, epidermal 
growth factor (EGF) and fibroblast growth factor (FGF) for 4-5 days with or without IFN-
g for 48 hours. In vivo cells were harvested from subcutaneous or intracranial (QPP4) 
tumors digested with collagenase H and DNAse for 30 minutes. Cells were then stained 
for the indicated markers and analyzed by flow cytometry. (% of indicated marker positive 
QPP cells/total QPP cells is presented. -, < 2%; +, 2-20%; ++, 20-40%; +++, 40-60%; 






Supplementary Fig. S1. The glioblastoma line GL261 is acutely sensitive to PD-
1 blockade. 1x105 GL261 cells were implanted orthotopically into the brain of female 
C57BL/6J mice by stereotactic injection and then treated with 3 doses of anti-PD-1 
(n=5), anti-CTLA-4 monoclonal antibodies (n=4) or phosphate buffer saline (PBS) as 
control (n=4) every 3 days starting on day 7.  
GL261 survival in C57BL/6J mice
 
 
Supplementary Fig. S2. Programmed cell death ligand 1 (PD-L1) expression on 
QPP cell lines in response to Interferon (IFN)-g. Cells were cultured in vitro in 
F12/DMEM supplemented with B27, FGF and EGF for 4-5 days with or without IFN-
g (200 ng/mL) for 48 hours. Cells were then collected, stained with fluorescently 
labeled PD-L1 antibody and analyzed by flow cytometry. Percent of PDL1+ QPP 
cells/total QPP cells after IFN-g stimulation is presented as fold change compared to 
the unstimulated controls (A). PD-L1 expression level with or without IFN-g stimulation 




Supplementary Fig. S3. T cell checkpoint blockade sensitivity of flank-
implanted QPP cell lines. 1x106 cells were implanted on the left flank of male 
C57BL/6J mice on day 0 and mice were treated via i.p. injection of anti-PD1 
(29F.1A12 or RMP1-14) or anti-CTLA-4 (9H10) monoclonal antibodies or control 
(PBS) on day 7, 10 and 13. Tumors were measured with calipers until reaching 1,000 
mm3. Each curve represents individual tumor volume over time. Two independent 









Supplementary Fig. S4. CD8 T cells over immune suppressive subset ratios in 
flank QPP8 tumors. 1x106 cells of QPP8 were implanted on the left flank of male 
C57BL/6J mice and treated with 3 doses of anti-CTLA-4 (9H10), anti-PD-1 (RMP1-
14) or PBS starting when tumor volume reached > 250 mm3. Mice were sacrificed 
and tumors were harvested 2 days after the last treatment. The tumors were digested 
with Collagenase H and DNAse and tumor immune infiltrates were enriched by Ficoll 
gradient centrifugation. The enriched immune cells were stained with the indicated 
antibodies and analyzed by flow cytometry. Ratios were calculated by dividing CD8 
T cell frequencies by indicated suppressive subset frequencies. Data are cumulative 
of 3 independent experiments with 3-5 mice per group. Statistical significance was 
determined using Student’s t-test. *, p < 0.05; **, p < 0.01. (Treg: CD4 regulatory T 
cells; Gr-/Mo-MDSC: granulocytic-/monocytic- myeloid derived suppressor cells; 








Supplementary Fig. S5. T cell effector function improves following checkpoint 
blockade in orthotopic GL261 glioblastoma. 1x105 cells of GL261 were 
stereotactically inoculated into the right striatum of female C57BL/6J mice. Mice were 
treated with i.p. anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14) or PBS on day 5, 8, 10 
and were sacrificed on day 12. Tumors were digested with Collagenase H and 
DNAase for 30 minutes. Next, the tumor infiltrating immune cells were enriched by 
Ficoll gradient centrifugation after removal of myelin via Percoll gradient separation. 
The enriched immune cells were stained with phenotypic and functional markers and 
analyzed by flow cytometry. Graphs show mean ± SEM for the indicated markers in 
CD4 effector T cells (A) and CD8 T cells (B). Data are from 1 experiment with 11 or 
12 mice per group. Statistical significance was determined by using Student’s t-test. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. (Gzmb: Granzyme B; LAP: 
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Supplementary Fig. S6. Decreased PD-1 expression on T cells in the anti-CTLA-
4 treated QPP7. 1x105 cells of QPP7 were implanted in the right striatum of male 
C57BL/6J mice. The mice were treated with 3 doses of i.p. anti-CTLA-4 (9H10), anti-
PD-1 (RMP1-14) or PBS every 3 days starting on day 33. Tumors were digested with 
Collagenase H and DNAase for 30 minutes. Next, the tumor infiltrating immune cells 
were enriched by Ficoll gradient centrifugation after removal of myelin via Percoll 
gradient separation. The enriched immune cells were stained for phenotypic and 
functional markers and analyzed by BD X-30 flow cytometry. Graph shows mean ± 
SEM for PD-1 MFI on the indicated T cell subsets. Data are from 1 experiment with 
5 mice per group. Statistical significance was determined by using Student’s t-test (*p 






Supplementary Fig. S7. Definition of the immune subset by flow cytometry 
analysis. Tumor infiltrating immune cells were stained with antibodies for the 
indicated markers and data were acquired using 18-color flow cytometry on a BD 
LSRII flow cytometer. FlowJo Version 10 was used to analyze the acquired data. After 
FSC/SSC and singlet gating, CD45.2+ cells were selected for analysis. Microglia was 
first separated from the rest of the population which was then divided into natural killer 
(NK), natural killer T (NKT), T cells and myeloid population. T cells were separated 
as CD8 T, CD4 regulatory T (Treg) and effector T (Teff) cells. The myeloid population 
was further identified as dendritic cells (DC), monocytic-/granulocytic- myeloid 
derived suppressor cells (Mo-/Gr-MDSCs) and tumor associated macrophages 
(TAMs). 
FSC and SSC gate Singlet gate CD45.2+ Immune cells
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